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ABSTRACT 
CHARACTERIZATION OF METASTASIS-ASSOCIATED CELL SURFACE 
GLYCOPROTEINS IN PROSTATE CANCER 
Lifang Yang 
Eastern Virginia Medical School and Old Dominion University, 2010 
Director: Dr. O. John Semmes 
Prostate cancer (PCa) is a major health problem in males in the United States. Its 
lethality is mostly attributed to the primary tumor metastasizing to distant sites that are 
highly resistant to conventional therapies. Serum Prostate Specific Antigen (PSA) is the 
only protein biomarker used in clinic for prediction of prostate cancer recurrence 
following local therapies. Nonetheless, PSA lacks the ability to predict the behavior of 
an individual tumor in an individual patient. Therefore, development of reliable 
biomarkers for detection of metastatic potential in primary tumors, as well as discovery 
of new therapeutic targets, is in a great need for improved disease survival and 
management. Tumor metastasis is a multistep process involving extravasation of a 
cancer cell subsequent invasion and expression at a site distal to the primary tumors. Cell 
surface glycoproteins play pivotal roles as recognition molecules in a range of cell 
communication and adhesion events. Aberrant cell surface glycosylation has been 
reported in various cancers including PCa, and strongly correlated with prognosis and 
metastasis. However, the staggering complexity of glycans renders their analysis 
extraordinarily difficult. This research project aims to develop a mass spectrometry-
based glycoproteomic approach for the selective isolation and identification of cell 
surface glycoproteins from cellular samples, and apply this technology to the discovery 
of new glycoprotein biomarkers which are indicative of prostate cancer progression and 
metastasis. To this end, cell surface glycosylation patterns were characterized by lectin 
flow cytometry and lectin cytochemistry on a human syngeneic PCa cell metastatic 
model, PC3 and its two variants with different metastatic potentials. It was found that 
metastatic potentials of PC3 variants were inversely correlated with cell surface oc2-6 
sialic acid levels. Targeted to cell surface sialoglycoproteins, a new glycoproteomic 
approach was successfully developed, which combined selective metabolic labeling of 
cell surface sialyl glycans, chemically probing the labeled sugar with a biotin tag, affinity 
purification of sialylated proteins, SDS-PAGE separation, and subsequent LC-MS/MS 
for protein identification. Application of this methodology in our prostate cancer model 
system resulted in unique identification of a total of 80 putative cell surface 
sialoglycoproteins differentally expressed between PC3 variants. After prioritization of 
the candidate biomarkers, one cell-based prioritized biomarker CUB-domain-containing 
protein 1 (CDCP1) was verified in prostate cancer cell lines and clinical samples, 
including tissues and body fluids, by immunoassays. Results indicated that expression 
of CDCP1 protein is dysregulated in prostate cancer and it has potential utility as a 
therapeutic target and a diagnostic marker for PCa progression. Overall, the data from 
this research project provided the proof-of-principle evidence for our targeted 
glycoproteomic approach, which we believe will help expedite the discovery of new 
cancer biomarkers and therapeutic targets in diseases and delineation of signal 
transduction pathways on a global scale. 
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1.1 Prostate Cancer Pathogenesis and Biomarker 
1.1.1 Incidence and mortality 
Prostate cancer (PCa) accounts for 9.7% of malignant tumors in men and is the most 
commonly diagnosed cancer among males in the Western world i. The highest PCa 
incidence rates (>100.0 per 100.000/year) are found in North America and the lowest in 
Asia . The American Cancer Society estimates there are 217,730 newly diagnosed cases 
and 32,050 deaths due to PCa in 2010 3. Incidence of PCa increases with age more 
rapidly than any other cancer. Autopsy studies have shown invasive carcinomas in 8% of 
men in their 20s rising to 80% for men in their 70s 4. Based on National Cancer Institute 
(NCI)'s Surveillance and Epidemiology and End Result (SEER) program statistics 
review, the average annual age-adjusted incidence rate in the United States has 
experienced 2.6% and 16.5% growth from 1975-1988 and 1988-1992, respectively. 
This dramatic increase in the late 1980s reflects improvements in detection and diagnosis 
through widespread use of prostate-specific antigen (PSA) testing, which received initial 
U.S. Food and Drug Administration approval in 1986. Since the early 1990s, PCa 
incidence has been declining (Fig. 1). From 2003-2007, the age-adjusted incidence 
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Figure 1 Annual age-adjusted prostate cancer incidence and mortality rate among 
males, US, 1975 to 2007. Figure was generated from Surveillance, Epidemiology, and 
End Result (SEER) program website (www.seer.cancer.gov). incidence source: 
SEER 9 areas (Connecticut, Iowa, Hawaii, New Mexico, Utah, Atlanta, Detroit, 
Settles, San Francisco). Mortality source: US Mortality Files, National Center for 
Health Statistics, CDC. Rates are age-adjusted to 2000 US-standard population. 
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rate was 156.9 per 100,000 men per year. The mean age at PCa diagnosis is 67 years, 
and 91% of the cases are diagnosed after 54 years and less than 1% before 45 years 5. 
PCa incidence also differs for different racial and ethnic populations. The rate is highest 
in Blacks and lowest in Asians. Black Americans have the highest PCa incidence in the 
world and are considered at high risk for the disease 6. In the United States, PCa is the 
second most frequent cause of cancer-related death in men. Overall, annual age-adjusted 
mortality remains relatively stable in last thirty years although the rate has declined 
slightly since the early 1990s (Fig. 1). The age-adjusted death rate was 24.7 per 100,000 
men per year and the median age at death was 80 years of age during 2003-2007 period5. 
1.1.2 Etiology and risk factors 
Despite the high prevalence of PCa, the pathogenesis of PCa remains unclear. Most 
experts believe the etiology of prostate cancer is multi-factorial, with advancing age, diet, 
race, and family history most often implicated . After age and ethnic background, the 
strongest epidemiological risk factor for PCa is a positive family history. 5-10% of PCa 
are reported to be hereditary or familial. A man with first degree relatives (father, 
brother, or son) who have had prostate cancer is two to three times more likely to develop 
Q 
the disease himself and generally associated with early onset . Several genes such as 
RNaseL, E1AC2, MSR1, BRCA2 have been identified as candidate susceptibility genes 9. 
But epidemiologic evidence suggests that familial PCa is agenetically heterogeneous 
disease and many gene loci rather than a specific major susceptibility gene predispose to 
familial PCa 10. Moreover, gene-environment interactions may play a crucial role in PCa 
development especially for these genes with low-penetrance and polymorphisms n . 
Recent studies have indicated that chronic inflammation and atrophy are very important 
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in PCa pathogenesis 12. In particular, there is growing evidence that asymptomatic 
chronic prostatic inflammation, defined as category IV prostatitis, is prevalent in cases of 
PCa . Several investigators have proposed a causal link between inflammation and PCa 
, but currently no firm statement on causality can be made. Dietary factors such as 
animal fat consumption and calcium from dairy foods are associated with increased risk 
of PCa, whereas anti-oxidative nutrients like selenium, vitamin E and tomato-based 
products containing lycopene probably protects against PCa 14. The elevated insulin-like 
growth factor (IGF) has been proposed to represent a link between western lifestyle or 
obesity and PCa 15, however, a contradictory association was also reported 16. Androgens 
are well known to regulate prostate growth and function and may also speed tumor 
growth, but no definite link between increased circulating androgen levels and PCa has 
been found 17. The etiology of PCa is thus poorly understood compared to other common 
human cancers. 
1.1.3 Pathological characteristics and natural history 
The prostate gland is located just beneath the bladder and in front of the rectum. It 
contains three major glandular regions-the peripheral zone, the central zone, and the 
transition zone. Each glandular zone has specific architectural and stromal features. But 
in all zones, both ducts and acini are lined by androgen-dependent glandular PSA-
secreting cells. Beneath it, there is a proliferative compartment of androgen-independent 
basal cells, which are recognized by their location, morphology and expression of high 
molecular weight cytokeratins and p63 as opposed to luminal cells. Endocrine-paracrine 
cells are irregularly distributed in the gland 18. Most prostate adenocarcinomas arise in 
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the peripheral zone, and are characterized by multi-focality and morphological and 
molecular heterogeneity, typically lacking basal cells 7'19'20. There are two types of 
prostatic intraepithelial neoplasia (PIN) one of which is considerate to be a forerunner of 
cancer. The first is low grade (LGPIN) which is not associated with PCa. The other, 
high grade (HGPIN) predicts risk of subsequent cancer 21'22. One characteristic of 
HGPIN is the retention of the basal cell layer which harbors over-proliferative phenotype. 
One study discovered that HGPIN co-exists with PCa in 85% of prostate surgery 
specimens, and that PIN may appear as soon as ten years before cancerous cells develop 
23
. The prostate lesions, named proliferative inflammatory atrophy (PIA), are usually 
located in the periphery of the gland near the prostate carcinoma, have been proposed as 
precursors for PIN or carcinoma 4, but the hypothesis presently remains controversial 25. 
The natural history of PCa is highly variable 26. Some tumors simply do not 
continue to grow or only grow at an extremely slow rate and never form metastases. 
Autopsies of men who died of unrelated causes have demonstrated that latent PCa is 
present in about 70% of men in their 60s ' . However, the majority of PCa grows and 
expands around the urethra, causing urinary problems similar to benign prostatic 
hypertrophy (BPH). When the cancer is still confined to the prostate itself, it is called a 
9R 
"localized disease" . By the time the tumor is large enough to cause symptoms, it has 
often spread beyond its capsule. PCa may invade surrounding fat and tissue, the seminal 
vesicles, and/or the neck of the bladder. The cancer cells may invade lymph nodes in the 
pelvic region. Later, PCa can spread to the bones, primarily those in the lower spine, 
pelvis, and femur. Other organs such as the liver, brain, or lungs can also be metastatic 
sites . Once the cancer has spread distantly from the prostate, it is difficult to 
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effectively treat and completely cure. If the cancer spreads without intervention, or if 
treatment has failed, PCa can ultimately result in death. 
1.1.4 Diagnosis and treatment 
Two standard screening examinations, digital rectal examination (DRE) and serum 
prostate-specific antigen (PSA), are the first step in diagnosing prostate cancer, no matter 
symptoms are present or not. If a man's PSA level is elevated and/or his digital rectal 
exam is abnormal, ultrasound directed needle biopsy and histological examination are 
usually performed . The widespread use of PSA monitoring for early detection has 
greatly changed the way PCa is diagnosed . The increase of PCa detected due to 
increased screening examinations has revealed problems with PSA, such as lacking 
specificity and without lower limit to completely exclude PCa , and cause some 
dilemmas in clinical practice. For example, there has been an increasingly large number 
of men with elevated PSA and an initial set of negative biopsies. The negative result 
does not exclude the presence of cancer. A high percentage of these men require repeat 
biopsies. However, the threshold level of PSA that should indicate biopsy, the optimal 
number of biopsy cores for detecting PCa in prostate biopsy, and when to stop biopsying 
remains controversial33. The absence of clear guidelines in this field can delay diagnosis 
and treatment of PCa patients, as well as cause cancer-free men anxiety and side effects. 
For patients who have been diagnosed with PCa, various diagnostic imaging tests such as 
MRI, CT, and PET are the options to determine the extent of the tumor in the prostate 
and whether cancer cells have spread to surrounding tissues or other parts of the body34. 
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Treatment for PCa depends on many factors: the patient's age, the risk of the 
disease, the presence of other medical conditions, and the patient's overall health. To 
date, there are five major treatment options for patients with PCa: watchful waiting, 
radical prostatectomy, radiotherapy (external and internal radiation), hormone therapy, 
and chemotherapy ' . For localized PCa, radical prostatectomy is standard treatment 
for patients with a life expectancy >10 years, whereas radiotherapy is an alternative. The 
randomized studies comparing these two therapies suggest that they provide similar rates 
of cancer control at 10 years, and that except for the youngest patients, choice of therapy 
should be based on toxicity and quality of life . Patients with a life expectancy <10 
years and low-moderate grade tumors may be offered "watchful waiting", in which 
patients are under active surveillance38. For locally advanced PCa, combined 
radiotherapy and neoadjuvant total androgen blockade (LH-RH agonist plus anti-
androgen) is the preferred treatment. The role of radical prostatectomy in this population 
has been debated39'40. Patients with metastatic disease are treated with individual or 
combined hormonal therapies, chemotherapy (docetaxel), radiotherapy, surgical 
treatments, and antiresorptive medications 29. 
1.1.5 Prognosis and risk stratification 
PCa is a markedly heterogeneous disease with considerable variation in clinical 
course ranging from asymptomatic disease to a rapidly progressing fatal malignancy. 
Sophisticated risk assessment is required in clinic. Reliable methods to identify high-risk 
patients are essential to help clinicians make therapeutic decisions to achieve maximal 
cancer control. Currently, three preoperative clinicopathologic parameters are used to 
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assess PCa risk. They are clinical tumor stage, biopsy grade and volume parameters, and 
preoperative serum PSA 41. 
PCa is staged anatomically. Stage I (A) corresponds to clinically inapparent tumors 
usually found microscopically. Stage II (B) refers to a palpable tumor confined with the 
prostate. Stage III (C) indicates that cancer extends outside of the capsule of prostate, but 
only barely. Stage IV (D) signifies involvement of cancer to lymph nodes or distant 
tissue 29. Since 1992, the consensus TNM staging (Table 1) has gained general 
acceptance and has replaced the old A-B-C-D system 42. The stage level is an important 
prognostic factor in PCa. In particular, seminal vesicle invasion and regional lymph node 
involvement are inversely associated with survival. Also, capsular penetration is 
associated with increased risk of recurrence 22 '4I. However, the prognostic role of 
substaging in organ-confined disease is less informative 43. 
PCa is also staged pathologically using the Gleason system, which is the method of 
predicting a prognosis based on the histological appearance of cells obtained from either 
a needle biopsy or a prostatectomy. Small samples of prostate cancer cells are reviewed 
under the microscope and assigned a pattern number from 1 to 5. Patterns 1 and 2 
correspond to well-differentiated cancers. Pattern 3 indicates a moderately differentiated 
cancer, and pattern 4 and 5 correspond to poorly differentiated or anaplastic lesions 29. 
The advantage of Gleason grading over other grading system is that it accounts for the 
remarkable heterogeneity of PCa. It records two predominant patterns and adds them 
together to give a Gleason score range from 2 to 10. If only one pattern is present, that 
pattern number is doubled to obtain the Gleason sum score (for example 4+4=8). The 
99 
higher the score, the more aggressive the cancer . In many multivariate analyses, the 
Gleason score proves to be an independent predictor of both pathologic tumor stage and 
time to biochemical recurrence 44_46. Gleason score is commonly stratified as: score 2-A 
(well differentiated); 5-6 (moderately differentiated); 7 (moderately to poorly 
differentiated); and 8-10 (poorly differentiated). Score 7 tumors can further be 
subclassified into 3+4 or 4+3, depending on which grade is most prevalent in the cores 22' 
1
. This type of Gleason score classification and subclassification has been validated to 
predict postoperative outcomes 47'48. However, the Gleason grading system has been 
hampered by poor reproducibility 49'50. Intra- and inter-pathologist variations of 
interpretation are common, reported in up to 64% of cases 51. Another limitation of 
Gleason score system is poorly correlation of scores from needle biopsies with Gleason 
scores of specimens obtained surgically during prostatectomies. Discordance rates of 
43% to 46%), with upgrading in 35% of cases, have been reported 52. 
Tumor volume is associated with adverse pathologic findings (high grade, 
extracapsular extension, seminal vesicle involvement, positive margins, lymph node 
metastasis, and ultimate disease progression) after a radical prostatectomy53. The 
prognostic impact of tumor volume however, is variable, largely depending how to 
quantitatively measure tumor volume 54. Several studies report the percentage of the 
prostate involved by the tumor and maximum tumor diameter to be an independent 
predictor of recurrence 55'56. In needle biopsies, tumor volume as measured by number of 
positive cores or the percentage of positive cores, is also associated with recurrence or 
progression after surgery or radiation therapy57. Tumor volume probably has little 
prognostic independence once the Gleason score and pathological stage are known 22. 
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Table 1 TNM staging system of prostate cancer 
T = Tumors that is: 
Tx: Cannot evaluate the tumor 
TO: No evidence of primary tumor 
Tl: Tumor present, but undetectable using DRE or imaging 
Tla: Incidental in the resected specimen (<5% tissue involvement) 
Tib: Incidental in the resected specimen (>5% tissue involvement) 
Tic: Found by biopsy with rising PSA 
T2: Tumor palpable and localized tumor 
T2a: Half or less than half of one lobe involved 
T2b: More than half of one lobe, but not both involved 
T2c*: Both lobes involved 
T3: Extended to the capsule, but not beyond prostate 
T3a: Extracapsular involvement (unilateral, bilateral) 
T3b: Seminal vesicle involvement 
T4: Fixed or invading adjacent organs (such as bladder or rectum) 
N = Lymph node metastasis in: 
Nx: Cannot evaluate the regional lymph nodes 
NO: No spread to the regional lymph nodes 
Nl: Spread to the regional lymph nodes 
M = Distant metastasis 
Mx: Cannot evaluate distant metastasis 
MO: No distant metastasis 
Ml: Distant metastasis 
Mia: Metastasis to lymph nodes beyond the regional ones 
Mlb: Metastasis to bone tissue 
Mlc: Metastasis to other organs (regardless of bone involvement) 
DRE = digital rectal examination; PSA = prostate-specific antigen. 
Data are from the AJCC 6th edition (2002) and UICC 6th edition. 
* "T2c" implies a tumor which is palpable in both lobes of the prostate. Tumors which are found 
to be bilateral on biopsy only but which are not palpable bilaterally should not be staged as T2c. 
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Despite limitations as a screening tool, PSA testing may still supply valuable clues 
to the risk of tumor recurrence and treatment response. Numerous studies have 
confirmed elevated serum PSA was associated with larger tumor volume, higher clinical 
stage, and Gleason grade 58. PSA seems to be a strong predictor of aggressive PCa. A 
Malmo Preventive Medicine study with 21,277 men participating showed that PSA level 
at age 44-50 was highly predictive of advanced prostate cancer diagnosed up to 25 years 
later, with advanced cancer defined as T3, T4 or metastasis at diagnosis. But the 
prognostic accuracy decreased with age 27'59. Preoperative PSA is also a sensitive 
indicator of recurrence after radical prostatectomy. In a large study with a cohort of 1582 
men who underwent radical prostatectomies, lower preoperative serum PSA was reported 
to be associated with a decreased incidence of positive surgical margins, extracapsular 
disease, seminal vesicle invasion and lymph node involvement. Multivariate analysis 
suggested that only serum PSA levels and the biopsy Gleason score predicted time to 
recurrence . However, contrasting results are reported. Stanley's group has shown PSA 
values may only presage pathologic Gleason scores if PSA values are either extremely 
high or low, and less reliable as a prognosticator when PSA level was between 2 and 9 
ng/mL ' . These results support a previous study in which no clinically useful 
relationship was found between preoperative PSA and biochemical progression in large 
volume cancers . Therefore, preoperative PSA seems insufficient to allow useful 
predictions for individual patients based on PSA as a single marker. Predictions can be 
improved by PSA derivatives such as PSA doubling time (PSADT) and PSA velocity 




. However, the use of these indications in the pretreatment setting is more 
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controversial, and none of the measures has been shown to increase diagnostic and 
77 fn 
prognostic accuracy better than a simple PSA test ' . 
Recognition of the limitations of above single prognostic factors has led to the 
development of multivariable tools that incorporate preoperative clinicopathologic factors 
in an array in an attempt to better predict pathological tumor features and treatment 
outcome. Current diagnosis employs a mix of biopsy Gleason score, clinical tumor stage 
and preoperative PSA levels ' . Currently, the most commonly used stratification 
system was developed by D'Amico et al. which divides patients into low, intermediate, 
and high risk (Table 2) 47. This tool has been validated for use in men treated with 
radical prostatectomy and radical radiotherapy 47'6 . Other combined prognostic tools 
include Partin Tables, and statistical model nomograms, which have different predictive 
significances and limitations, and their universal application still needs to be validated ' 
68 
1.1.6 Current challenges in clinical PCa management 
The introduction of prostate-specific antigen (PSA) into the paradigm of early 
detection, as well as a lower PSA threshold (in the range of 2.5-3.0 ng/mL rather than 
traditional 4.0 ng/mL) used in clinic for recommending prostate biopsy, have resulted in 
profound changes in stage and grade of PCa. As expected due to increased PSA 
screenings, stage has migrated towards more localized, and curable diseases (Tlc-T2a) 70. 
Results from the SEER database also showed that the percentage of PCa patients with 
metastatic disease at the time of diagnosis dropped from 16% in the 1980s to 4% in 2003 
71 
. Unexpectedly, grade has shifted heavily toward moderate differentiation (Gleason 5-
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Table 2 D'Amico et al. risk stratification for clinically localized prostate cancer 
PCa Risk Serum PSA (ng/mL) Gleason Score Clinical Stage 
<=10 <=6 Tic, T2a 
10-20 7 T2b 
> 20 8-10 T2c, T3 
PSA = prostate-specific antigen 
The risk stratification scheme, developed by D'Amico et al. is currently in widespread 
use for prognostic assessment of clinically localized prostate cancer. Patients are divided 
into three risk groups (low, intermediate, or high) of occult micrometastases and relapse 
by the combination of three preoperative clinicopathologic factors: biopsy Gleason score, 
serum PSA, and clinical stage. When there is a conflict in three parameters, the worse 
factor wins and determines the risk category assignment. For example, a patient with a 
low Gleason Score of 6 combined with a PSA of 25 ng/mL is considered high risk. Table 






7), whereas rates of poorly (Gleason 8-10) and well-differentiated (Gleason 2-4) disease 
70 
have remained relatively stable . According to D'Amico's risk categories, most 
diagnoses of PCa belong to the low-risk group, the proportion of which increased from 
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30% in 1990 to 45% in 2000 . The low-risk tumors, however, can be either indolent or 
aggressive. There is currently no means that allow urologist/oncologist to differentiate 
the minority of men with potentially lethal cancer from a large proportion of those whose 
PCa pose no threat to life or health. The net result is an unfortunate trend to over-
diagnosis and over-treatment of clinically insignificant PCa73. This can create the 
potential for patient's mental burden and the morbidity and mortality associated with 
aggressive local therapies. On the other side, patients with potential aggressive disease 
may omit adjuvant intervention and miss a crucial opportunity to be cured. There is a 
significant need for an improved risk-stratification system that incorporates novel 
biomarkers to better determine the risk of recurrence and allow patients to make more 
informed decisions about treatment. 
For patients with significant disease, the major challenge is the prediction of clinical 
progression and survival after defined local therapy. It is reported that about 25% of men 
with PCa ultimately will experience subsequent recurrent disease after radical 
prostatectomy within 15 years. A portion of these men will go on to experience clinically 
expressed extracapsular disease, with as many as two-thirds having evidence of bone 
involvement29. Monitoring of post-treatment PSA provides a means of detecting 
recurrent disease long before the tumor is detected by other means such as imaging or 
symptoms. Increasing PSA levels after treatment, also called 'biochemical recurrence", 
generally indicates the presence of tumor cells. However, It is noteworthy that PSA 
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recurrence merely represents a surrogate endpoint marker74, as only 34% of these 
patients develop distant metastases after a median follow up of 8 years 75. In line with 
this, many patients will experience a post-treatment PSA elevation that confers no 
prognostic information, referred to PSA only progression7'74. In addition, there is 
considerable debate on the best criteria for defining biochemical recurrence. No single 
PSA value is invariably associated with clinical metastasis or cancer-specific survival27' 
. Moreover, PCa can recur in the absence of a PSA increase or detectable PSA level ' 
. Hence, biochemical failure after local therapy does not perform well in this field, and 
there is an equally urgent need for new biomarkers which can serve as surrogate end 
points for clinical recurrences or cancer specific survival. 
The first choice to manage distant metastatic disease is hormonal modulation. But 
nearly all cancers will eventually acquire androgen independence, becoming refractory to 
androgen deprivation therapy (ADT). The median survival of a patient after developing 
hormone-refractory prostate cancer (HRPC) is approximately 12 months, and few 
palliative treatment options are available which have shown benefit at this stage 29. PSA 
tests are frequently used to monitor the effects of the treatment in men with HRPC. 
However, PSA level in patients with such an advanced stage is only moderately 
associated with survival, and PSA can't accurately reflect the treatment response 27'79. 
Currently the greatest need for stage IV patients is to find more accurate makers of 
response as well as develop novel agents to prolong survival. 
In summary, PCa is a major public health issue in the United State. The 
development of PSA for PCa detection and prognostication has revolutionized the 
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management of this disease. Nevertheless, the limitations of PSA, as described above, 
underscore the necessity to find more accurate diagnostic and prognostic biomarkers that 
can predict the natural history of the disease, assess recurrent risk, and facilitate 
stratification of patients to different treatment protocols aimed at improving survival 
outcome. 
1.2 Protein Glycosylation 
Covalent attachment of carbohydrates to proteins is one of the most common and 
versatile post-translational modifications with more than 50% of eukaryotic proteins 
thought to be glycosylated 80. Protein glycosylation is prevalent in membrane and 
secreted proteins where they play a decisive role in cellular recognition events involved 
in cell adhesion, cell-to-cell communication, and receptor-ligand interactions " . 
Glycans also critically influence the physicochemical properties of proteins that impact 
protein folding, solubility, and turnover84'85. Hence, glycans expand the biological 
information carried by proteins. Glycans also confer glycoproteins the nature of 
complexity which arises from both the structural diversity and elaborate bio synthetic 
processes. 
The glycans associated with human proteins are composed of various combinations 
of seven monosaccharide units . The monosaccharide units are glucose (Glc), mannose 
(Man), galatose (Gal), fucose (Fuc), N-acetylgalactosamine (GalNAc), N-
acetylgluctosamine (GlcNAc) and sialic acid (SA). Free monosaccharides can exist in an 
open form, but in nature they are usually found as five or six sided ring structures. For 
carbohydrates in a cyclic form, the configuration is given as a or P anomers. 
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Monosaccharides are commonly joined together to form di-, tri-, oligo-, and 
polysaccharides by linking the anomeric carbon atom of one monosaccharide to any 
hydroxyl group on another monosaccharide. This reaction determines the type of linkage 
(a- or P-bond), which is essential for enzyme recognition . Furthermore, bonds can be 
made between the different carbon atoms of the two monosaccharides, for example, 
carbon 1 of one monosaccharide and carbon 3 of the adjacent monosaccharide, denoted 
as (1—»3). In addition, the monosaccharides can form both linear and branching chains. 
Therefore, a combination of the number and sequences of monomeric units, their linkage, 
a number of conformations, as well as occurrence of branch points means there are 
theoretically astonishingly large number of different structures possible. Although not all 
possible oligosaccharides are observed in nature, glycan structures are still extremely 
varied and complex. Moreover, glycan structures can be modified by diverse 
substitutions including sulfation, phosphorylation, methylation, and acetylation , which 
also contribute to the structural diversity. 
The point of attachment of the sugar chain to the polypeptide is another level of 
complexity. Glycosylation can occur at different amino acid residues in the protein 
sequence. Several types of glycosylation are known: (i) the N-linked glycans which 
attached to the amide group of asparagine residues in a consensus Asn-X-Ser/Thr 
sequence (X can be any amino acid except proline) via an N-acetylglucosamine 
(GlcNAc) residue; (ii) the O-lined glycans where the sugar is commonly attached to the 
hydroxyl group on serine/threonine residues or rarely to other amino acids, e.g. tyrosine, 
hydroxyproline and hydroxylysine. (iii) glycosylphosphatidylinositol anchors which are 
attached to the carboxyl terminus of some membrane-associated proteins; (iv) C-
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glycosylation that occurs on tryptophan residues in certain membrane-associated and 
on 
secreted proteins ; (v) S-linked glycosylation where the sugar is attached through a 
sulfur atom on cysteine or methionine 90. The most common and widely studied forms 
are N-linked and O-linked glycosylation. Fluctuations can occur in both the occupancy 
rate of O- and N-linked sites on a protein and in the substructures of carbohydrates 
attached to a specific site. The former, referred to macroheterogeneity, results from the 
fact that not all potential glycosylation sites are actually glycosylated. The later, called 
microheterogeneity, is normally a range of glycan structures associated with each site. 
These phenomena are a consequence of the competitive action of diverse enzymes during 
biosynthesis . 
Glycan structural diversity requires a finely tuned glycosylation process to 
accomplish. N-linked glycosylation is a highly specific cotranslational reaction which 
occurs during protein synthesis before the protein is folded into its final conformation. 
When the nascent protein enters the endoplasmic reticulum (ER), a block of core 
precursor sugars (Glc3Man9GlcNAc2), which is a highly conserved evolutionary process 
in ER, is transferred to the amino group in the asparagine side chain by the 
oligosaccharyltransferase complex 91. The glycan is later processed by stepwise 
trimming and stepwise addition of new monosaccaride residues by a number of enzymes 
in the ER and Golgi, generating the three main classes of N-glycans found in mature 
glycoproteins with a common conserved pentasaccharide core MansGlcNAc2 (Fig. 2A). 
The three main classes of glycans are: (i) High mannose - only mannose residues are 
attached to the core structure, (ii) Complex N-glycans - characterized by the 
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Figure 2 The subclasses and oligosaccharide structures of N- and O-linked 
glycoproteins. (A) The representative three types of N-linked oligosaccharides. N-
glycans are attached to the protein backbone by linkage to asparagine in the 
consensus sequence Asn-Xaa-Ser/Thr. They share a universal pentasaccharide core 
sequence Man3GlcNAc2, and are classified into three types: (1) high mannose, in 
which only mannose residues are attached to the core; (2) complex, in which various 
antennae are attached to the core; and (3) hybrid, in which only mannose residues 
are attached to the Manal-6 arm of the core and one or two antennae are on the 
Manal-3 arm. (B) The representative four types of O-glycan cores. The O-glycans 
are commonly attached to the protein via serine or threonine residues. The most 
basic O-glycan core structures are observed linked to a single Gal residue, however 
it can be extended by lactosamine repeats, fucosylation and sialylation with different 
linkages. In both figure, directionality is from nonreducing end at the top to the 
reducing end at the bottom with the arrows indicating the extension at the 
nonreducing end. Linkages between monosaccharides contain the anomeric 
configuration of the monosaccharide (a, alpha and (3, beta). Glycan symbol 
nomenclature is indicated in the low panel. In the case of complex JV-linked glycans, 
the common terminal motifs attached to Gal are shown in a dotted box. Adapted 
from Raman, R. et al. Nat Methods 2, 817 (2005). 
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presence of variable numbers of antennae as well as N-acetyllactosamine (LacNAc, 
Gaipi-3/4GlcNAc) in their antennal region. They can be further capped by fucose and 
sialic acid residues to form a variety of oligosaccharide structures. These N-glycans 
constitute the most abundant class of mammalian oligosaccharide, (iii) Hybrid N-glycans 
- containing both a mannose residue and N-acetyllactosamine attached to the trimannosyl 
chitobiose core, sharing structural features of the high mannose type and complex type . 
The presence or absence of an oc-fucosyl residue on the core mannose of three types of N-
glycans further adds to the structural diversity of the oligosaccharides. 
In contrast to N-glycans, the biosynthesis of O-glycans is a post-translational event 
that takes place in Golgi after protein N-glycosylation, folding and oligomerization. 
Because there is no clear consensus sequence analogous for O-glycans, the synthesis is 
simpler than for N-glycans. An example of the process is the most prevalent form mucin-
type of O-glycosylation. Generally, the process involves sequential single 
monosaccharide transfer steps. The first step is normally the transfer of N-
acetylgalactosamine (GalNAc) to Ser/Thr residues of the protein backbone, by the action 
of specific polypeptide GalNAc transferases (ppGalNAcTs). To date, more than 24 
ppGalNAcTs have been described, with differential tissue expression and overlapping but 
different specificities 87'93. Subsequent addition of galactose (Gal) and/ or GlcNAc by 
specific transferases leads to the formation of the common O-glycan core structures (Fig. 
2B). There are at least eight core structures, four of which are particularly widespread in 
human . The basic core structures can be further extended and terminated by the 
transfer of lactosamine repeats, sialic acid and fucose residues to give a heterogeneous 
range of glycans. Besides GalNAc, single GlcNAc can also be attached to Ser/Thr 
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residues to ubiquitously modify cytoplasmic and nuclear O-linked glycoproteins. O-
GlcNAcylation has been found to be as abundant and dynamic as phosphorylation to 
regulate cellular signal transduction 94. 
Carbohydrates are constructed stochastically by a complicated pathway. Unlike 
genes and protein, carbohydrates are generated through non-template-driven biosynthesis 
and regulated by multiple factors, including metabolic levels of sugar nucleotides, 
competitive expression and localization of glycosylation enzymes (glycosyltransferases, 
glycosylhydrolases), and protein-trafficking mechanisms 88'95. Due to these features, 
glycans are expressed in a cell type-specific fashion and subjected to alterations under 
different physiological and pathological settings. 
1.3 Altered Cell surface Glycosylation and Cancer 
During malignant transformation and cancer progression, tumor cells express a 
unique repertoire of glycosylation patterns. The common types of aberrant 
glycosylaytion associated with cancer are: (i) hypo, hyper or newly glycosylated protein 
glycosylation sites; (ii) change in the glycan biosynthetic machinery including 
upregulation of fucosyltransferase (FucTs), sialyltransferases (SiaTs), N-
acetylglucosaminyltransferase V (GnTV) which is involved in the elaboration of highly 
branched N-linked glycans 96; (iii) increased levels of fucosylation 97; (iv) alterations in 
sialylation 98'99; (v) addition of polylactosamine units 10°; (vi) increased (31-6 GlcNAc 
branching in N-linked structures 101'102; (vii) truncated glycoforms such as terminal N-
acetylgalactosamine (GalNAc) 103, or Tn and STn antigens 104 in O-linked structures; 
(viii) inappropriate synthesis of blood group related carbohydrate antigens such as histo-
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blood group A/B antigens 105'106, or Lewis antigens (i.e. sialyl-Lex, sialy-Lea, and Ley)107' 
108
 in either N-linked or O-linked structures. Among these changes, altered sialylation of 
tumor cell surface glycoconjugates is most often correlated with a metastatic tumor 
phenotype. Changes have been reported reflecting the amount, type, distribution, and 
bonding of sialic acids to adjacent molecules 6'109. Several reports showed a positive 
correlation between the levels of cell surface sialylation and the metastatic ability of 
various experimental tumors 110>m. For instance, an increase in the amount of N-
acetylneuraminic acid (Neu5 Ac) on glycan chains has been reported in colorectal cancers 
and associated with the metastatic spread of colon cancer cells . However, the 
correlation between cell surface sialyaltion and metastatic potentials of tumor cells is not 
absolute. Sometimes the distribution of sialic acid on specific N- or O-linked 
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oligosaccharides or alterations in the attachment of sialic acid to its neighboring 
monosaccharide , rather than the total quantity of sialic acid, may affect the metastatic 
properties of these cells. For example, Neu5Ac is usually attached to adjacent 
monosaccharides via an a2->3 or an a2-»6 bond. However, the attachment in an a2-»8 
bond results in the structure called polysialic acids, which are at an increased levels in 
lung cancer I14 and breast cancer 115 and are associated with pancreatic tumor cell 
invasion 116. Moreover, altered sialylation can also results from other glycosylation 
changes. One example is increased pi-6 branching can increase the number of Gal(31-
4GlcNAc structures that can be sialylated, leading to a total increase in cell surface 
sialylation I17. Therefore, alternation in cell surface sialylation is a complex and dynamic 
process. 
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Alterations of the carbohydrate structures have important clinical and functional 
relevance. Clinicopathological studies showed that high expression of some glycosyl 
epitopes promotes invasion and metastasis, leading to a shorter 5-10 year survival rate for 
patients, whereas expression of the glycosyl epitopes suppress tumor progression, leading 
to higher postoperative survival rates 118. The concept of glycosylation-dependent 
promotion or inhibition of tumor progression has been further supported by the data from 
human tumor cell lines and experimental animal studies 119'120. Modification of surface 
carbohydrate expression by specific strategies such as glycosylation inhibition, enzymatic 
treatment, gene transfection, and gene knockout mice, brings direct evidence that cell 
surface carbohydrates are very important in the regulation of metastatic behavior of 
tumor cells, as detailed below. 
Metastasis is defined as the growth of a cancerous cell in an environment 
noncontiguous with its tissue of origin I21. It is a complex process occurring in a step-
wise fashion (Fig. 3). At the beginning, individual primary tumor cells gain the capacity 
to degrade and migrate through the basement membrane and extracellular matrix (ECM). 
Then the tumor cells access and intravasate into the local vasculature, interacting with 
host cells such as endothelial cells, platelets, and leukocytes. After traveling around the 
body, tumor cells lodge in the small vessels of distant organs and exit from the circulation 
by extravasation. Eventually tumor cells survive and proliferate at the secondary sites to 
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become a pathological metastasis . The mechanisms of each event are functionally 
maintained by a combination of defined molecules involved in the process, each of which 
is affected directly or indirectly by glycosylation 123. Particularly tumor cell proliferation, 
invasion, and extravasation of metastatic cascade are of high relevance in glycobiology. 
24 
A Primary tumor grows B Break through basal C Intravasate 
D Extravasate E Mlcrom«tastasis F Macrometastasis 
Figure 3 The process of tumor metastasis. Metastasis is a complex and multiple-stage 
process. (A) Tumor proliferation at the origin site is crucial at early stages of 
progression. (B) During invasion, tumor cells gain the capacity to degrade, and migrate 
through, basement membranes and extracellular matrix. (C) Tumor cells access the 
local vasculatures and intravasate into the bloodstream or lymphatic glands, where 
they aggregate with host cells such as platelets and lymphocytes and eventually lodge 
in the small vessels of distant organs. (D) During extravasation, tumor cells adhere to 
capillary wall and escape from the blood vessel. (E) In the distal organ, tumor cells 
proliferate to form micrometastases. (F) Once new angiogenesis is set up, tumor cells 
are able to form pathological macrometastases. Adapted from Alberts, B. et al. 
Molecular Biology of the Cell, 4th ed., New York: Garland, 1325 (2002). 
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Tumor proliferation is very important in the early stages of progression and after 
metastasis. A broad spectrum of glycans affects tumor proliferation. For example, many 
studies indicate that N-glycans of many growth factor receptors regulates signal 
transduction by modulating receptor functions 1 0 2 ' m . N-glycosylation of the epidermal 
growth factor receptor (EGFR) is required for receptor dimerization and transforming 
activity . Treating U251 glioma and BXPC3 pancreatic adenocarcinoma cells with N-
glycosylation inhibitor tunicamycin can disrupt EGFR signaling and enhance 
radiosensitivity . Similarly, O-lined glycans and mucins play a role in tumor cell 
proliferation. Mucins are glycoproteins that contain numerous O-glycans in clustered 
domains along the core protein. Most tumor cells express mucins as transmembrane 
proteins on the cell surface or as secreted proteins I27. MUC4 is reported to be involved 
in the pathogenesis of pancreatic cancer and aberrantly expressed in many other epithelial 
carcinomas ' . MUC4 contains an EGF-like domain on its extracellular part, which 
can directly interact with ErbB2 initiating phosphorylation of the receptor tyrosine kinase 
in the absence of typical ErbB2 ligands. Therefore, MUC4 can modulate HER2/ErbB2 
signaling and is a determinant of therapeutic outcome of Herceptin-based therapy for 
patients with breast cancer 130. High expression of another mucin family member MUC1 
has been also implicated in many solid tumors including prostate cancer 131'132. Recent 
investigation suggests that MUC1 can be associated with intracellular signal molecules 
such as Ras and [3-catenin to regulate tumor cell growth 
During invasion, tumor cells detach from each other, invade, and migrate through 
the neighboring tissues. This requires the coordinated remodeling of cell surface 
adhesion molecules and secretion of degradative enzymes (proteases and glycosidase). 
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Glycans are involved in each of these stages . The presentation of cancer-related 
glycans generally reduces cell-cell adhesion and promotes migration. Studies show 
structural modification of N-glycans on N-cadherin with increased branched structures by 
enzyme GnTV, led to decreased cell-cell adhesion, promoting tumor cell detachment and 
invasion. However, small interfering RNA-directed knockdown of GnTV in HT1080 
fibrosarcoma cells resulted in enhanced N-cadherin-mediated cell-cell adhesion as well as 
decreased cell migration and invasion 134. Expression of sialylated glycans is also 
reported to promote dissociation of tumor cells. Transfection of breast cancer cells with 
enzyme ST6Gal-I, which is responsible for sialic acid capping of terminal galactose 
residues on N-linked glycans, increased cell migration and reduced cell to cell adhesion. 
In contrast, transfection with antisense ST6Gal-I RNA enhances homotypic cell-cell 
adhesion. Enhanced expression of sialic acid is also found on the O-linked sugars such as 
sialyl Tn antigen (STn), which is commonly overexpressed in the mucin-rich surfaces of 
cancer cells. Transfection of breast cancer cells with cDNA that encodes the human 
sialyltransferase responsible for STn biosynthesis (ST6GalNAc-I) reduced cell to cell 
interaction and increased the migration potential of transfected cells. Besides altered cell 
to cell interaction, local ECM remodeling is essential for tumor cell invasion. Integrins 
represent a very important class of cell surface adhesion receptors mediating attachment 
to ECM protein ligands, such as fibronectin and laminin. Numerous integrin biological 
processes including expression, heterodimerization, ligand binding, and downstream 
signaling, are modulated by glycosylation 96'135. For instance, sialylation led to integrin 
activation, increased adhesion to ECM ligands, and augmented migration and invasion of 
colon cancer cell lines in vitro . In addition to sialylation, integrins are also modified 
by GnTV, and as a result, carry high level of pi,6-branched structures . Increased 
GnTV expression disrupts the ability of integrins to cluster on the tumor cell membrane, 
which in turn, reduces the formation of tumor cell focal adhesion and increases tumor 
motility and invasion. Similarly, in vivo, spontaneous mammary tumors, which 
developed in a GnTV-deficient mouse model, exhibited decreased growth, metastasis, 
and signaling downstream of the focal adhesion kinase 
Like invasion, extravasation requires a series of steps. After entry into the 
vasculature, tumor cells, stimulated by some blood-borne factors, aggregate with 
activated platelets, and/or leukocytes to form microvascular occlusions in the small 
vessels of distant organs, initiating extravasation 123. The molecular mechanisms by 
which cancer cells traverse the vasculature is thought to occur through "hematapoietic 
mimicry", an identical traffic control axis used by hematopoietic progenitor cells (HPC) 
into bone marrow and lymphocytes homing to sites of inflammation. This shear stress-
dependent process begins with rolling on endothelia cells, which leads to tethering and 
integrin-dependent stable adhesion. The first step of extravasation, rolling of tumor cells 
along the endothelium, is regulated by glycosylation 96. Rolling is mediated by the 
adhesion of selectins to carbohydrate ligands on the surface of tumor cells. The selectin 
family consists of three members each exhibiting differential expression patterns. 
Endothelial cells display E-selectin, platelets express P-selectin, and leukocytes present 
L-selectin 139. It is thought that tethering and rolling of tumor cells occurs through 
selectin-mediated interaction between malignant cells and the endothelium. However, 
interactions between malignant cells and host cells, such as circulating platelets and 
leukocytes, are also indicated to participate in tumor cell extravasation 140. Carbohydrate 
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ligands for selectins typically consist of clustered arrangements of oligosaccharides that 
bear sialic acid, fucose, and sulfate, predominantly present at the outmost layer of O-
linked glycans . One class of carbohydrate ligands are Lewis type blood group 
antigens, sialyl Lewis X (sLex) and sialyl Lewis A (sLeA). Tumor cells frequently 
overexpress sLex and sLeA bearing glycoforms of cell surface molecules such as 
glycoprotein CD44, CEA, PCLP, MCAM, and glycolipids 141. The presence of these 
ligands corrects with metastatic formation and patient survival for several types of 
cancers 142. Recent experimental animal studies confirmed a clinical correlation is a 
reflection of a causal relationship. Mice lacking L-selectin, P-selectin, or both, exhibit 
greater resistance to the metastasis of colon carcinoma cells 143. The expression pattern 
of E-selectin also governs metastasis. In a mouse model in which E-selectin was 
overexpressed in the liver, melanoma cells expressing E-selectin ligands formed liver 
metastasis but not tumor cells lacking E-selectin ligands 144. 
In summary, altered glycosylation is a universal feature of malignant transformation 
and tumor progression. The highly selective glycosylation changes have the greatest 
functional consequences in the metastatic cascade. Exploiting these differences would 
likely afford excellent opportunities to identify sensitive and specific cancer biomarkers, 
as well as uncover potential new cancer therapeutic targets. 
1.4 Glycoproteomics in Cancer Biomarker Discovery 
Cancer related changes in glycosylation can lead to biomarker discoveries. In fact, 
many of the clinical tests currently used to diagnose and manage the treatment of cancer 
have exploited changes in glycosylation that accompany the disease process. Table 3 
lists some of the FDA approved cancer biomarkers that are glycosylated. These include 
many glycoproteins, such as carcinoembryonic antigen (CEA), commonly used as a 
marker of colon cancer 145; cancer antigen 125 (CA-125), frequently used to diagnose 
ovarian cancer ; a-fetaprotein (AFP), usually used in screening and diagnosing liver 
cancer 147; and PSA, a marker for prostate cancer as described earlier. Other clinically 
useful cancer biomarkers directly detect glycan epitopes. One of the examples is CA19-9 
which binds to sialy-Lea and commonly used for diagnosing and monitoring pancreatic 
1 AQ 
cancer . Despite the fact that these serum biomarkers remain the diagnostic gold 
standard in clinic, their diagnostic value is more frequently questioned, due to poor 
sensitivity and specificity of the assays 27'145'147"149. Alternatively, researchers have 
found capitalizing upon changes in cancer-related glycoforms affords the possibility of 
increasing diagnostic sensitivity and specificity. The separation of serum AFP by lectin 
LCA highlights this point. Based on the binding capacity of AFP towards LCA, AFP has 
three different glycoforms with different diagnostic function: AFP-L1, AFP-L2 and AFP-
L3. While AFP-L1, known as the non-LCA-binding fraction, is the most abundant 
isoform of AFP in serum of patients with benign liver disease, chronic hepatitis and liver 
cirrhosis; AFP-L2 has intermediate affinity to LCA and is present in maternal serum 
during pregnancy and frequently derived from yolk sac tumors. AFP-L3 or the LCA-
reactive AFP glycoform, carrying an additional a 1-6 fucose residue, appears to be 
produced by cancer cells. It is the major glycoform in serum of HCC patients and a 
marker for biologic malignancy of HCC 147. Overall, detection of these glycoprotein 
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BTA, bladder tumor-associated antigen; CA, cancer antigen; CEA, carcinoembryonic antigen; 
FDP, fibrin degradation protein; IHC, immunohistochemistry; PSA, prostate-specific antigen 
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glycoform changes is nearly all at the cytological and histological levels, as shown with 
lectins and glycoreactive antibodies, the availability of which is limited. Thus, sensitive, 
fast, and robust analytical methodologies are required to identify cancer-specific 
glycobiomarkers. 
The complex and heterogeneous nature of carbohydrate structure and synthesis has 
constrained the pace of glycosylation study. Traditional analytical techniques including 
capillary electrophoresis, gel filtration, high-pressure liquid chromatography, and thin 
layer chromatography are time consuming and most have only been applied to a single 
glycoprotein 150. With recent advances in proteomics, chemical biology, and mass 
spectrometric instrumentation, glycoproteomics is rapidly emerging as a critical sub-field 
of proteomics. Mass spectrometry (MS), due to its high sensitivity and versatility, has 
been a state-of-art technology in glycoproteomics. While the knowledge of the mass of a 
glycoprotein or glycan provides initial information regarding composition, the 
fragmentation ions of glycopeptides and glycans can determine structural sequence 
directly. There are two basic levels of glycoproteomics analysis by MS: (1) examination 
of the glycoproteome (glycoproteomics), which includes identification of glycoproteins 
and mapping glycosylation sites; (2) survey of the glycome (glycomics), which is 
o n 
concerned characterizing glycan repertoires released from glycoproteins . 
Protein biomarker discovery is a complex and challenging task. Five conceptual 
phases of biomarker development have been proposed: preclinical exploratory (I), 
clinical assay and validation (II), retrospective longitudinal repository studies (III), 
prospective screening studies (IV) and cancer control studies (V)151. The conventional 
pipeline for the preclinical exploratory phase involves four essential stages: initial 
discovery of differentially abundant proteins; prioritization of qualified candidates; 
candidate verification; assay development and pre-clinical validation . MS-based 
glycoproteomics is now playing a principle role in the initial phase of discovering cancer-
related glycobiomarkers. Glycoprotein enrichment techniques, coupled with and high-
resolution MS have greatly increased the analytical sensitivity to reach the depth of 
glycobiomarker coverage in complex samples such as plasma, serum, other bodily fluids, 
tissue lysate or cell line homogenates 153. In addition, with the current drive towards 
larger panels of multiplexed biomarkers, candidate-based quantitative glycoproteomics 
platforms, such as multiple reaction monitoring (MRM), have been introduced recently 
154,155 Y ^
 n £ w quam:jtative MS approaches perform full biomarker discovery, 
quantification, and verification on the same technology platform, allowing targeted 
detection of glycoprotein candidates in complex samples in a multiplexed fashion. 
Furthermore, the new approaches have greatly enhanced both the specificity and 
sensitivity to the point of rivaling immunoassay for some analytes, providing a 
complementary tool for glycoprotein biomarker verification in addition to antibody based 
approaches 156. It is clear that glycoproteomics is playing an increasingly important role 
in biomarker discovery. 
1.5 MS-based Glycoproteomics Approaches 
A comprehensive analysis of glycosylation in a complex biological sample requires 
a concerted approach. Technology platforms incorporating MS for glycobiomarker 
discovery typically consists of glycoprotein or glycopeptide enrichment, multi-
dimensional protein or peptide separation, tandem MS analysis and bioinformatic data 
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interpretation (Fig. 4) . A bottom-up approach (the analytes introduced into the mass 
spectrometer are peptides) is the most mature and most widely used approach in 
proteomics, most glycoproteomics workflows adapt it into the platform. Proteolytic 
digestion can be performed before or after enrichment step, with different rationales for 
each strategy. Major advantages of the former, enrichment at glycopetide level, include a 
lower possibility of nonspecific protein-protein interactions, a particular concern about 
glycoprotein capture efficiency 157. In contrast, enrichment at glycoprotein level can 
increase the sequence coverage from multiple peptides, which in turn facilitates 
glycoprotein identification . The separation procedures for glycoproteins or 
glycopeptides closely parallel the methodologies of mainstream proteomics. For 
glycoproteins, various fractional approaches, such as gel electrophoresis, multiple forms 
of chromatography (size exclusion, hydrophobic interaction, ion exchange, affinity 
chromatography), and chemical immobilization can be applied, depending on the specific 
workflow. For glycopetides, multidimentional liquid chromatography (LC) and capillary 
electrophoresis (CE) favor their separation 92'159. It is notable that the reliable analysis of 
MS data in glycoproteomic studies largely relies on available bioinformatics tools and 
glyco-related databases. The well-built proteomics softwares and databases allow the 
fully automatic assignment of fragment spectra of unknown peptides. Once protein 
sequence is identified, glycosylation status of the targeted proteins can be annotated by 
UniProt Knowledgebase (UniProtKB) database. The high-throughput tools for glycan 
characterization are evolving, and there are several software platforms such as 
GlycoMod, Cartoonist, GlycoPep DB, Peptoonist, and GlycoMiner that aid in the 
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Figure 4 The workflows of mass spectrometry-based glycoproteomic analysis. The 
pipeline parallels the mainstream of proteomic analysis, typically consisting of four 
steps: glycoprotein or glycopeptide enrichment, glycoprotein or glycopeptide 
separation, tandem mass spectrometric analysis, and bioinformatic data 
interpretation. After enrichment step, the workflow can split into three directions: 
intact glycoprotein or glycopetide analysis, glycan analysis and deglycosylated 
protein analysis. Adapted from Pan, S. et al. Mol Cell Proteomics. (2010). 
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however, are still primitive and require manual assignment and interpretation of the 
spectra. Data evaluation is therefore the bottleneck in this field. Looking back to the 
glycoproteomic pipelines, however, the key stages developed in recent years are the 
isolation of glycoproteins/glycopeptides and MS analysis of glycoproteomes. 
1.5.1 Enrichment of glycoproteomes 
Most mass spectrometers can only analyze samples in which the concentrations of 
protein cover three to four orders of magnitude, whereas the protein concentrations of 
biological samples span up to 10 to 12 orders of magnitude 160'I61. Naturally occurring 
glycoproteins are often present at low levels . In a complex protein digest, the signal 
intensities of glycopeptides are relatively low since the extensive microheterogeneity of 
the carbohydrate gives rise to different glycoforms, each present at a low concentration in 
the total peptide pool159. Moreover, glycopeptide signals generated by MS are often 
suppressed in the presence of other peptides, especially when the glycans are terminated 
with a negatively charged sialic acid moiety 159'162. Therefore, it is essential to enrich 
glycoproteins present in complex biological samples prior to MS analysis. Two main 
specific approaches for glycoprotein/glycopeptide enrichment have been widely applied: 
lectin affinity based enrichment methods and chemical-based methods. 
1.5.1.1 Lectin affinity chromatography 
Lectins are a class of proteins isolated from plants, fungi, bacteria, and animals that 
have a unique affinity towards carbohydrates . Lectin affinity enrichment is based on 
the specific and reversible binding interaction between a lectin and a distinct glycan 
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structure attached on a glycoprotein/glycopeptide. A variety of lectins can selectively 
bind to different oligosaccharide moieties. For example, concanavalin A (ConA) binds to 
high mannose, hybrid and biantennary complex-type N-glycans; wheat germ agglutinin 
(WGA) binds to N-acetyl-glucosamine and sialic acid; PNA is specific to T-antigen 
found commonly in O-glycans, and jacalin (JAC) specifically recognizes galactosyl 
(P—*1,3) N-acetylgalactosamine and O-linked glycans 164. Lectin affinity enrichment has 
been applied to enrich glycoproteins/glycopeptides with specific glycan attachment from 
plasma, serum, urine, tissue and other biological samples of human and mice through 
affinity chromatography and other methods . The typical lectin affinity 
chromatography protocol involves immobilization of lectins onto appropriate matrices 
such as agarose, silica or magnetic beads in a number of chromatographic formats 
including tubes, columns and microfluidic channels 165'166, whereby protein sample or 
trypsin-digested peptides are loaded by gravity-flow mode or low-pressure pumps. The 
unbound material is removed by washing the column while the captured 
glycoproteins/glycopetides are displaced from the column by elution buffer and identified 
by MS/MS 92'96. Multiple lectin species with distinct specificities can also be used in 
combination or in series to achieve a comprehensive enrichment of 
glycoproteins/glycopetides from complex biological mixtures 167'168. For instance, our 
group analyzed human plasma glycoproteins captured by various lectins and found a 
difference between sera from subjects with benign prostatic hyperplasia and prostate 
cancer or between sera from hepatocellular carcinoma patients and control subjects 169. 
Likewise, Hancock and co-workers developed a multilectin affinity column which 
combines ConA, WGA and Jacalin to perform a comparative glycoproteome analysis of 
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sera from breast cancer patients and normal controls. The authors identified 813 
glycoproteins in the serum samples including low-abundance components such as 
neuropilin-1 and pregnancy zone protein, and a number of proteins associated with lipid 
transport and cell growth were detected of changes in expression 167. In related work, 
Qiu and Regnier utilized an extended strategy called serial lectin affinity chromatography 
(SLAC) for fractionation and comparison of glycan site heterogeneity on glycoproteins 
derived from human serum through a series of different lectins with precisely elucidated 
binding specificities 170. To date, most of the work using lectin affinity for targeted 
glycoprotein enrichment has been limited to N-glycosylation because the binding 
specificity of lectin for O-glycosylation is less satisfactory. To overcome such caveat, 
efforts have been made using serial lectin columns of Con A and JAC in tandem to 
remove N-glycosylated species from a complex mixture with Con A before Jacalin 
selection, which greatly improves O-glycopeptide selection specificity and allow the 
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identification of a broad variety of O-glycosylated proteins from human serum 
Lectin-based affinity selection has successfully purified glycoproteins/glycopeptides with 
specific structures and identified some cancer biomarker candidates. Numerous 
advantages of the lectin affinity approach including its simplicity, cost-effectiveness, and 
capability of discrimination of glycan structures among different proteins and different 
glycoforms of the same protein. The weakness of this method does exist, such as the low 
binding affinity between oligosaccharides and most lectins (the affinity constant Ka in the 
low micromolar range), broad binding specificity for certain lectins, and the fact that the 
binding capacities of lectins are affected by the tertiary structure of glycoconjugate. 
These disadvantages could result in some of the proteins/peptides captured by the lectins 
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actually have no designated sugar and linkage that is ascribed to lectin affinity. In this 
case, further validation of the oligosacchride structure of candidate proteins by other 
methods will be required. 
1.5.1.2 Chemical-based Methods 
Alternative approach for glycosylation characterization stems from the exploitation 
of glycan chemical reactivity. Two similar approaches, including hyarazide and boronic 
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acid chemistry, capitalize on the c/s-diols present in monosaccharides 
Aebersold and colleagues et ah first described the use of hydrazide chemistry for the 
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N-linked glycoproteome examination . In this scheme, carbohydrate cz's-diols are 
converted to aldehydes by sodium periodate treatment, which sequentially react with the 
immobilized hydrazide groups. Bound glycoproteins are trypsin-digested in situ, and 
nonglycosylated /unbound peptides are removed by washing. Covalently coupled N-
linked glycoproteins are then released by PNGaseF treatment and analyzed by LC-
MS/MS. Using this approach, the author identified 145 glycopeptides from 57 unique 
proteins. The same technique was applied to examine the changes in the N-linked 
glycoproteome profile of sera from cancer-bearing and genetically identical normal mice 
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'. As a result, glycoproteome profiles of mouse sera from mice with cancer formed a 
distinct cluster from the profiles of normal mice as examined by unsupervised 
hierarchical clustering. Interestingly, when the entire proteome was examined, clustering 
analysis did not distinguish cancerous from non-cancerous sera samples, indicating the 
potential of glycoproteomics for cancer biomarker discovery. To date, hydrazide-based 
glycoprotein enrichment has been applied to various biological samples including cell 
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lines, body fluids, and tissues 175. For example, Soltermann et al. used the method to 
capture the glycoproteins from malignant pleural effusions of patients with lung cancer 
and controls . They were able to analyze the glycoproteins with low protein abundance 
([xg/mL to ng/mL) and identified several proteins associated with tumor progression or 
metastasis, e.g. CD44, CD166, CA-125, and lysosome-associated membrane glycoprotein 
2 (LAMP-2). In 2007 the Aebersold group published a revised version of this method 
that captured glycopeptides rather than intact glycoproteins, resulting in a claim of an 
improved glycopeptide recovery (>90%) I77. Later the same group further modified the 
protocol by substituting hydrazide functionalized beads with biotinylated hydrazide, and 
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employing streptavidin beads to capture extracellular N-glycoproteins on live cells 
By integrating of quantitative proteomic workflows such as stable isotope labeling by 
amino acids in cell culture (SILAC), the group demonstrated the ability to monitor 
abundant changes of the cell surface glycoproteome between related cell types and upon 
perturbation of a specific cell type. The main advantage of hydrazide approaches is the 
high specificity. The method simplifies the peptide mixture by only isolating and 
analyzing on average one to two deglycosylated peptides from each glycoprotein. This 
character also raised issues such as low sequence coverage and potential false 
identification for glycoprotein. Another drawback of hydrazide methods is limited to 
only the isolation of broad classes of N-linked glycoproteins/glycopeptides regardless of 
the glycan structure, therefore, lacking the specificity and selectivity required for analysis 
of cancer-related glycosylation changes. 
Recent studies have compared lectin affinity and hydrazide chemistry methods for 
performance and efficiency in isolating glycoproteins/glycopeptides from a complex 
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biological sample " . The two methods are complementary in enriching glycoproteins 
due to their different mechanisms and the structural and complexity of a specific protein. 
When both methods were applied, it significantly improves the coverage of the 
glycoproteome, resulting in an increased number of glycoproteins identified. 
The second chemical-based method takes advantage of the principle that 
heterocyclic boronic diesters formed by the reaction of geminal diol groups in glycans 
with boronic acid are stable under basic conditions. Using this method, Sparbier et al. 
recently showed boronic-acid-functionalized magnetic beads could be used to capture 
low-abundance glycoproteins from human serum 182. In addition, Xu et al. synthesized a 
novel diboronic acid functionalized mesoporous silica (FDU-12-GA) and successfully 
applied it for specific glycopeptide enrichment183. 
1.5.2 MS Analysis of Glycoproteomes 
Central to all glycoproteomic strategies is the MS analysis of glycopeptides 
generated by the digestion of glycoproteins. The complete analysis of glycosylation 
includes the determination of the peptide sequence, the carbohydrate structure (sequence, 
branching points, and heterogeneity), and the sites of attachment to the protein backbone. 
However, it is technically challenging to simultaneously perform such comprehensive 
analysis in a complex biological sample. First, compared to peptides, glycans exhibit 
poorer ionization efficiencies. Second, glycosidic bonds are highly labile under 
conventional fragmentation condition so that different instrument parameters are required 
for peptide backbone and glycan analysis 160. For example, quadrupole-TOF MS/MS has 
been widely used for analysis of N-glycopeptides. With low collision-induced 
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dissociation (CID) fragmentation energy, B-type and Y-type fragmentation ions of the 
glycan moiety prevails and information on the composition and sequence of 
carbohydrates is predominantly achieved (Fig. 5A). At higher collision energy, glycan 
ions are hardly observed any more. Instead, a series of y- and b-type peptide ions 
dominate the MS/MS spectra (Fig. 5B)184. Third, mixed fragmentation ion spectra from 
the peptide backbone, the carbohydrate group and the combinations of both, complicates 
the interpretation and may be sometimes misleading 153. As a standard setup, most 
workflows employ deglycosylation before MS analysis and splits glycosylation study into 
two directions: glycan analysis and peptide analysis (Fig. 4). To define the total glycan 
repertoire of the samples, specific released glycan populations are derivatised, 
fractionated, and analyzed by MS, as described below. For peptide analysis, a standard 
proteomic pipeline is applied. 
1.5.2.1 Glycan release from the glycoproteins/glycopeptides 
Glycans can be released from glycoprotein/glycopeptide by using enzymatic and 
chemical methods I 5 9 ' m . Each procedure has certain advantages and disadvantages. 
Enzymatic release is straightforward, but depending on the substrate specificity not all 
types of glycans are liberated. Chemical methods, can suffer from several limitations, 
such as low specificity, destruction of non-carbohydrate substituents and polypetide 
backbone, and modifications of the amino acid residues. Hence, some glycosylation 
information (extent and sites) is lost. 
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Figure 5 The nomenclature of peptide and glycan fragment ions from a tandem 
mass spectrum. (A) Peptide fragmentation notation. Fragments will only be 
detected if they carry at least one charge. If this charge is retained on the N 
terminal fragment, the ion is classed as either a, b or c. If the charge is retained on 
the C terminal, the ion type is either x, y or z. A subscript indicates the number of 
residues in the fragment. (B) Glycan fragmentation nomenclature. In this 
nomenclature, ions retaining the charge on the non-reducing terminus are named 
A, B and C, and the ions retaining charge on the reducing terminus are X, Y and 
Z. A and X correspond to cross-ring cleavages, whereas B, C, Y and Z correspond 
to glycosidic cleavages. Subscript numbers denote the cleavage position, starting 
at the reducing terminus for the X, Y and Z ions, and at the non-reducing terminus 
for the others. In the case of ring cleavages, superscript numbers are given to show 
the cleaved bonds. Adapted from Morelle, W. et al. Nat Protocols 2, 1585 (2007). 
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Intact N-glycans are usually released using enzymatic methods. Several enzymes 
are commercially available. The most popular is peptide N-glycosidase F (PNGase F), 
which cleaves the linkage between the core GlcNAc and the asparagine residues of all 
classes of N-glycans, with the exception of N-glycans containing a (al-»3)-linked fucose 
attached to the core GlcNAc residue 185. PNGase A, an enzyme found in almond 
emulsion, is sensitive to such PNGase F-resistant glycans . Two other enzymes for N-
glycans cleave the glycosidic bond between the two GlcNAc residues within the 
chitobiose core, differ in their substrate specificities: endoglycosidase D (endo D) 
releases all classes of N-glycans, while endo H selectively cleaves oligomannose- and 
hybrid-type structures . 
Since O-glycans lack a common core and may contain extended sugar chains, the 
enzymes are quite limited for their release. So far, only one enzyme, endo-a-N-
acetylgalactosaminidase (O-glycanase) targeted to the core 1 O-glycan structure, has 
been described . Most assays rely on chemical methods, such as 
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trifluoromethansulfonic acid, hydrazinolysis, P-elimination, and periodate oxidation 
Among these, P-elimination has been widely adopted. Reductive P-elimination uses 
NaOH to cleave the glycosidic bond and NaBFLj to reduce the free reducing end of the 
released glycan to an alditol form 189. This procedure has even been applied to 
glycoproteins separated on SDS-PAGE or blotted to PVDF membranes 190. However, the 
degradation of glycan at the high pH remains a problem. Another drawback is the 
reduction conversion prevents downstream glycan labeling and derivatization. A newly 
introduced method is ammonia-based non-reductive p-elimination. This method avoids 
these drawbacks and becomes the favored choice of many glycan analysis 191'192. 
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1.5.2.2 Mapping glycosylation sites 
In nature, not all potential glycosylation sites are actually occupied, and this 
characteristic (carbohydrate macroheterogeneity) also correlates the disease states 
Since direct intact glycopeptide analysis is difficult, one way around this problem is to 
remove the sugar chains and concomitantly incorporate a MS-amenable tag at the 
glycosylation sites. This strategy is particularly suitable for mapping N-glycosylation 
sites because PNGase F not only cleaves all types of N-glycans, but also possesses 
additional amidase activity during this process. Therefore, PNGaseF converts asparagine 
to aspartic acid during the cleavage reaction. This results in a 1-Da mass shift detectable 
by high resolution mass spectrometers 57. Stable isotope labeling with 180 during 
deglycosylation can further enhance the precise of site identification I94. The study of 
Kaji et al. represents one of the earliest efforts to apply this strategy to glycosylation 
analysis 195. The approach, termed isotope-coded glycosylation-site-specific tagging 
(IGOT), involves the capture of glycopeptides by lectin affinity chromatograph, followed 
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by PNGase F mediated incorporation of O into the N-glycosylation site and LC-
MS/MS analysis. Using IGOT, Kaji et al. identified 250 glycoproteins containing 400 
unique N-glycosylation sites. In a similar manner, Lewandrowski et al. coupled 
glycopeptides enrichment by lectin affinity chromatography and hydrazide beads with 
PNGase F deglycosylation to elucidate N-glycosylation sites on human platelet proteins 
. Over 70 glycosylation sites from 41 unique proteins were identified, and the majority 
had not been found in previous studies. 
Deglycosylation can also be used to determine O-glycosylation sites. A method, 
called BEMAD- |3-elimination followed by Michael addition with dithiothreitol (DTT) or 
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biotin pentylamine (BAP) yielded a unique tag on O-GlcNAc sites, allowing for 
enrichment via affinity chromatography as well as O-GlcNAc site identification by LC-
MS/MS . Three previously known and three new O-GlcNAc sites on Synapsin 1 were 
identified by this strategy. Vosseller et al. used BEMAD in a quantitative manner, where 
two samples were compared by using deuterated (d6) DTT for one sample and unlabled 
(dO) DTT for anther sample 198. Combining thiol chromatography and LC-MS/MS, the 
team could identify the BEMAD-labeled peptides, determine the sites of modification, 
and perform comparative quantitation of large number of O-GlcNAc proteins in one 
study. However, BEMAD is not specific for O-GlcNAc glycosylation. Any 
modification of serines and threonines that is susceptible to ^-elimination, such as O-
phosphorylation and O-sulfation, may be targeted by this method 197. Therefore, extra 
experiments are required to distinguish between O-glycosylation and other types of 
modification. 
1.5.2.3 Glycomics Methods 
Various MS techniques can be employed to decipher glycan structures. Matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) and electrospray 
inonization (ESI) are the two major inonization techniques used for glycan analysis. 
MALDI-MS, usually with a time-of-flight (TOF) analyzer, can be used for 
monosacchride composition analysis, in which predominantly singly charged ions are 
formed with very little fragmentation 159. The major advantage of MALDI-TOF-MS is 
the relative simplicity of instrumentation, the speed of analysis, the high mass range and 
the robustness towards low concentrations of contaminants. Together with automated 
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sample spotting, MALDI-TOF provides a valuable tool for high-throughout glycan 
profiling 199. However, this type of analysis only provides a snapshot of the most likely 
structures to be present, but does not allow the assignment of defined carbohydrate 
structures. ESI-MS is also applied to analysis of glycan mixtures. The advantage of ESI-
MS over MALDI-MS is that ESI-MS can be coupled with glycan separation column 
online to enhance the detection sensitivity. But ESI-MS usually generates doubly or 
triply charged ions, thus leading to high complex mass spectra when heterogeneous 
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mixtures of glycans are analyzed . 
Monosaccharide sequence, branching, and linkages can be determined through 
fragmentation. With CID function, ESI-MS/MS, and MALDI-TOF/TOF are currently 
the most frequently used methods, and both can be performed in the positive or in the 
negative ion mode . In general, glycans show two types of fragmentation: cleavage of 
the glycosidic bonds between the sugar rings and cleavage within the rings, so-called 
cross-ring cleavages (Fig. 5B). Glycosidic cleavage ions provide information on 
carbohydrate sequence and branching as well as non-carbohydrate substitutes, whereas 
the cross-ring cleavage ions are usually weak and may be used to define linkage 159. 
Recently, MSn-based analytical methods and new fragmentation technologies have been 
introduced to enhance the identification of structural isomers 200'201 . In the case of MS" 
in iron trap, sequential fragmentation of glycan was found to result in cross-ring 
cleavages that are highly informative in the determination of linkage position and 
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anomeric configuration identification 
Fragmentation analysis may be performed with underivatized or derivatized 
oligosaccharides. To ensure the highest sensitivity and to facilitate unambiguous 
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sequencing in MS/MS experiments, glycans are usually derivatized by permethylation, by 
methylesterification of sialic acids, or by reducing-end tagging before MS analysis 
Permethylation, which generates methyl derivatives for each free OH and NH group and 
esterifies the carboxy group in the sialyl residues, often prevails in glycomic analysis 
(especially in MALDI-MS analysis) with some benefits. First, the addition of methyl 
groups stabilizes sialylated structures and enhances overall sensitivity. Second, the 
hydrophobic nature of methylated glycans facilitates their separation from salts and other 
impurities that may affect the MS analysis. Third, the fragmentation of methylated 
glycans is more predictable than that of their native counterparts, leading to accurate 
structural assignments 204. A recent multi-institutional study by the Human Proteome 
Organization revealed that MALDI-TOF-MS of permethylated N-glycans is consistent 
and comparable to HPLC analysis of reductive animation derivatives for quantitation ' 
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1.5.2.4 Site-specific glycosylation analysis 
One of the disadvantages of glycoproteomic analysis involving glycan release is that 
this strategy does not allow site-specific glycosylation profiling. For this purpose, the 
direct analysis of the intact glycopeptides is required. As described earlier, CID ESI-
MS/MS, the most frequently employed technique, prefers to detect fragmentation ions of 
the glycan moiety other than that of peptide. This limitation can be overcome by using 
modern high-speed tandem MS (or MSn) technologies. So far, a variety of instruments 
with MS" capacity have been introduced, including ESI based ion trap (IT), quadrupole 
ion trap (QIT), Fourier transform ion cyclotron resonance (FT-ICR), ion trap/time-of-
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flight (IT/TOF) and quadrupole/time-of-flight (Q/TOF); MALDI based Q/TOF, 
quadrupole ion trap/time-offlight (QIT/TOF) and tandem time-of-flight (TOF/TOF) mass 
spectrometers 153. However, different instruments require pronounced distinct 
fragmentation conditions, and provide different structural information for glycopeptides. 
For instance, ESI-IT-MS, which allows repetitive ion isolation / CID fragmentation 
cycles, has been recently shown to characterize both peptide and glycan in a single 
measurement184. In this approach, the glycan fragment ions are collected at the first 
cycle (MS2 stage), and peptide fragment ions carrying a single sugar are selected and 
subjected to a second ion isolation/fragmentation, providing information on the peptide 
sequence and glycosylation site. This technology has successfully applied to determine 
the three glycosylation sites and the glycoform structures in Thy-1, a GPI-anchorred 
protein, and determined the structures of neutral and sialylated N-glycans attached to 
chicken egg yolk glycopeptides 201'206. 
The invention of new fragmentation technologies of electron capture dissociation 
(ECD) in FT-ICR-MS, can also facilitate the single amino acid localization of labile 
modifications . ECD produces cleavage specifically at N-aC backbone of the peptide 
leaving the modification intact on the peptide backbone, thus allowing unambiguous 
assignment of glycosylation sites in N- or O-glycopeptides 160. In quadrupole ion traps, a 
similar type of fragmentation method to ECD, electon transfer dissociation (ETD), has 
been recently introduced 208. ETD uses the same principle as ECD and can generate the 
cleavage of peptide backbone while preserving labile modifications. Together ECD/ETD 
with CID complementary information can be thus obtained. Hogan et al. demonstrate the 
power of combination of CID and ETD in a 3D-quadrupole IT for the structural 
49 
characterization of a tryptic N-glycopeptide 209. CID experiments on the multiply 
protonated glycopeptide ions yielded, almost exclusively, cleavage at glycosidic bonds 
and therefore glycan structure information. ETD reactions resulted in cleavage of the 
peptide backbone with no loss of the glycan structure. Although the application of this 
complementary multistage fragmentation technique has been limited to model 
glycopeptides, it holds promise for complete chemical structural determination of 
glycopeptides in complex biological mixtures. 
1.5.3 Concluding remarks 
In the past decade, MS in combination with modern enrichment methodologies has 
become one of the most powerful and versatile techniques for glycosylation analysis. 
There are different strategies for characterization of glycosylation at the levels of intact 
proteins, glycopeptides, and free glycans. Therefore, MS-based glycoproteome analysis 
is a multidimensional task. There is no universal method for rapid and reliable 
interrogation of the global glycoproteome. Research goals must dictate the best method 
or combination of methods for analysis. Sometimes other non-MS-based approaches 
such as HPLC glycan analysis, exoglycosidase digestion and chemical treatment are 
necessary for full structural elucidation of glycoproteome. 
Looking to the future, we envision that a large-scale, automatic, quantitative 
glycoproteomic analysis of complex biological samples is on the way, with the continued 
evolution in mass spectrometry, enrichment approach, separation technology and 
bioinformatics. There is no doubt that glycoproteomics is gaining momentum in 
biomarker research and clinical studies. 
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CHAPTER II 
DISSERTATION RATIONALE AND SUMMARY OF AIMS 
The objective of this research project is to develop a mass spectrometry-based 
glycoproteomic approach for the selective isolation and identification of cell-surface 
glycoproteins from cellular samples. This technology is applicable in the discovery of 
new glycoprotein biomarkers which are indicative of prostate cancer progression and 
metastasis. 
Prostate cancer is the most prevalent cancer and second leading cause of cancer 
deaths in men in the USA. Its lethality is mostly attributed to the primary tumor 
metastasizing to distant sites. Cancer metastasis involves a series of sequential steps 
consisting of tumor invasion at the site of origin, followed by intravasation, survival in 
the bloodstream or lymphatic glands, arrest in a distal organ, extravasation, and finally 
growth and angiogenesis in the distal organ. The steps requiring interactions between 
tumor cells and the surrounding microenvironment are tightly regulated by cell surface 
mechanisms. Most membrane and secretory proteins are glycosylated. Glycans not only 
affect properties of the proteins but also regulate diverse biological functions through 
particular protein-carbohydrate interaction. At the cell surface, sugar moieties of 
glycoproteins contribute to molecular recognition events involved in cancer metastasis. 
Aberrant glycosylation of cell-surface glycoproteins have been repeatedly reported in a 
wide variety of cancers, including prostate cancer, and are strongly correlated with cancer 
prognosis, metastasis, and the organ specificity of metastasis. It is possible that a portion 
of these alternatively glycosylated molecules can reach the bloodstream and serve as 
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early sentinels that enable cancer detection. In fact, many of the oldest and most widely 
used clinical cancer biomarkers are based on glycoproteins or glycans. It is clear that 
glycoproteins become important targets for the development of cancer biomarkers. With 
recent advances in carbohydrate chemistry, analytical technologies, and mass 
spectrometric instrumentation, glycoproteomics is rapidly emerging as a sub-field of 
proteomics with high biological and clinical relevance. By focusing on the glycoprotein 
subproteome, glycoproteomic analysis greatly reduces sample complexity, which 
significantly increases the detection sensitivity for low abundant proteins. Therefore, 
the central hypothesis of this dissertation is that cell-surface glycoproteins with 
aberrant glycosylation, mediating the key events during prostate cancer metastasis, 
can be indentified using mass spectrometry-based glycoproteomics. An improved 
understanding of metastasis-associated cell-surface glycoproteins may not only provide 
diagnostic and prognostic indicators, but also enable the discovery of new therapeutic 
targets for prostate cancer. The central hypothesis will be tested and our overall research 
objective will be achieved by addressing the following specific aims: 
Aim I. Characterization of cell-surface lectin-binding patterns associated with metastasis 
in human prostate cancer cells. This aim entails: 
A. Optimization of lectin staining protocols to cultured live cells. This includes 
finding the suitable cell dissociation methods which preserve both cell viability and cell-
surface carbohydrates, and determining optimal staining conditions that allows the 
reliable quantitation of lectin binding. 
B. A syngeneic PCa cell line model, which consists of human prostate cancer cell line 
PC3 and its two syngeneic variants with different metastatic potentials, will be profiled 
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by flow cytometry using a panel of lectins with different carbohydrate specificities to 
delineate the carbohydrate contents on their surface and identify different glycosylation 
patterns associated with metastasis. 
C. The cells described above will be stained by lectin cytochemistry and observed 
under confocal microscopy to evaluate the distribution of the existing sugars. 
Aim II. Targeted identification of metastasis-associated cell surface sialoglycoproteins in 
prostate cancer cell lines. This aim entails: 
A. Development of a targeted glycoproteomic methodology which combines advanced 
carbohydrate labeling technologies with high performance mass spectrometry to 
selectively identify cell-surface glycoproteins. 
B. Examining the sensitivity and specificity of cell-surface carbohydrate labeling by 
flow cytometry and confocal microscopy. 
C. Optimization of carbohydrate labeling protocol in order to maximize carbohydrate 
labeling performance and maintain cell viability. 
D. Evaluating the efficiency of glycoprotein capture and enrichment by our targeted 
glycoproteomic approach using in-blot streptavidin detection and ID-PAGE. The 
efficiency will be assessed by comparing the number and intensity of protein bands 
before versus after enrichment and labeling vs control groups. 
E. Application of the optimized glycoproteomic approach to our prostate cancer cell 
line model system and analysis of the recovered glycoproteins by LC-MS/MS in an 
attempt to identify panels of cell-surface glycoproteins as potential PCa metastatic 
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biomarkers. The identified proteins will be analyzed by bioinformation tools for their 
subcellular location and glycosylation status. 
F. Evaluating the utility of this methodology for glycoprotein isolation and 
identification from a mass spectrometric perspective. It will be completed by comparing 
glycoproteins identified by our targeted glycoproteomic with those from total cell lysate 
proteome as well as other publications. 
G. Functionally mapping differentially expressed glycoproteins between PC3 variants. 
Analysis will be performed by Ingenuity Pathway Analysis software across glycoprotein 
biomarker lists to prioritize biomarker candidates based on key biological characteristics 
and to shed light on mechanisms linking potential biomarkers to prostate cancer 
metastasis. 
Aim III. Verification of expression of cell-based biomarkers in clinical samples. This 
aim entails: 
A. Confirming the differential expression of glycoproteins identified in Aim II in our 
cell line models using available antibodies. We will employ several methods for analysis 
glycoproteins in cell lines. Initially, we will perform Western blot analysis on 
glycoprotein enriched fractions and whole cell lysates to determine their expression 
differences. Next, we propose to extend analysis of whole cell lysates to other prostate 
cancer cell line model systems. We will also examine candidate expression by antibody-
based flow cytometry and confocal microscopy. 
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B. Characterization of glycosylation status of biomarkers in prostate cancer cells. The 
specific glycosidases and glycosylation inhibitors will be employed to investigate the 
carbohydrate residues on the biomarkers. 
C. Verification of expression of biomarkers in clinical samples. Using a cohort of 
prostate cancer patient samples including tissues and Expression Prostate Secretion (EPS) 
urines with different risk factors but no extra-prostatic disease at the time of their 
prostatectomy, the clinical utility of biomarkers and their expression will be compared by 
immunohistochemistry/immunocytochemistry and/or Western blot techniques. 
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CHAPTER III 
AIM I: CHARACTERIZATION OF CELL SURFACE LECTIN-BINDING 
PATTERNS ASSOCIATED WITH METASTASIS IN HUMAN PROSTATE 
CANCER CELLS 
3.1 Introduction ' 
Prostate cancer is the most prevalent cancer and second leading cause of cancer 
deaths in men in the USA3. It affects men after middle age, and accounts for 
approximately 30% of all male malignancies . In nature PCa is pathologically and 
clinically heterogeneous ranging from indolent, low grade disease to aggressive high 
grade disease which frequently metastasizes. Its prognosis rate varies greatly for patients 
with different clinical stages and pathological grades. Despite early detection through 
testing for serum PSA and the efficacy of surgery and radiation therapy for treating 
clinically localized PCa, about 30% of men with PCa will experience relapse and develop 
a PSA recurrence within 10 years after radical prostatectomy 210. Metastatic PCa claimed 
• 911 
the lives of 28,660 American men in 2008 . PCa metastasis has organ tropism. 
Bubendorf et al. examined metastatic patterns of PCa from a postmortem study of 1,589 
patients and reported hematogeneous metastases were present in 35% patients, with the 
most frequent locations being bone (90%), lung (46%), liver (25%), pleura (21%), and 
adrenals (13%)212. The mechanisms responsible for this phenomenon remain largely 
undefined. Most advanced or metastatic PCa show an initial response to androgen-
ablation therapy in up to 80% of cases 213, but ultimately it progresses to hormone 
refractory prostate cancer (HRPC) after 18-24 months 214. At this stage, despite castrate 
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levels of testosterone, the tumor will become independent of androgens resulting in death 
within a few years from diagnosis. Moreover, choices of therapeutic regimens for late 
stage patients are very limited and the major goal of the treatments is just to improve the 
quality of life. Eventually, these patients die 215'216. 
The clinical fate of PCa patients is ultimately determined by the primary tumor's 
malignant potential, which is controlled by many factors: (i) apoptotic susceptibility of 
tumor cells; (ii) matrix-destroying protease activity; (iii) adhesion of tumor cells to target 
cells, particularly to platelets, leukocytes, and microvascular endothelia cells; (iv) the 
ability to extravasate into the target organ parenchyma; (v) the capacity to evoke 
angiogenesis in tumor cell surroundings; (vi) cross-talks with the host microenvironment 
1X1
. The underlined mechanisms of each determinant are functionally maintained by a 
combination of molecules, each of which can be affected directly or indirectly by N- or 
O-linked glycosylation . Glycosylation is critical in determining a protein's stability, 
conformation, folding, and binding affinity for other molecules 85. Moreover, glycsns per 
se are adhesion molecules directly involved in cell recognition events through protein-
carbohydrate and carbohydrate-carbohydrate interactions . In mammals, most secreted 
and membrane proteins are glycosylated. Given their important location and interactive 
roles in biological and pathological processes, aberrant cell surface glycosylation, 
including altered sialylation and fucosylation, polylactosaminylation, higher-ordered N-
linked branching, and truncated O-linked glycans, is often observed in a variety of 
tumors, and are strongly correlated with cancer prognosis, metastasis, and the organ 
specificity of metastasis ' 10°. Nevertheless, the expression of cell surface carbohydrates 
is cell-type specific and developmentally regulated by the activity of glycosyltransferases 
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219
'. Examining the relationship between cell surface oligosaccharide structures and 
metastatic phenotype variants within a defined tumor-cell population has been mostly 
done in breast cancer " . In PCa, the exact nature of glycosylation changes 
accompanying metastasis is ill defined. Characterizing such patterns is thus critical both 
to understanding their role in PCa progression as well as to provide diagnostic tools and 
therapeutic targets to help clinical PCa management. 
Specific carbohydrate-binding ligands such as lectins have proven to be invaluable 
994 
tools for the analysis of complex glycoconjugates . These proteins, derived from non-
99S 
immune origin, recognize and bind to specific carbohydrate structural epitopes . In 
most previous studies, lectins were tagged with a fluorophore or enzyme and used for 
histochemical analysis of formalin-fixed paraffin embedded (FFPE) tissues 226. Although 
such analysis is very powerful, it does suffer from some limitations. First, histological 
processing of tissues can render carbohydrates inaccessible due to protein denaturation 
and glycolipid losses 226. Second, visual assessment of such stained samples is subjective 
and probably with considerable error, particularly for complex samples with 
7 9 ^ 
heterogeneous staining patterns . Third, the quantitation across multiple areas of 
99"i 
tissues is difficult and fairly lengthy . In contrast, lectin flow cytometry offers several 
advantages. It can perform on a large number of live cells, and the extent of lectin 
binding can be expressed in a defined quantitative fashion within a short period. 
In Aim I we refined and optimized a lectin staining protocol for prostate cultured 
cells with emphasis on compatibility with flow cytometic analysis. We then applied this 
approach to delineate the carbohydrate alterations on a human syngeneic metastatic PCa 
cell line model by using a battery of lectins with defined specificities. Additionally, we 
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evaluated the distribution of the existing sugars over PCa cell surface with lectin 
cytochemistry. 
3.2 Materials and Methods 
Materials — Dulbecco's modified Eagle media (DMEM), RPMI 1640 medium, 
penicillin, streptomycin, and fetal bovine serum (FBS) were from Invitrogen (Carlsbad, 
CA, USA). Antibiotics-antimycotic, propidium iodide, nonenzymatic dissociation buffer, 
fluorescein conjugated streptavidin (streptavidin-FITC), 4-12% NuPAGE® Bis-Tris gels, 
and lithium dodecyl sulfate (LDS) buffer were from Invitrogen. Halt™ protease inhibitor 
cocktail was from Pierce (Rockford, IL, USA). Cell proliferation reagent WST-1 {4-[3-
(4-iodophenyl)-2-(4-nitrophenul)-2H-5-tetrazolio]-l,3-benzene disulfonate} was from 
Roche (Indianapolis, IN, USA). Prestained protein standard was from Bio-Rad 
(Hercules, CA, USA). Murine anti-a-tublin mAb was provided by Sigma (St Louis, MO, 
USA). Murine anti-androgen receptor mAb was from BD PharMingen (San Diego, CA, 
USA). Rabbit anti-PSA polyclonal antibody was from Dako (Carpinteria, CA, USA). 
IRDye 700 or IRDye 800 conjugated secondary reagents were from Li-COR Biosciences 
(Lincoln, PA, USA). All chemicals were of analytic grade and were purchased from 
Sigma. 
Lectins — Seven biotin- or FITC-conjugated lectins were purchased from EY 
Laboratories (San Mateo, CA, USA) or Vector Laboratories (Burlingame, CA, USA). 
Common name, abbreviation, source, and normal sugar specificity were as follows: 
anguilla anguilla lectin (AAA) from Fresh water eel: fucose in an (a-1,6) linkage; 
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concanavalin A agglutinin (ConA) from jack bean seeds: oc-mannose/ a-glucose; Helix 
pomatia lectin (HPA) from Edible snail: N-acetyl-galactosamine (GalNAc); Umax flavus 
lectin (LFA) from Garden slug: sialic acid; maackia amurensis lectin (MAL) from 
Maackia amurensis seeds: sialic acid in an (a-2,3) linkage; sambucus nigra lectin (SNA) 
from elderberry bark: sialic acid in an (a-2,6) linkage; wheat germ agglutinin (WGA) 
from Triticum vulgaris: sialyloligosaccharide/N-acetyl-glucosamine (GlcNAc). 
Cell Lines — PC3-N2 and PC3-ML2, two sublines of PC3 prostate cancer cells 
(originally obtained from a skeletal metastasis in a patient with primary prostate 
adenocarcinoma) were kindly provided to us by Dr. Stearns' group at Drexel University. 
The N2 and ML2 cell lines have been developed on the basis of their invasiveness in 
vitro and metastatic potential in vivo. Both cells were tumorigenic when injected 
subcutaneously in SCID mice. However, N2 cells were unable to migrate through a 
Matrigel-coated membrane in vitro as well as induce metastases following tail vein 
injections in SCID mice, whereas ML2 cells were highly invasive in vitro and induced 
skeletal metastases in more than 80% of cases 227. Human prostate bone metastasis PC3, 
prostate carcinoma lymph node metastasis LNCaP, and prostate carcinoma brain 
metastasis DU145, and HPV-18 immortalized prostate epithelial cell line RWPE-1 were 
obtained from the American Type Culture Collection (ATCC). PC3 and its sublines were 
routinely cultured in growth medium (DMEM medium, 10% FBS, 1% Antibiotic-
antimycotic) at 37°C in a humidified atmosphere containing 5% carbon dioxide. DU145 
and LNCaP cells were cultured in the growth medium and passaged according to the 
manufacturer's instructions. 
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Cell Proliferation Assay — Cells were seeded into 96-well microplates under 200 |j.l/well 
complete medium. At the indicated time point, WST-1 reagent was added to 10% per 
well and incubated for 2h at 37°C in 5% CO2. The absorbance was measured at 450 nm 
by ELISA reader (ELx800, Bio-Tek Instruments, Winooski, VT, USA). 
Flow Cytometric Assessment of Lectin Binding— Cells were grown in 150-mm dishes to 
90% confluence and detached by nonenzyme dissociation buffer at 37°C. After washing, 
0.5 xlO6 cell suspension was incubated with lectins in appropriate buffers and at 
optimized concentrations for 30min at 4°C. Then cells were washed three times with 
PBS/TBS and resuspended in 0.5 ml PBS/TBS. Before subjected to flow cytometry, they 
were counterstained with 1 fig/ml PI for a minimum of 20 min at 4°C. For biotin-labeled 
lectins, streptavidin-FITC staining was applied (4°C, 30 min) before PI staining. A flow 
cytometer (FACScalibur, BD Biosciences, San Jose, CA) equipped with 488 nm 
excitation source was used for data collection. The fluorescent signal of FITC and PI was 
recorded in FL1 (525 nm band pass) and FL2 (585 nm band pass), respectively. Control 
samples including unstained cells, lectin-stained cells only and Pi-stained only from each 
cell line, were prepared for flow cytometric compensation setting. Flowjo software (Tree 
Star Inc., Ashland, OR, USA) were employed for data analysis. To address the 
specificity of lectin binding, the inhibitory sugar was preincubated with lectin overnight 
and mixture was used for lectin staining. 
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Lectin Cytochemistric Analysis — Cells were seeded onto 6-well plates containing glass 
coverslips and cultured in growth medium up to 80% confluence. After rinsing with ice 
cold PBS/TBS three times, cells were incubated with lectins in appropriate buffers and at 
indicated concentrations for 30 min at room temperature in dark. Then cells were fixed 
with 2% paraformaldehyde (PFA) in PBS/TBS for 12 min at room temperature. For 
biotin-labeled lectins, streptavidin-FITC staining was applied for 30 min at 4°C. Finally 
coverslips were mounted to the slides with VectorShield medium (Vector Labs, 
Burlingame, CA, USA), and sealed with nail polish. Fluorescent images were examined 
and captured under a confocal microscope (Carl Zeiss, Thornwood, NY, USA). 
Western Blot Analysis — Whole cell lysates were collected in the M-PER lysis buffer 
containing lx protease inhibitor cocktail. Protein concentration was measured by the 
BCA protein assay. Protein samples (20 ug each) were separated by electrophoresis 
through 4-12% SDS-PAGE and then transferred to Immobilon-FL PVDF membranes 
(Millipor, Billerica, MA, USA). Prestained protein standard was used to assess transfer 
efficiency and to determine the size of blotted proteins. Membranes were blocked in 
LiCor blocking buffer (Rockland Immunochemicals, Gilbertsville, PA, USA) diluted 
with PBS (1:1), and then incubated with anti-PSA primary antibodies (1:1000) or anti-
androgen receptor (1:3,000) overnight at 4°C. Following extensive washing, membranes 
were incubated with species-specific IRDye700 or 800-conjugated secondary antibodies 
(goat anti-rabbit, 1:15,000; goat anti-rabbit, 1:15,000) for 1 h at room temperature, and 
visualized with a LiCor Odyssey infrared imager (LiCor, Lincoln, NE, USA). Consistent 
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protein loading was determined by reprobing membranes stripped in Restore Western 
blot stripping buffer with anti-a-tubulin antibody (1:4,000). 
3.3 Results 
3.3.1 The properties of prostate cancer PC3 cells and its sublines 
To study cell surface glycosylation changes accompanying metastasis, we need a 
suitable model which accurately recreates the histopathological metastatic process 
observed in humans. Clinically, the lethal phenotypes of human PCa are characterized by 
their progression to HRPC and their propensity to form osseous metastases. Here we 
employed a syngeneic PCa cell line model which consists of two sublines derived from 
the widely used PCa PC3 cell line. PC3, originated from a patient bone lesion, is an 
androgen-independent cell line. PC3-N2 (non-metastatic) and PC3-ML2 (metastatic) was 
previously selected for their ability to both invade in vitro and generate skeletal 
metastases in SCID mice in vivo . To better support our following experiments, we first 
tested two basic characteristics of PC3 variants: proliferation and androgen dependence. 
Proliferation of PC3, N2, and ML2 cells was assessed using the cell proliferation reagent 
WST-1 (Fig. 6A). Compared to parent PC3 cells, N2 cells grow slower and ML2 faster. 
Immunoblot analysis of total cell lysates shows that these cells don't express androgen 
receptor and androgen-regulated gene products such as PSA, therefore verifying that they 
are androgen-independent cell lines (Fig. 6B). 
3.3.2 Optimization of cell dissociation methods 
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Figure 6 The properties of prostate cancer PC3 cell line and its sublines. (A) WST-
1 assessment of cell proliferation of PC3, N2 and ML2 cells. (B) Western blot 
analysis of AR and PSA expression in PC3, N2, and ML2 total cell lysates. 
Androgen-dependent cell line LNCaP and androgen refractory cell line DU145, 
were included as positive and negative controls, a-tublin was used as a loading 
control. 
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Since PC3 cells and its sublines are adherent cells, and traditional cell dissociation 
method, trypsinization, cleaves or strips some cell surface glycoproteins, we need to find 
the best method to dislodge the cells from the plastic flask surface. Five cell detachment 
methods (Fig. 7) were compared on ML2 cells. They are enzyme preparation, trypsin-
EDTA; mechanical disruption, gentle scraping; and three nonenzymatic reagents, 
commercial dissociation buffer, EDTA only, and sodium citrate only. The following 
three parameters were concerned: (1) cell dissociation efficiency; (2) cell viability; (3) 
cell surface carbohydrate retention. As expected, trypsinization lifted cells very 
efficiently with only 5-10 min incubation. In contrast, nonenzymatic reagents needed 20-
30 min and gentle tapping of the flask to take effect. Cells removed by these three 
preparations resulted in some cell clumping, but all formed a single cell suspension after 
repeated pipetting. The integrity conservation of the dissociated cells was compared by 
flow cytometric analysis (Fig. 7A). Scraping pronouncedly changed cell light scatter 
properties with more than 50% cell debris generated, while other methods could keep cell 
physically intact. To assess cell viability, we incubated the dissociated cells with 
propidium idodide (PI) and discriminated viable cells by flow cytometric analysis. As 
shown in Figure 7B, trypsinization led to minimal cell death (about 9.5%) whereas cell 
scraping damaged cells the most (>50% cell death). Three nonenzymatic preparations 
resulted in different cell viability rate, and commercial buffer had the advantage over 
EDTA and sodium citrate both in terms of percentage of the main population (intact 
cells) and the total population (all detached events, including debris). These results 
agreed with trypan blue exclusion counts shortly after dissociation (data not shown). For 
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Figure 7 Flow cytometric assessment of different cell dissociation methods. (A) Cell 
light scatter properties of ML2 cells dissociated by different methods. A polygon 
delimits the main population of intact cells, whereas events outsides of main 
population consist of aggregated cells and cellular debris. Number indicates main 
population as a percentage of total events. (B) Cell viability within the main 
population. Positive PI staining indicates dead cells. Numbers indicate percentages of 
live (PI-) cells within main population. (C) Effect of dissociation methods on 
carbohydrate retention. ML2 cells were dissociated by different methods, incubated 
with FITC- or biotin-conjugated lectins (LFA, SNA, MAL, WGA), followed by 
streptavidin-FITC (only for biotin-lectins), and analyzed by flow cytometry. PI 
staining was used to gate live cells. Histogram for each lectin is shown by red line and 
nonspecific staining (unstained cells) is overlaid in grey line for comparison. 
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for sialic acid to measure cell surface carbohydrate levels on living cells. Flow cytometry 
data revealed a homogenous fluorescent staining for all examined lectins on cell surface. 
Scraping compromised most cell surface carbohydrates and trypsin selectively ate up 
some sugars such as WGA (Fig. 7C). Sodium citrate also exhibited poor carbohydrate 
retention. Conversely, commercial dissociation buffer preserved all carbohydrates best 
followed by EDTA procedure. 
On the basis of above results, we concluded that the commercial dissociation buffer 
provides the best balance of dissociation efficiency, viability, and cell surface 
carbohydrate retention. The reagent will be used for the following experiments in this 
study. 
3.3.3 Optimization of lectin staining protocols 
Because of their extensive availability and the wide spectrum of carbohydrates that 
may be specifically bound, lectins have become essential reagents for glycosylation 
analysis. They bind non-covalently to carbohydrate residues and can be used in the same 
types of application as monoclonal antibodies. However, lectin binding has different 
characteristics. For example, some lectins at high concentration can induce apoptosis, 
resulting in global changes of cell surface glycosylation 228. In addition, some lectins 
require divalent cations (Ca2+ and Mg2+) to take effect while the binding of other lectins 
990 
may be interfered by phosphate ions . On the other side, cell surface glycans are 
910 
expressed in a cell type and lineage-specific manner . Therefore, when applying lectin 
staining to cultured live cells, we need to work out a lectin binding protocol that allows 
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the reproducible determination of carbohydrate moiety profiles, as well as reliable 
quantitation of lectin binding. 
A blocking reagent contains a high concentration of immunoglobulin and is often 
used in immunostaining to minimize the non-specific antibody-base staining. But for 
lectin staining, how to decrease the non-specific binding is largely unknown. Here we 
compared three different blocking buffers with respect to their preservation of cell 
viability and SNA binding to non-malignant prostate RWPE-1 epithelium cells (Fig. 8). 
Although blocking buffers either with 1% FBS or 1% BSA can effectively protect the cell 
death arisen from the high concentrations of SNA (Fig. 8B), they also significantly 
decreased cell surface fluorescent signals (Fig. 8A). It is not surprising since serum 
contains a lot glycoconjugates which can competitively inhibit lectin binding. BSA is not 
a glycoprotein, but it is often contaminated by serum glycoproteins during its commercial 
preparations. 
Next we investigated the effect of two different buffers, PBS and TBS containing 
9 + 9-4-
divalent cations Mg and Ca , on lectin binding and cell death. As shown in Figure 
9A, the addition of divalent cations induced RWPE-1 cell death as well as loss of MAL 
binding. Similar results have been obtained for lectins SNA, WGA, and AAA. There is 
no obvious change for ConA regarding binding signal and cell death between the two 
buffers (Fig. 9B). Since an improvement in binding was not gained in most cases, the 
addition of divalent cations is not recommended for most lectins. 
As cell surface glycosylation is involved into cell-cell contact, the cell confluence 
status may influence the expression level of carbohydrate. Figure 10 summarized the 
relationship of SNA binding and the degree of PC3 cell confluence. In general, cells with 
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Figure 8 Comparison of different blocking buffers on SNA binding. Prostate 
epithelium RWPE-1 cells were stained with 2.5-50 ug/ml SNA-FITC (A) and PI (B) 
after blocking with three different buffers: PBS, 1% BSA/PBS, 1% FBS/PBS, and 
analyzed by flow cytometry. PI staining was used to gate live cells. Top panels: FITC 
(A) or PI (B) fluorescence histogram overlays of cell populations blocked with 
different buffers. Unstained cell and cells stained only with PI are also included as 
controls. Bottom panels: comparison of Mean fluorescence intensity (MFI) of SNA 
binding (A) and cell death (B) with different blocking buffers. 
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Figure 9 The effect of different staining buffers on lectin binding. Prostate non-
malignent epithelium RWPE-1 cells were stained with 100 ug/ml MAL (A) and 20 
Hg/ml ConA (B) in different buffer: PBS and TBS + CaCl2+ MgCl2, and analyzed 
by flow cytometry. PI staining was used to gate live cells. Dual parameter correlated 
dot plots display the fluorescence of FITC and PI. MFI of lectin staining for PI-
population are indicated. Numbers at corner mean percentages of main population 
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Figure 10 The effect of cell confluence on SNA staining. PC3 cells with different 
confluence were stained with 10 ug/ml SNA in PBS, and analyzed by flow cytometry. 
PI staining was used to gate live cells. Left panel: FITC fluorescence histogram 
overlays of cells with different confluence rates. Nonspecific staining (unstained 
cells) is overlaid in grey filled line for comparison. Right panel: mean fluorescence 
intensity (MFI) of SNA binding upon different cell confluence rates. 
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low confluence showed lower fluorescent intensity than cells with higher confluence. 
However, the intensity was no different after cells reached 60% confluence. 
Some lectins such as SNA, WGA and ConA are potential inducers of apoptosis 
The optimal concentration of these lectins which can best distinguish positive from 
negative cell population and cause minimum cell death was determined. Figure 11 
showed the example of SNA dose curve. The short incubation of PC3 cells (30 min at 
4°C) with a series of diluted SNA generated a dose-dependent increase in fluorescent 
signal; however, it also produced dose-dependent cell agglutination and cell death. 
Balance of the signal intensity and cell death, SNA at 10 ug/ml was chosen for the 
subsequent flow cytometric experiments. By contrast, some lectins such as LFA had 
minimal cytotoxic effects on cells (Fig. 12). So the optimal concentrations for these 
lectins (100 ug/ml for LFA) were based on their best capacity to tell positive population. 
The same procedures were performed to optimize conditions for other lectins used in this 
study, and their optimal working concentrations and buffers were indicated in Table 4. 
Lastly, we examined the specificity of lectin binding by their hapten sugars. Five 
free sugars were chosen to for the examined lectins: lactose (SNA, MAL), GlcNAc 
(WGA), fucose (AAA), GalNAc (HPA), and mannose (ConA). Representative 
histograms of the various blocking experiments can be seen in Figure 13. Preincubation 
of lectin with their corresponding competitive sugars exclusively blocked or reduced 
lectin binding (p<0.05, range 1.4-74.4 fold), confirming the binding specificity of these 
lectins. However, the degree of reduction was various. For instance, 0.2 M GalNAc 
almost completely reduced the fluorescence to the auto fluorescence level while the same 
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Figure 11 Titration of SNA against PC3 cells. PC3 cells were stained with 5-100 
|j.g/ml SNA-FITC (A) in PBS and PI (B), and analyzed by flow cytometry. PI staining 
was used to gate live cells. Top panels: FITC (A) or PI (B) fluorescence histogram 
overlays of cell populations with different concentrations of SNA. Unstained cell and 
cells stained only with PI are also included as controls. Bottom panels: mean 
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Figure 12 Titration of LFA against ML2 cells. ML2 cells were stained with 5-100 
ug/ml LFA-FITC (A) in TBS + CaCl2+ MgCl2 and PI (B), and analyzed by flow 
cytometry. PI staining was used to gate live cells. Top panels: FITC (A) or PI (B) 
fluorescence histogram overlays of cell populations with different concentrations of 
LFA. Unstained cell and cells stained only with PI are also included as controls. 
Bottom panels: mean fluorescence intensity (MFI) of LFA binding (A) and cell 
death (B) upon different LFA concentrations. 
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Table 4 Lectins and the optimized protocol for flow cytometric analysis 






a2-6 sialic acid 































LFA, Limax Flavus Agglutinin; SNA, Sambucus Nigra Agglutinin; MAL, Maakia Amurensis 
Lectin; WGA, Wheat Germ Agglutinin; AAA, Anguilla Anguilla Agglutinin; HPA, Helix 
Pomatia Agglutinin; ConA, Concanavalin A. NANA, N-acetyl neuraminic acid; GlcNAc,N-
acetyl-D-glucosamine; GalNAc, N-acetyl-D-galactosamine. Glc, D-glucose; TBS, Tris buffered 
saline; PBS, phosphate buffered saline. 
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Figure 13 The carbohydrate specificities of lectin binding. (A-F) Lectins were 
preincubated with their corresponding inhibitory sugars for overnight. The mixtures 
or lectins only were incubated with PC3 cells in PBS or TBS + CaCl2+ MgC^. The 
lectin binding signal was analyzed by flow cytometry. PI staining was used to gate 
live cells. Fluorescence histograms of cells stained with lectin only (red), lectin+ 
inhibitory sugar (blue), and unstained (gray), are overlaid. 
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the application of optimal concentrations as well as binding conditions of inhibitory 
sugars. 
3.3.4 Flow cytometric assessment of lectin-binding profiles 
Having established an optimized lectin staining protocol (Table 4), we next 
compared the cell surface glycosylation profiles among PC3 and its metastatic variants by 
lectin flow cytometric analysis. Mean fluorescent intensity (MFI) of living cells (PI-) 
was used to quantitate lectin binding. The results of cell-binding assays for each of the 
three cell lines on the panel of 7 lectins are shown in Figure 14. In general, control 
unstained samples emitted very low levels of fluorescence (MFI average: PC3 6.63; N2 
4.91; ML2 6.54). Four lectins (SNA, MAL, ConA, and WGA) showed very strong 
binding compared to control samples (p<0.05). The MFI for the remaining lectins was 
low, but still significantly different (p<0.05) from control value. Among cell lines, 
distinct binding between N2 and ML2 cells was observed for sialic acid. N2 cells 
showed higher binding than ML2 cells for SNA (2.14 fold, p<0.05) which recognizes a2-
6 linked sialic acid, and for WGA (1.25 fold) which has the carbohydrate specificity for 
sialyloligosaccharide/ GlcNAc. In terms of MAL which binds preferentially to a2-3 
linked sialic acid, ML2 cells showed a little higher binding (1.2 fold) than N2 cells, but 
the difference was not significant. Neither was those detected between cell lines for other 
lectins. 
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Figure 14 Cell surface carbohydrate profile analysis by lectin flow cytometry. PC3, 
N2, and ML2 cells were stained with seven lectins with different carbohydrate 
specificities under the optimal experiment conditions, and analyzed by flow 
cytometry. PI staining was used to gate live cells. Mean fluorescence intensity (MFI) 
of each lectin binding for three PCa cell lines was compared. Error bars represent the 
standard deviation of three independent experiments. Mann-Whitney U test was used 
to ascertain statistical differences. * denotes significant difference (p<0.05). 
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The spatial distribution of lectin binding was revealed by confocal microscopy. 
Because cells need to be fixed in this experiment, we first assessed the effect of PFA 
fixation on lectin binding. Lectin binding on postfixed cells (staining before fixation) 
was compared with that on prefixed cells (staining after fixation). In general, the staining 
patterns under two different experimental conditions were close except that prefixation 
resulted in loss of LFA binding to all three cell lines (data not shown). In fact, It was 
documented that fixation can change lectin binding patterns of cells. Unfavorable 
combinations of fixatives and buffers can cause a loss of more than 90% bound lectin 231. 
For example, a loss of lectin mistletoe lectin-1 binding was observed during lectin 
cytochemistry analysis of fixed colon cancer HT 29 cells . Based on these findings, 
postfixation of cells is more effective and we applied it for all coverslip staining. 
Under confocal microscopy, similar subcellular staining patterns were observed 
across three cell lines for all lectins (Fig. 15). Binding was typically seen along the cell 
membranes, with long or short cell surface projections. In very few cells, granular uptake 
of the glycoconjugate complexes into the cytoplasm could be visualized as a granular 
fluorescence. WGA and ConA displayed the brightest fluorescence over the entire cell 
membrane, while SNA and MAL exhibited moderate signals. The binding sites for 
lectins LFA, AAA, and HP A, which showed low fluorescent intensities in flow analysis, 
were also evident during microscopic evaluation except LFA, which gave a totally 
negative binding to ML2. Due to the variations in capture conditions, we didn't 
quantitate the staining intensity across cell lines. But above results confirmed that lectin 
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Figure 15 Cell surface carbohydrate expression analyzed by lectin cytochemistry. 
PC3, N2, and ML2 cells were cultured on coverslips in 6-well plates. They were 
stained with seven lectins with different carbohydrate specificities under the optimal 
experiment conditions, fixed, and examined by cofocal microscopy. 
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3.4 Discussion 
In this aim we presented a study using a panel of lectins to characterize carbohydrate 
expression patterns on PC3 and its metastatic variants. Our approach was first to 
delineate the types and levels of carbohydrates using flow cytometry, and second to 
localize specific carbohydrate residues with respect to the subcellular regions. Because 
several factors such as blocking buffer, cell confluence, and specificity of lectin are 
important considerations, an optimized protocol and suitable controls were included to 
verify accurate data interpretation. For flow cytometry, counterstaining with an 
impermeable nuclear stain, propidium iodide, and analyzing the fluorescence signals of 
intact cells ensure that lectin binding is localized to the cell surface rather than 
intracellular sites. For microscopic analysis, fixation performed after lectin binding 
avoids the interference by various artifacts. By adopting these strategies, we have 
evaluated the carbohydrate profiles on PCa cells and identified the specific carbohydrates 
associated with PCa cell metastatic potentials. 
Flow cytometry assessment of lectin binding revealed that cell surface carbohydrate 
of PC3 and its variants is composed mainly of glycoconjugates containing a-mannose/a-
glucose, GlcNAc, and sialic acid as terminal saccharides, based on the high fluorescence 
intensity values obtained from SNA, MAL, ConA, and WGA. These results were not 
surprising since a-mannose/a-glucose and GlcNAc are present in all N-linked glycans, 
and sialic acid is capped on both O- and N-linked glycans. Few residues of fucose (a-1, 6 
linkage) and GalNAc were detected by flow cytometry, suggesting that these 
carbohydrates were minor. But another possibility is that these sugars are present on the 
core structure of glycans and masked by the terminal sialic acid . In this case, 
81 
neuraminidase treatment in combination of lectin flow cytometry can uncover more 
binding sites and reveal their real abundance. It is noteworthy that lectin LFA 
recognizing the same broad carbohydrate group as SNA, MAL, and WGA, however, 
provided the very low fluorescent intensity. This apparent conflict in carbohydrate 
identification can result from several factors affecting binding site access, which include 
subtle differences in binding specificity within carbohydrate groups, as well as steric 
configurations of lectins 225. In addition, the differences in fluorescence conjugated to 
each lectin also influence lectin performance. Therefore, a diversity of glycoconjugates 
containing unique sugar structures or sequences may be present on PCa cell surface, and 
a wider spectrum of reliable lectins is necessary to properly characterize glycan 
composition. 
The most remarkable difference in cell surface glycan composition among three cell 
lines was observed for a2-6 linked sialic acid. SNA binding was greatly decreased in 
metastatic ML2 cells compared to non-metastatic N2 cells, suggesting a possible negative 
role for the expression of a2, 6-linked sialic acid in metastasis. Sialic acids are nine-
carbon monosaccharide typically terminating the out ends of cell surface glycan chains. 
They are greatly diversified and more than 50 structural variations exist in nature m ' 2 3 4 . 
Increases in cell surface sialylation are often linked to transformation and metastatic 
phenotype. For instance, Yogeeswaran et al. reported the positive correlation between 
the quantity of cell surface total sialic acid and metastatic ability of murine tumor cells 
l i e
 m 
. Similarly, Sata et al. demonstrated an increased a2,6-sialylation on human colon 
cancer cell membranes using the lectin SNA . A high level of SNA reactivity was 
found to be an independent parameter for poor prognosis in colorectal carcinoma 237. 
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However, the opposite evidence was also documented. In a comparison of cell surface 
glycoconjugates between a highly metastatic murine melanoma cell line B16-BL6 and its 
positive sialidase transfectants, which showed markedly decreased metastasis in vivo and 
invasiveness in vitro, lectin flow cytometry and lectin blotting didn't revealed significant 
differences using either sialic acid- recognizing lectins or anti-sialyl Lex antibody 238. In 
addition, Takano et al. described a WGA-resistant mutant of MDAY-D2 cell line (W16) 
which showed a small increase in total sialic acid, but accompanied by slower growing 
subcutaneous tumors and less liver metastasis 239. Therefore, some researcher pointed out 
that metastatic ability does not correlate with the overall sialic acid content but only with 
specific molecules such as pi integrin ' . In another direction, there are observations 
that specific sialic acid linkage correlated with the metastatic growth of cancer cells. For 
example, analysis of B16 melanoma metastatic variants showed no difference in the total 
levels of sialic acid, but the highly metastatic subline contained more oc2-3 sialylation in 
SAoc2-3Gal|31-4GlcNAc oligosaccharides whereas low metastatic variants exhibited 
i n 
higher oc2-6 sialylation in SAa2-6Gaipi-4GlcNAc chains . These results provide 
supporting for our finding. Alternations in the distribution of sialic acid on cell surface 
glycoconjugates in cancers might lead to changes in cell-cell adhesion by the exposing of 
sub-terminal glycans, and/or inappropriate exposure of peptides. These changes may be 
important in the process of cancer cell dissemination and may influence the ability of 
cancer cells to adhere to endothelia at distant sites for the formation of metastasis 8 ' 4. 
In summary, the study in Aim I showed that cell surface glycoconjugates of PC3 and 
its variants are extensively sialylated and contain residues of a-mannose/a-glucose, 
GlcNAc, fucose, and GalNAc in variable amounts. The differences in metastatic abilities 
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of PC3 variants did correlate with the relative levels of a2-6 sialic acid on their surfaces. 
Characterization of carbohydrate residues related to PCa metastasis represents the first 
step in our investigation. Studies would move forward to specifically isolate and identify 
the metastasis-associated cell surface sialoglycoproteins. 
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CHAPTER IV 
AIM II: TARGETED IDENTIFICATION OF METASTASIS-ASSOCIATED CELL 
SURFACE SIALOGLYCOPROTEINS IN PROSTATE CANCER 
4.1 Introduction 
Altered cell surface glycosylation is a hallmark of cancer86. Specific glycan 
structures have been identified on tumors and serve as diagnostic indicators of the 
malignant and metastatic phenotype 86'96. Sialic acid (SA) residues are located on the 
nonreducing terminus of the glycans on many cell surface glycoproteins where they play 
a pivotal role in viral infection, leukocyte-endothelial cell adhesion, neuronal 
development, immune cell activation, cancer metastasis, and many other normal and 
pathological processes 41. Our previous data from lectin staining demonstrated changes 
of cell surface sialylation in a syngeneic prostate cancer cell model. Evidence from both 
patient histochemical analysis and experimental tumor models also indicate that altered 
sialylation of tumor cell surfaces is associated with a metastatic tumor phenotype " ' m . 
As we described earlier, the surface sialylation changes have been reported reflecting the 
amount, type, distribution, and bonding of sialic acids to adjacent molecules. For 
instance, a positive correlation can be reported between the levels of cell surface 
sialylation and metastatic ability of various experimental tumors 110'242. In addition, the 
distribution of sialic acid on specific N- or O-linked oligosaccharides has been 
demonstrated to alter the metastatic potential of cancer cell lines 113. In some cases tumor 
development has been associated with overexpression of P1-6 branching that results in 
increased number of Gaipi-4GlcNAc structures available for sialylation 117243. 
Therefore, exploring cell surface sialylation changes during tumor development and 
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disease progression likely affords excellent opportunities to identify sensitive and specific 
cancer biomarkers. 
Elucidation of structural details of cell surface glycosylation by mass spectrometry 
is hampered by the limited relative abundance of surface proteins compared to cytosolic 
components, the complex and microheterogeneous nature of glycans, and the inherent 
complexities of deciphering low energy carbohydrate fragmentation ions versus higher 
energy peptide fragments in complex mixtures l 4. The type of mass spectrometer and 
ionization energies to be used, and the complexity of the sample, are critical parameters 
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for successful glycoprotein analysis . In recent years, lectin- and antibody-based 
affinity selection has been used with some success to purify glycoproteins/glycopeptides 
with specific structures 169'170'244"246. Other approaches for glycopeptide characterization 
arise from the exploitation of glycan physical and chemical reactivity. Larsen et al. took 
advantage of the high affinity of titanium dioxide microcolumns toward SA residues to 
isolate SA-containing peptides from serum under highly acidic conditions . Two 
similar approaches, involving hydrazide and boronic acid chemistry, capitalize on the cis-
diols present in monosaccharides. Zhang et al. described the use of hydrazide chemistry 
for the purification by directly coupling of glycoproteins to a solid support173'174. 
Similarly, Sparbier et al. used boronic acid-functionalized beads to covalently capture 
1 89 
glycoproteins followed by elution with acid . Although these methods are effective at 
the enrichment and identification of broad classes of glycoproteins/glycopeptides, they 
still lack the specificity and selectivity required for analysis of specific cell surface 
glycoproteins that could serve as potential cancer biomarkers. 
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In recent years, a growing area of chemical biology strives to probe glycans in living 
systems by using bioorthogonal chemical reactions 248. These strategies, first described 
by Bertozzi's group, modulate cell surface glycan structures by biosynthetic introduction 
of unnatural sugars containing bioorthogonal chemical reporters, namely, functional 
groups that possess unique reactivity orthogonal to those of natural biomolecules. The 
process entails two steps. First, cells (or organisms) are incubated with a metabolic 
monosaccharide precursor adorned with a unique functional group-the chemical reporter. 
Once the chemical reporter is incorporated into the target glycans, it is treated in a second 
step with a probe molecule bearing complementary bioorthogonal functionality 249'250. In 
principle, a chemical handle such as a ketone, azide, or thiol carried by unnatural 
monosaccharides, can be metabolically incorporated into glycoproteins of cells or in 
1 79 
living organisms . Azide has proven the most useful analogs owing to the small size, 
metabolic stability, selective reactivity profile, and lack of reactivity with natural 
179 94R 
biofunctional structures ' . In sialic acid biosynthesis, as shown in Figure 16, the 
first committed step is the conversion of UDP-JV-acetylglucosamine (UDP-GlcNAc) to N-
acetylmannosamine (ManNAc). Six subsequent steps, including five enzymatic 
transformations and one transport step, produce a sialic acid residue appended to a 
glycoprotein or glycolipid destined for cell surface or secretion 251. Interception of the 
pathway with N-azidoacetyl-D-mannosamine (ManNAz), an unnatural analog of 
ManNAc which competes with ManNAc in the sialic acid pathway, results in the cell 
surface presentation of the azide-labeled glycans (Fig. 17A). The azide can be 
• 9^9 9^"3 
chemically probed with phosphine via the Staudinger ligation ' , linear alkynes via 
the Cu-catalyzed azide-alkyne cycloaddition (CuAAC)254, and with a variety of 
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Figure 16 Schematic representation of sialic acid biosynthetic pathway in human 
cells. Cytosolic glucose is converted in several steps into UDP-GlcNAc, which serves 
as substrate for the bifunctional, rate-limiting, committed enzyme of sialic acid 
biosynthesis, UDP-GlcNAc 2-epimerase (GNE) (a). The GNE catalytic activity 
epimerizes UDP-GlcNAc to ManNAc, followed by the phosphorylation of ManNAc 
to ManNAc-6-phosphate (MaNAc-6-P) by ManNAc 6-kinase (b). ManNAc-6-P is 
then further converted into NeuAc (sialic acid) by the sequential action of sialic acid 
9-phosphate synthase (c) and sialic acid 9-phosphatase (d). NeuAc is activated into 
cytidine monophosphate-sialic acid (CMP-NeuAc) by CMP-sialic acid synthetase (e) 
in the nucleus. Cytosolic CMP-NeuAc displays strong feedback inhibition (dotted 
line) of GNE enzymatic activity by binding to its allosteric site, thereby contributing 
to the tight regulation of intracellular sialic acid biosynthesis. CMP-NeuAc can 
subsequently be transported into the Golgi complex (f) as a substrate for the 
biosynthesis of sialyl-oligosaccharides by sialyltransferases (g). Adapted from 
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Figure 17 Bioorthogonal chemical reactions for sialic acid. The process entails two 
steps: metabolic labeling (A) and click chemistry (B). (A) Cells are fed with 
peracetylated Af-azidoacetylmannosamine (Ac4ManNAz), an unnatural analog of JV-
acetylmannosamine (ManNAc). Ac4ManNAz penetrates the cell-surface membrane 
easily due to the hydrophobic nature of the modified sugar. In the cytosol, it is 
enzymatically deacetylated and then metabolically converted to the corresponding N-
azidoacetyl sialic acid (SiaNAz), which is subsequently incorporated into 
sialoglycoconjugates. (B) Glycoproteins selectively labeled with azide can be 
detected with a fluorescent or biotinylated alkynes via the Cu-catalyzed azide-alkyne 
cycloaddition or "click chemistry". In this reaction, an azide and a terminal alkyne 
form a very stable triazole conjugate with the help of Cu (I) catalysis. Adapted from 
Invitrogen website (www.invitrogen.com). 
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cyclooctynes via the strain-promoted azide-alkyne cycloaddition 255. As a result, the 
reporting sugars have been coupled with a plethora of tags such as FLAG peptides, 
biotin, fluorescent or fluorogenic molecules, with the potential for visualization and 
isolation. Each chemicalselective reaction has its own advantages and disadvantages. 
The Staudinger ligation, which forms an amide bond between the azide and an ester-
derivatized phosphine, suffers from slow reaction kinetics and competing oxidation of the 
phosphine reagents 249. By contrast, CuAAC, often referred to classical click chemistry, 
offers high-sensitivity and fast rate by forming a triazole from an azide and a terminal 
alkyne with the help of Cu (I) catalysis (Fig. 17B). But it may hurt live cells by Cu 
cytotoxicity249. The successful application of bioorthogonal chemical reactions to label 
and detect several types of cell surface glycans, such as sialiac acid ' ' and mucin-
type O-linked glycans (GalNAC) 258>259, or cytosolic O-GlcNAcylated glycans (GlcNAc) 
, has been reported by some groups. However, their application for proteomics is 
limited to only O-GlcNAc modified cytosolic glycoproteins based on the Staudinger 
ligation reaction 261'262. 
In this study, we described a novel glycoproteomic identification strategy for the 
selective detection, isolation and identification of cell surface sialoglycoproteins from 
cultured cell lines. The method utilizes the sialic acid biosynthetic pathway for the 
incorporation of monosaccarides bearing bioorthogonal functional handles 
(tetraacetylated N-azidoacetyl-D-mannosamine, AC4ManNAz) into cellular sialic acid. 
This reagent has primarily been used to label and visualize cell surface sialyl 
glycoconjugates by Staudinger ligation ' . We extended its application to detect cell 
surface azide-modified sialoglycoproteins by click chemistry. To illustrate the potential 
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of using this cell labeling procedure in biomarker discovery, we combined it with an MS-
based proteomics approach as applied to our syngeneic metastatic PCa cell line model. 
4.2 Materials and Methods 
Materials — Complete™ protease inhibitors were purchased from Roche Applied 
Sciences (Indianapolis, IN, USA), sequencing grade trypsin was from Promega (Madison, 
WI, USA), and Immobilon-FL PDVF membrane was from Millipore (Billerica, MA, 
USA). Protein-free blocking buffer and high capacity streptavidin agarose resin was 
from Thermo Scientific (Rockford, IL, USA). Dulbecco's modified Eagle media 
(DMEM), fetal bovine serum (FBS), antibiotics-antimycotic, Click-iT™ ManNAz 
metabolic glycoprotein reagent, Click-iT™ Biotin Protein Analysis Detection Kit, 
propidium iodide, fluorescein conjugated streptavidin (streptavidin-FITC), 4-12% 
NuPAGE® Bis-Tris gels, and lithium dodecyl sulfate (LDS) buffer were from Invitrogen 
(Carlsbad, CA, USA). 2 x Laemmli buffer, 7.5% Criterion® Tris-HCl Gel, and Bio-Safe 
coomassie blue were from Bio-Rad (Hercules, CA, USA). The anti-P-actin mAb were 
provided by BD PharMingen (San Diego, CA, USA). The streptavidin-IR 800 and goat 
anti-mouse antibody conjugated to IR 800 were from Li-COR Bioscences (Lincoln, PA, 
USA). 
Cell Culture and Metabolic Labeling—PC3-N2 and PC3-ML2, as described in Aim I, 
were cultured in DMEM medium supplemented with 10% FBS and 1% antibiotics at 37 
°C with 5% CO2. For metabolic labeling, growth medium was replaced at 70% cell 
confluence with complete DMEM medium containing various concentrations of an azido-
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modified sugar, tetraacetylated N-azidoacetyl-D- mannosamine (AC4ManNAz), or a 
control sugar, N-acetyl-D-mannosamine (ManNAc), and cells were incubated for 1-3 
days. Cells then were dissociated from the plastic surface by non-enzyme dissociation 
buffer. 
Flow Cytometric Analysis of Cell surface Sialic Acid Labeling—After metabolic 
labeling, N2 and ML2 cells were harvested, washed with 0.1% FBS/PBS, and 
resuspended (106 cells) in 100 ul click reaction solution with the indicated amount of 
each component. The reaction was incubated at room temperature for 30 min, and then 
cells were washed three times with 0.1% FBS/PBS. Cells were subsequently stained with 
streptavidin-FITC (1 ug/sample in 100 ul 2% FBS/PBS) for 30 min at 4°C, and washed 
with 2% FBS/PBS three times. Before subjecting to flow cytometric analysis, cells 
incubated with 1 ug/ml propidium iodide in 500 ul 2% FBS/PBS at 4°C for 20 min. Data 
was acquired by FACScalibur and analyzed by Flowjo software. 
Confocal Microscopy Analysis of Cell surface Sialic Acid Labeling—N2 and ML2 cells 
were seeded onto 6-well plates containing glass coverslips and cultured in 10% 
FBS/DMEM. Growth medium was supplemented with 40 uM AC4ManNAz or ManNAc 
for 3 days. Cells were washed with ice-cold PBS, fixed with 2% paraformaldehyde, and 
then subjected to click reaction solution (25 ul biotin-alkyne, 2.5 ul CuS04, 2.5 ul and 5 
ul for component D and E, 65 ul PBS). Subsequently, the fixed and labeled cells were 
washed with PBS and stained with streptavidin-FITC (same as above) or streptavidin 
Alexa fluor 488. To visualize intracellular sialylation, permeabilization with 0.5% Triton 
X-100 was performed after fixation and before click reaction. PI or TO-PR03 was used 
to stain nuclei. Finally coverslips were mounted to the slides with VectorShield medium, 
and sealed with nail polish. Fluorescent images were examined and captured under a 
confocal microscope. 
Cell surface Sialoglycoprotein Labeling and Detection in Cell Extracts — N2 and ML2 
cells were seeded in 15-cm dishes and treated with the optimized labeling conditions for 
AC4ManNAz and ManNAc (20 uM for 1 day) in growth medium. After cells were 
harvested with non-enzyme dissociation buffer, 5x10 cells were collected and washed 
with 0.1% FBS/PBS. Subsequently, cells were subjected to click reaction solution as 
described above. Upon conjugation, cell pellets were washed with ice-cold PBS twice to 
remove unreacted reagents and then lysed in lysis buffer 1(1% NP-40, 150 mM NaCl, 
protease inhibitor, 100 mM sodium phosphate, pH7.5) using a Dounce homogeniser. 
The total cell lysate were further cleared by methanol-chloroform precipitation and 
resolved in lysis buffer II (1% SDS, protease inhibitor, 50 mM Tris-HCl, pH 8.0). 
Protein concentrations were measured using the BCA protein assay (Pierce). To detect 
biotin-labeled sialoglycoproteins in cell extracts, 20 ag of labeled protein lysate was 
resolved by SDS-PAGE. Electrophoresed proteins were transferred onto PVDF 
membrane, blocked with Odyssey Blocking Buffer (Rockland Immunochemicals, 
Gilbertsville, PA, USA), probed with streptavidin-IR 800, and visualized and quantified 
using an Odyssey infrared imaging system. 
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Sialoglycoprotein Capture — Streptavidin (SAv) beads were pretreated with protein-free 
blocking buffer overnight at 4°C and washed five times with PBS. Cell lysate (2 mg) was 
incubated with 100 ul beads in 0.3% NP-40/ PBS overnight at 4°C with a rotating shaker. 
The captured glycoproteins were washed intensively with modified RIP A buffer (150 
mM NaCl, 2% SDS, 1% NP-40, 1% Na Deoxycholate, 50 mM Tris-HCl, pH 7.5). Bound 
material was eluted by boiling for 10 min in 100 ul 2 x Laemmli sample buffer. For 
assessment of capture efficiency, 10 ul of the eluent, along with the input and flow-
through fractions were separated by SDS-PAGE and visualized with streptavidin-IR 800 
as stated above. 
ID Gel Electrophoresis andln-gel Digestion — Captured glycoproteins (45 ul) were 
separated through on 1.0 mm 7.5% Tris-HCl polyacrylamide gels. Gels were stained 
with Coomassie blue and imaged on a Typhoon 9410 (GE Healthcare, Piscataway, NJ, 
USA). Twenty-seven equally-spaced gel pieces were excised from each lane, spanning 
the full height of the gel (40-300 kDa). Individual gel pieces were destained with 25 mM 
NH4HCO3 in 50% acetonitrile (ACN), reduced with 20 mM dithiothreitol in 25 mM 
NH4HCO3 for 45 min at 56°C, and alkylated with 55 mM iodoacetamide in 25 mM 
NH4HCO3 in the dark for 1 hr at room temperature. After washing, the gel pieces were 
dehydrated with ACN and dried using a speed vac. Trypsin (12.5 ng/ul in 25 mM 
NH4HCO3, pH 8.0) was added to each gel piece, and the gel pieces were allowed to swell 
on ice for 1 hr. Excess trypsin was removed, replaced with 25 mM NH4HCO3, 10% 
ACN, pH 8.0, and the mixture was incubated overnight at 37°C. The digest was collected 
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and peptides were extracted with 50% ACN/5% formic acid twice. The combined 
extracts were then dried using a Speed-Vac for subsequent LC-MS/MS analysis. 
Whole Cell Extract and In-solution Digestion— For N2 and ML2 cell lysate experiments, 
both cell lines were cultured in complete growth medium to 80% confluence. Cells were 
then washed with PBS and the pellet resuspended in 160 ul dissolution buffer containing 
100 mM NH4HCO3 and TFE (1:1 v/v). The samples were sonicated for 20 seconds three 
times and incubated at 60°C for 1 h. The lysates were centrifuged to remove cell debris 
and unbroken cells and the supernatant was collected. The protein concentration of the 
samples was determined by BCA assay and normalized for each sample and before 
reduction and alkylation with TCEP and iodoacetamide respectively. The concentration 
of TFE was reduced to 5% by the addition of 1.4 ml 100 mM NH4HCO3. Trypsin was 
added at a ratio of 1:50 protease to protein and the digestion proceeded at 37°C for 18 hrs 
with constant mixing. After digestion the sample was dried down in a Speed-Vac, 
desalted and lyophilized before LC-MS/MS analysis. 
LC-MS/MS analysis — Digests were resuspended in 20 ul Buffer A (5% ACN, 0.1% 
Formic Acid, 0.005% heptafluorobutyric acid) and 15 ul loaded onto a 12-cm x 0.075 
mm fused silica capillary column packed with 5 uM diameter C-18 beads (The Nest 
Group, Southboro, MA) using a programmed automatic injection. Peptides were eluted 
over 80 minutes, by applying a 0-80% linear gradient of Buffer B (95% Acetonitrile, 
0.1% Formic Acid, 0.005% HFBA) at a flow rate of 200 ul/min with a pre-column flow 
splitter resulting in a final flow rate of -300 nl/min directly into the source. In some 
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cases, the gradient was extended to 150 minutes to acquire more MS/MS spectra. A 
LTQ™ Linear Ion Trap (ThermoFinnigan, San Jose, CA, USA) was run in an automated 
collection mode with an instrument method composed of a single segment and five data-
dependent scan events with a full MS scan followed by four MS/MS scans of the highest 
intensity ions. Normalized collision energy was set at 35, activation Q was 0.250 with 
minimum full scan signal intensity at 1 x 10 with no minimum MS intensity specified. 
Dynamic exclusion was turned on utilizing a three-minute repeat count of 2 with the mass 
width set at 1.0 m/z. Sequence analysis was performed with MASCOT (Matrix Sciences, 
London GB) using the SwissProt 57.1 database with a human taxonomy filter enabled. 
The database searches were performed with fixed modification as carbamidomethy (Cys) 
and variable modifications as oxidation (Met) and deamidation (Asn, Gin). Enzyme 
specificity was selected to typsin. The spectra from 27 LTQ runs in each gel lane were 
combined to search SwissProt. All the MS/MS spectra were manually inspected to verify 
the validity of the database search results. False discovery rates were estimated to be 
0.25% on the protein level by searching a decoy version of the SwissProt protein 
database. The relative abundance of peptides was estimated by spectral counting. 
Bioinformatic Analysis — Initial basic information on the structure of the identified 
proteins was obtained through literature reports. The ProteinID Finder (Proteome 
Solutions) program was employed to extract such available information from the UniProt 
database. Due to the limited annotation of protein glycosylation for most human proteins 
and the shortage of subcellular location information for hypothetical proteins and 
functionally uncharacterized proteins, we also subjected each identified protein to 
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prediction algorithms based on protein sequence analysis. For protein glycosylation we 
used NetNGlyc (http://www.cbs.dtu.dk/services/NetNGlyc/) to predict the possible 
presence of the consensus NXS/T glycosylation motif. For subcellular location, all 
identified proteins were analyzed with two transmembrane prediction algorithms SOSUI 
(http://bp.nuap.nagoya-u.ac.ip/sosui/sosui) and TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM-2.Of) indicating hydrophobic protein sequence 
regions. As a group, the total identified proteins were analyzed by Ingenuity Pathways 
Analysis (IPA) software to determine their molecular function and interacting networks. 
To generate the lists of cell surface glycoproteins uniquely expressed in N2 or ML2 
cells, identified proteins were required to meet the following 3 criteria: (a) identified from 
one cell line; (b) unique peptide > 1, and NXS/T motif > 1 or UniProt indicated N-linked 
or O-linked glycosylation; and (c) transmembrane region > 1, or UniProt membrane 
subcellular location. 
4.3 Results 
4.3.1 Methodology Overview. 
Our strategy for interrogation of cell surface sialoglycoproteins using selective 
chemical tagging followed by high-affinity enrichment and GeLC-MS/MS analysis is 
summarized in Figure 18. The method consists of several steps: 1) metabolic labeling of 
N2 and ML2 cells with the azide-containing mannose analogue, AC4ManNAz; 2) 
chemoselective conjugation of azide sugars with a biotinylated alkyne capture reagent via 
Cu (I) catalyzed click chemistry in live cells; 3) affinity enrichment of the labeled cell 
97 
ACjMariHA: y-"\^. BistitMlHytwi y 
Figure 18 Outline of Aim II experimental work-flow. (1) metabolic labeling cells with 
an unnatural mannose analogue, peracetylated azido-mannose (AC4ManNAz); (2) 
chemoselective conjugation of azido sugars with a biotinylated alkyne capture reagent 
via Cu (I) catalyzed click chemistry on live cells; (3) cell lysis; (4) streptavidin (SAv) 
affinity purification; (5) sialoglycoproteins elution; (6) SDS-PAGE for protein 
separation; (7) gel slice digestion and peptide release; (8) peptide analysis by LC-
MS/MS; (9) database search and protein identification; (10) bioinformatic analysis. 
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surface sialylated proteins by streptavidin (SAv) capture; and 4) separation by ID gel 
electrophoresis and identification by LC-MS/MS. When compared with other published 
approaches, the theoretical advantage of our approach is the targeted selectivity for sialyl 
glycosylated proteins on the cell surface. 
4.3.2 Efficient Cell Surface Expression of AC4ManAz-Sialoglycoproteins. 
A critical parameter in the proposed strategy is the efficient labeling and surface 
expression of the azide-containing sialoglycoproteins. In order to evaluate the efficiency 
of surface expression of azide-containing sialoglycoproteins, N2 and ML2 cells were 
subjected to metabolic incorporation of AC4ManNAz, conjugated with biotin with the 
click reaction, and subsequently stained with streptavidin-FITC to visualize the glycans 
harboring the azide group. We conducted fluorescence-assisted flow cytometric analysis 
of non-permeabilized cells for determining the efficiency of streptavidin-FITC labeling. 
As quantified by flow cytometry (Fig. 19A), the AC4ManNAz-treated N2 and ML2 cells 
displayed 80-100 fold greater FITC-specific fluorescence intensity than the control 
ManNAc-treated and untreated cells. This result demonstrates that the azide moieties 
were efficiently incorporated into cellular glycans. We next conducted confocal 
microscopy analysis of streptavidin labeled cells to specifically assess the cellular 
location of the azide-modified glycans. As seen in Figure 19B, prominent FITC staining 
primarily at the cell membrane was observed when the cells were subjected to metabolic 
incorporation of ManNAz. Consistent with flow cytometric data, confocal microscopic 
analysis of cells treated with control ManNAc displayed much reduced staining, 














Figure 19 Efficient and selective labeling of sialoglycoproteins on the cell surface. (A) 
Flow cytometry analysis of N2 and ML2 cells treated with AC4ManNAz or ManNAc. 
Nonpermeablized cells were biotin-tagged through click reaction, and stained with 
streptavidin-FITC. PI negative gated FACS histogram showing three populations of 
cells: control cells (red), cells treated with ManNAc (gray filled), and cells treated with 
AC4ManNAz (green). (B) Confocal imaging of N2 and ML2 cells for visualization of 
the tagged cell-surface sialoglycoproteins. Cells were treated with AC4ManNAz or 
ManNAc, labeled with biotin-alkyne via click reaction and stained with streptavidin-
FITC (green) and PI (red) after fixation. Left panel: AC4ManNAz -treated cells; right 
panel: ManNAc-treated control cells. 
no evidence of cell surface labeling for the control groups. 
4.3.3 Visualization of sialylated glycoconjugated inside the cell. 
The biosynthesis of cell surface sialoglycoconjugates involves a lot of intracellular 
processes (Fig. 16). After confirming that azide-modified sialyl glycans resided on the 
cell surface, we were curious how the metabolism of AC4ManNAz looked inside the 
cells. To this end, we changed cell staining protocol by permeabilizing cells before 
performing click reaction. As demonstrated in Figure 20, treatment with ManNAz 
resulted in membranous staining as well as a strong juxtanuclear pattern inside the cells 
after clicking on the biotin-alkyne and staining with Alexa 488-conjugated streptavidin. 
This pattern seems typical for the Glogi apparatus, but need verification in future study. 
In contrast, cells incubating with natural ManNAc and following the same staining 
procedures showed minimal fluorescence. These data documented that metabolic 
labeling in combination with click reaction is an option to study intracellular sialyl 
residues, likely those trafficking through the secretory pathway. 
4.3.4 Optimization of metabolic labeling and click reaction. 
We further optimized the azide labeling and click reaction to maximize cell 
viability/vigor (Fig. 21). The first concern was whether exogenous sugar analogs 
affected cell growth since cell toxicity may lead to global protein expression changes. 
We measured cell proliferation with WST-1 reagent after cells were treated with 
AC4ManNAz. As shown in Figure 21 A, the addition of 200 uM ManNAz greatly 
Figure 20 Fluorescent imaging of intracellular sialylation. N2 and ML2 cells were 
treated with AC4ManNAz or ManNAc, fixed and permeabilized. Then cells were 
conjugated with biotin-alkyne via click reaction and stained with streptavidin Alexa 
Fluor 488 (green) and TO-PR03 (blue). Fluorescent images were captured by cofocal 
microscopy. Left panel: AC4ManNAz -treated cells; right panel: ManNAc-treated 
control cells. 
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Figure 21 Optimization of azide labeling and click reaction. (A) N2 cells were grown 
in a 96-well plate with different doses of AC4ManNAz (0-200 uM) for up to 3 days. 
Cell viability and proliferation was determined using WST-1 reagent. Each point was 
tested in 6 replicates. (B) Dose-dependency of click reaction. ML2 cells were treated 
with 40 uM AC4ManNAz for 3 days, probed with different volumes of click reagents, 
and stained with streptavidin-FITC. The fluorescent intensity was monitored by flow 
cytometry. (C) Dose curve of ManNAz labeling. ML2 cells were treated with 0-80 
|aM AC4ManNAz for 3 days, probed with 25 \i\ biotin-alkyne. (D) Time course of 
siaNAz glycoconjugate labeling. The optimized conditions of 20 uM AC4ManNAz 
and reaction with 25 jal biotin-alkyne were used in a time course of incorporation and 
detection in ML2 cells. 
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inhibited cell growth up to 90% at day 1-3. However, ManNAz up to 50 uM had no or 
minimal toxicity on cells. We next optimized the click reaction with the emphasis on the 
dose of biotin-alkyne and copper. Both showed a dose-dependent increase of fluorescent 
signal on the cell surface (Fig. 21B). Considering the potential toxicity of Cu (I), we 
choose 25 ul of biotin-alkyne with 2.5 ul CUSO4 for future experiment because this 
amount of reagents is enough to provide strong azide-alkyne reaction (50 fold greater 
than control). Dose-curve of ManNAz labeling (Fig. 21C) showed a dose-dependent 
increase of fluorescent signal up to 20 uM. After that the MFI decreased gradually. 
However, the MFI of ManNAz treated cells was still with 24-fold at 80 uM greater than 
control ManNAc. Time-course experiments (Fig. 2ID) revealed the saturation of 
ManNAz incorporation within one day of incubation. Surprisingly, two-day incubation 
led to a decrease of azide-bearing sialyl glycans on the cell surface whereas the level of 
labeled glycans on day 3 restored to 55% level of day 1. This result might reflect turnover 
status of cell surface sialyl glycans. Base on these cumulative results, the optimal 
concentration and time of ManNAz for labeling sialyl glycans fall between 20-40 uM for 
1 day and 25 ul of biotin-alkyne reagent. 
4.3.5 Targeted Isolation of Cell surface Sialoglycoproteins. 
Having demonstrated efficient labeling of cell surface glycoconjugates, we 
continued with a general characterization of whole cell lysates of Biotin-labeled 
glycoconjugates via SDS-PAGE separation and visualization by reaction with 
streptavidin-IR800. Expression of P-actin was used for normalization. Overall 
sialylation, as judged by streptavidin staining, was restricted to extracts from the 
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ManNAz labeled cells (Fig. 22). In addition, there appeared to be greater sialylated 
glycoproteins in the ML2 cell line when compared to the N2 cell line. We also observed 
a major protein band that migrated just under 150 kDa and reacted with streptavidin. 
These observations were consistent with the prior fluorescence imaging analyses in 
demonstrating a specific uptake and labeling of the ManNAz treated cells. 
We next examined the efficiency of our system for the enrichment of biotin-labeled 
sialoglycoproteins. The streptavidin-derivatized beads were used to isolate targeted 
proteins from N2 and ML2 cell lysates. The effect of various parameters on the binding 
of non-glycoproteins versus glycoproteins to the streptavidin beads was evaluated by ID-
PAGE and streptavidin-FITC reaction to develop an optimized enrichment (Fig. 23). For 
example, a variety of protein/streptavidin bead ratios were investigated for efficient 
capture of the targeted glycoproteins (Fig. 24). The capture efficiency was analyzed by 
ID-PAGE followed by silver staining as well as in-blot streptavidin-FITC detection. 
Compared to the control groups, the number of bands and band intensity observed on 
silver-staining gels and streptavidin-FITC blot for treated groups were increased 
dramatically when the ratio of sample loading/SAv beads increased. 500 (a.g cell lysate 
on 20 ul bead slurry resulted in the maximum isolation. Using the similar criteria, we 
optimized other parameters including S Av beads preblocking buffer, binding buffer, 
washing buffer, and elution buffers. We found that targeted glycoprotein binding to SAv 
beads was optimal when the beads were preblocked with protein-free blocking buffer and 
binding was performed at 4°C with a detergent (0.3% NP-40) present in the binding 
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Figure 22 Detection of azide-tagged sialoglycoproteins in cell lysates. After N2 and 
ML2 cells were metabolically labeled with ManNAc analogs and conjugated with 
biotin-alkyne under the optimized conditions, the cells were lysed and total protein 
was extracted as stated in Experimental procedures. Top panel: 20 ug of labeled 
protein was resolved in 4-12% gel by SDS-PAGE and visualized by incubation with 
streptavidin-IR 800. Reactive bands indicate sialylated glycoproteins. The same blot 
was probed with |3-actin to verify equal protein loading. Bottom panel: the numbers 
showed relative expression of sialylated glycoproteins after normalization with the 
P-actin. 
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Figure 23 Schematic representation of streptavidin (SAv) pull down assays. SAv 
beads were pretreated with protein-free blocking buffer and washed with PBS. Then 
they were incubated with cell lysate in 0.3% NP-40/ PBS. The bound proteins were 
washed intensively with modified RIPA buffer to reduce nonspecific protein 
binding. Precipitated proteins were eluted from SAv beads with Laemmli buffer by 
boiling. The optimized steps such as SAv beads preblocking, protein/beads ratio, 
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Figure 24 The effect of different protein/beads ratios in S Av pull down assays. (A 
and B) ML2 cells were metabolically labeled with ManNAc or its analogs (ManNAz), 
conjugated with biotin-alkyne, and lysed. Different amounts of lysate (25-200 ug) 
were subjected to SAv pull down assays by incubating with 20 ul SAv beads slurry. 
The eluted proteins were resolved in 4-12% gel by SDS-PAGE and visualized by 
silver staining. (C) Blot staining was performed on the same set of samples with 
streptavidin-FITC to confirm the specific enrichment. The blot was scanned by 
typhoon imager. 
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reduced nonspecific protein binding. Efficient elution of bound glycoproteins was 
achieved by boiling samples in 2 x laemmli buffer. 
With the optimized streptavidin binding protocol, we added 2 mg whole cell lysates 
to 100 ul bead slurry and performed pull down assay as described. The eluted 
sialoglycoproteins were subjected to in-blot streptavidin-IR 800 detection. In both cell 
types we observed a dramatic enrichment for biotin-conjugated proteins in the bound and 
eluted fractions from the ManNAz-treated cells (Fig. 25). In contrast there was 
dramatically reduced overall staining of biotin-labeled protein in the ManNAc-labeled 
control cells. We again observed an intense signal at sub-150 kDa in eluted fractions 
from cells treated with ManNAz, and absent or minimal signal in flow-through fractions 
and eluents from the control group. These results demonstrate efficient capture and 
enrichment of the azide-labeled proteins. 
4.3.6 Identification of Surface Glycoproteins by Mass Spectrometry. 
Since we were able to establish both efficient cell surface labeling and effective 
isolation of sialoglycoproteins, we next performed a proof-of-principle experiment for the 
application of this approach to the identification of sialoglycoproteins differentially 
expressed between metastatic (ML2) and non-metastatic (N2) prostate cancer cell lines. 
The cells were processed for metabolic labeling as described above, the tagged proteins 
were enriched with SAv resins, and the eluted proteins were separated by SDS-PAGE 
(Fig. 26) and analyzed by LC-MS/MS. In total, 536 non-redundant proteins were 
identified (Fig. 27). This total derived from 324 proteins from the N2 line and 372 
proteins from the ML2 line when metabolically labeled with ManNAz. In contrast the 
N2 ML2 
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Figure 25 Efficient capture and enrichment of azide-tagged sialoglycoproteins. 
Azide-tagged and biotin-conjugated sialoglycoproteins from the total lysate of N2 
and ML2 cells were captured by streptavidin beads, separated in 7.5% gel and 
visualized by streptavidin-IR 800. Shown are the results from 20 (j,g of post-click 
lysate (N for neat), 5% of the flow through material that did not bind to the beads 
(FT for flow through), and 5% of material captured from 2 mg of protein that bound 
to beads (E for eluent). 
Figure 26 Separation of proteins enriched by SAv pull down assays. Azide-tagged 
and biotin-conjugated sialoglycoproteins from 2 mg total lysate of N2 and ML2 
cells were enriched by streptavidin beads. The eluents were separated in 7.5% gel 
and visualized by Coommassie blue staining. Twenty-seven equally-spaced gel 
pieces spanning the full height of the gel (40-300 kD) were excised from each 
lane, in-gel digested by trypsin, and analyzed by LC-MS/MS. 
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Figure 27 Number of proteins identified in PC3 variants by LC-MS/MS. Venn 
diagrams showed the overlap of proteins identified in N2_ManNAz group, 
ML2_ManNAz group, and ManNAc_pool group which combined N2_ManNAc and 
ML2_ManNAc groups. Proteins identified with significant peptide scores (p<0.05) 
and expect scores (p<0.5), and at least one unique peptide were included in the 
analysis. 
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control cells lacking ManNAz yielded 132 proteins from the N2 line and 75 proteins from 
the ML2 line. The total number of proteins identified using a sliding scale for unique 
peptides is shown in Table 5. Approximately 60% of proteins identified contained two 
or more unique peptide hits. Another purpose of setting up control groups was to 
evaluate the extent of nonspecific interaction between the SAv resin and proteins in the 
N2 and ML2 cell lystes. Although a pre-blocking step and high detergent resin wash was 
carried out, a number of proteins were still identified in the control groups. Most of 
these proteins were high abundant house-keeping proteins, such as actin, tubulins, 
plectin-1, pyruvate carboxylase, pyruvate kinase and heat shock proteins. These proteins 
were subtracted from the list of total proteins identified in the treated groups, further 
narrowing the pool of proteins identified as cell surface molecules (216 proteins for N2 
and 245 for ML2 group). 
The enrichment efficiency for sialoglycoproteins is a key factor in characterization 
of the utility of this methodology. As shown in Figure 25, the presence of 
sialoglycoproteins was significantly enhanced after affinity chromatography by SAv 
beads when compared to raw cell lysate or processed control extracts (ManNAc). The 
specific enrichment of glycoproteins was further examined using the results from the 
mass spectrometry characterization. As an initial analysis we determined the top 10 most 
abundant glycoproteins from each cell line. The expression of these abundant proteins 
were estimated and ranked by spectral counts and unique peptides as shown in Table 6A 
and Table 6B. We then compared the relative abundance of these top 10 glycoproteins, 
as derived from the sialoglycoprotein-targeted enrichment/isolation, between the 
ManNAz and ManNAc labeled cells. Based upon this comparison, the top most 
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Table 5 Total number of proteins identified for each experimental group 
No. ofUniqpep N2_ManNAz N2_ManNAc ML2_ManNAz ML2_ManNAc 
1 128 64 153 44 
2 62 24 72 10 
3 29 13 47 6 
4 23 11 22 8 
>5 82 20 78 7 
Total 324 132 372 75 
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Table 6 Top 10 abundant glycoproteins identified in N2 and ML2 cells ranked by 
unique peptides 
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abundant glycoproteins were present in far higher incidence from the ManNAz-treated 
group. We observed a similar enrichment by the ManNAz group when we employed 
emPIA score to rank the glycoproteins (Table 7A and Table 7B). These results clearly 
demonstrate a substantial increase in the selective capture of the most abundant known 
cellular glycoproteins via this methodology. 
As a final assessment of the extent of enrichment of glycoproteins on the cell surface 
and in the extracellular compartment, we compared our targeted method to a non-
selective global proteomic analysis of whole cell lysates of the same cell model. Whole 
cell lysates were prepared from N2 and ML2 cells, directly digested by trypsin and 
subjected to LC-MS/MS as described in materials and methods. Three nano-LC-MS/MS 
runs of tryptic digests showed that a significant number of total proteins (310 for N2 and 
280 for ML2) could be detected utilizing this simple non-fractionation approach. 
When analyzed for protein content, we found that 3.8% of the N2 proteome and 2.9% of 
the ML2 proteome identified from this global approach were annotated as glycoproteins 
using the UniProt database. In comparison, our targeted approach yielded 9.3% and 
13.5% respectively (Fig. 28). Although the use of the UniProt database to determine if a 
protein is glycosylated is notoriously under-representative, a four-fold enrichment was 
revealed. Most striking was that 10 of 12 internal glycoproteins, found to be abundant 
and identified in the targeted approach, were not identified in the whole cell proteome 
approach. 
We next conducted a comparative analysis of the two approaches with specific 
emphasis on which cellular compartment the proteins were derived. Figure 29 displays 
the UniProt-designated subcellular distribution of proteins identified from the whole cell 
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Table 7 Top 10 abundant glycoproteins identified in N2 and ML2 cells ranked by 
emPIA scores 
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Figure 28 Improved capture of known glycoproteins. Identified proteins were cross-
referenced to the UniProt Knowledgebase for known glycoproteins. The percent of 
total proteins that were matched to known glycoproteins is shown, in comparison to 
that typically determined by global proteomic approaches. 
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Figure 29 Subcellular location of identified proteins. The cellular location was 
determined by cross-referencing the annotations from UniProtKB. Each protein was 
designated with only one subcellular location. The protein classes are shown as 
percent of total protein on the x axis. This analysis was conducted for both the 
surface glycoprotein and global methodologies. 
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proteome and the cell surface glycoproteome. We observed that about 13.2% of proteins 
from the whole cell analysis of N2 and ML2 were classified as being extracellular and 
membrane-bound. This result is consistent with studies using whole cell proteome 
approaches to examine breast cancer cell and ovarian cancer cell proteome263'264. In 
contrast, our cell surface glycoprotein approach resulted in a proteome for N2 and ML2 
with 25.9% and 29.8% of proteins being secreted or cell surface proteins, respectively. 
These cell surface proteins include CD markers, cell surface receptors, membrane 
transport, and cell adhesion proteins, such as CD44, CD 166, integrins, anexins, calnexin, 
etc. In contrast, a small portion of proteins identified using our targeted approach was 
classified as having ER/golgi location (~2%). A large portion of proteins were classified 
as intracellular (>50%), either cytoplasm or nucleus, whereas 18 proteins for N2 and 13 
proteins for ML2 remain unclassified. Sardana et al. conducted a cellular secretome 
analysis in which the conditioned medium of three prostate cancer cell lines (including 
PC3) were examined to identify just over 2000 proteins of which 12% were classified as 
known extracellular proteins . We observed 32 proteins that were in common with the 
"secretome" study and that 85% of these were classified as membrane proteins (Fig. 30). 
These findings underscore the value of our targeted strategy to capture and isolate cell 
surface glycoproteins. 
4.3.7 Selective Identification of Differentially Expressed Cell surface 
Sialoglycoproteins 
Currently less than 5% of proteins are annotated as glycoproteins in the UniProt 
database . This is a striking number when current estimates suggest that more than 
Figure 30 Overlap of our cell surface proteins with prostate cancer secretome. 
Venn diagram shows the overlap between cell surface proteins identified by our 
targeted glycoproteomic approach and prostate cancer secretome reported by 
Diamandis' group (Sardana, Ref.32). Since subcellular location classification in 
prostate cancer secretome is redundant, the combination of 329 extracellular and 
504 membraneous proteins results in total 730 proteins. 
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50% of eukaryotic proteins are glycosylated. Therefore, we assembled the identified 
proteins that could be attributed to membrane-bound and extracellular compartments by 
UniProt database or predicted to contain transmembrane domains (SOSUI, TMHMM). 
These were further analyzed for the prediction of sites for N-linked glycosylation 
(NetNGlyc). Using these criteria, we compared the surface sialoglycoprotein expression 
profiles of the metastatic variants. Ultimately, 36 and 44 cell surface glycoproteins were 
uniquely identified in N2 and ML2 respectively. A list of these proteins, their UniProt 
accession number, and molecular function is presented in Tables 8 and 9. Known 
functions of these proteins include cell-cell or cell-matrix adhesion, protein transporter, 
signaling in response to cytokines and growth factors, induction of coagulation, and 
proteolysis. 
5.3.8 Functional Mapping of Differential Expressed Sialoglycoproteins 
Among those 36 differentially expressed cell surface glycoproteins in non-metastatic 
N2 cells (Table 8), many proteins, such as, complement decay-accelerating factor 
(CD55), Catenin beta-1 (CTNNB1), focal adhesion kinase 1 (PTK2), Myosin-VI 
(MY06), A kinase anchor protein 1 (AKAP1) and symplekin (SYMPK), can positively 
or negatively regulate apoptosis pathway (Fig. 31). The several proteins, including 
catenin beta-1, catenin delta-l(CTNNDl), disks large homolog 5 (DLG5) and symplekin, 
are involved in regulation of cell adhesion. The protein transports, Secl6A, Sec23B and 
Sec24C are involved in transport from the endoplasmic reticulum to the Golgi apparatus. 
Whereas coatomer subunit gamma (COPG) reversibly associates with Golgi non-clathrin-
coated vesicles and protein YIPF5 can assist transport between endoplasmic reticulum 
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Table 8 Cell surface N-linked glycoproteins differentially expressed in N2 Cells 
Spect_ Uniq 
counts _pep Acc# 
Gene 
Name Protein Name 
Predicted Observed 
MW (Da) MW (Da) Functions 
4 4 P28290 SSFA2 Sperm-specific antigen 139,554 170,000 Actin binding 
2 
1 1 Q92667 AKAP1 A kinase anchor 
protein 1, 
mitochondrial 
1 1 Q00341 HDLBP Vigilin 
98,250 120,000 Protein binding 
















Q8NFJ5 GPRC5A Retinoic acid-induced 40,624 
protein 3 
Q9Y678 COPG Coatomer subunit 98,967 
gamma 
P50416 CPT1A Carnitine O- 88,995 
palmitoyltransferase 1, 
liver isoform 
P35222 CTNNB1 Catenin beta-1 86,069 
















Disks large homolog 5 215,446 
P50570 DNM2 Dynamin-2 98,345 
Q9BW60 ELOVL1 Elongation of very 32,755 
long chain fatty acids 
protein 1 




Focal adhesion kinase 119,956 
1 






300,000 Signal transduction 
90,000 ER-Golgi vesicle 
transport 
300,000 Lipid metabolism 
90,000 Cell adhesion; 
signal transduction 




130,000 ATP binding; ATP-
dependent helicase 
activity 
140,000 Receptor binding 
240,000 Cell adhesion; 
signal transduction 
95,000 Vesicular trafficking 
300,000 Fatty acid 
biosynthesis 
300,000 Lipid metabolism 
120,000 Integrin-mediated 
signaling pathways 
300,000 Translation activator 
300,000 Proteolysis; protein 
binding 
Table 8 continued 
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Q86YT6 MIB1 E3 ubiquitin-protein 112,461 
ligase MIB1 
1 Q9UM54 MY06 Myosin-VI 150,965 
2 4 Q5SRE5 NUP188 NucleoporinNUP188 198,369 
homolog 
1 075781 PALM 
1 000408 PDE2A 
















cGMP-dependent 3',5'- 107,360 50,000 Signal transduction 
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Cell adhesion; mRNA 
8 6 P14923 JUP 
1 1 Q15063 POSTN 
4 3 PI 8031 PTPN1 
8 7 P46060 RANGAP1 
1 1 Q9GZS1 POLR1E 
3 3 P04843 RPN1 




receptor type 1 
Ran GTPase- 63,958 
activating protein 1 
DNA-directed RNA 54,441 








85,000 Junctional plaque 
formation 
70,000 Cell adhesion. 
55,000 Regulation of insulin 
signal pathways 
80,000 Signal transduction 
55,000 rRNA transcription 
70,000 N-linked glycosylation 
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Figure 31 Functional pathway analysis of glycoproteins unique to N2 cells. Ingenuity 
Pathway Analysis (IPA) was employed to functionally map the cell-surface 
glycoproteins unique to N2 cells. The network diagram shows the biological functions 
that these glycoproteins are associated with, in the context of disease. Apoptosis 
involved in tumor development has been listed as the top function, as reflected by the 
number of glycoproteins (highlighted in blue) connected with it. 
and Golgi. Other candidates are involved in different functions, such as T cell activation 
(Plastin-2), N-oligosaccharyl transferase (dolichyl-diphosphooligosaccharide—protein 
glycosyltransferase subunit STT3 A), mRNA and protein transporter (nucleoporin 
NUP188 homolog and nuclear pore membrane glycoprotein 210), fatty acid beta-
oxidation (carnitine O-palmitoyltransferase 1, liver form), fatty acid biosynthetic process 
(elongation of very long chain fatty acids protein 1), unsaturated fatty acid biosynthetic 
process (fatty acid desaturase 2), and RNA splicing, mRNA processing (pre-mRNA-
processing factor 40 homolog A), etc. 
Among those 44 differentially expressed cell surface glycoproteins in metastatic 
ML2 cells (Table 9), a large number of proteins are involved in cell movement, cell-cell 
signaling and interaction, and cellular growth and proliferation. There are 11 proteins 
involved in cell movement (Fig. 32). Notably, 6 proteins, Basigin (BSG), Periostin 
(POSTN) and Glucose-6-phosphate isomerase (GPI), Calreticulin (CALR), Leucine-rich 
repeat-containing protein 15 (LRRC15), Myristoylated alanine-rich C-kinase substrate 
(MARCKS), are involved in the invasion of tumor cell lines. Other 5 proteins, Junction 
plakoglobin (JUP), Tyrosine-protein phosphatase non-receptor type 1 (PTPN1), 
Niemann-Pick CI protein (NPC1), Sodium-coupled neutral amino acid transporter 2 
(SLC38A2) and Adenylyl cyclase-associated protein 1 (CAP1), are involved in migration 
or movement of eukaryotic cells, embryonic cells or cancer cells. Of above proteins, 
SLC38A2, JUP, PTPN1, POSTN, CALR, BSG, and Pinin (PNN), CUB domain-
containing protein 1 (CDCP1), DNA-directed RNA polymerase I subunit RPA49 
(POLR1E), Collagen alpha-1 (VI) chain (COL6A1), are involved in growth, colony 
formation of eukaryotic cells, leukocyte, fibroblast or cancer cell lines. Other 
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Figure 32 Functional pathway analysis of glycoproteins unique to ML2 cells. 
Ingenuity Pathway Analysis (IPA) was employed to functionally map the cell-surface 
glycoproteins unique to ML2 cells. The network diagram shows the biological 
functions that these glycoproteins are associated with, in the context of disease. Cell 
movement, invasion and migration have been listed as the top functions, as reflected 
by the number of glycoproteins (highlighted in blue) connected with them. 
glycoproteins differentially expressed in ML2 are associated with cell signaling 
(Syntaxin-binding protein 3), cell assembly (Ran GTPase-activating protein 1), nuclear 
protein export (Nucleoporin 50 kDa), innate immune defense against viruses 
(Mitochondrial antiviral-signaling protein), et al. Interestingly, several proteins, Very 
long-chain specific acyl-CoA dehydrogenase (ACADVL), Long-chain-fatty-acid—CoA 
ligase 3 (ACSL3), Synaptic glycoprotein (TECR), Serine palmitoyltransferase 1 
(SPTLC1) and Niemann-Pick CI protein, are involved in unique lipid/steroid 
metabolism. 
4.4 Discussion 
Metastatic spread of cancer involves tumor cell extravasation and subsequent 
invasion of surrounding tissue, all processes that are tightly regulated by cell surface 
mechanisms 123'140. The identification of surface-accessible glycoproteins, which are 
altered in the metastatic process, will reveal the underlying biological events that support 
cancer metastasis, may facilitate the discovery of new biomarkers for cancer diagnosis, 
prognosis, and help define new therapeutic targets. In this study, a novel surface 
glycoprotein targeted strategy, based on metabolic labeling and click chemistry, was 
developed for purification and characterization of sialoglycoproteins. Metabolic labeling 
of glycans with sugar analogues and subsequent probe capture via Click chemistry have 
been applied to cellular microscopy . However, to our knowledge, our data is the first 
to demonstrate its application to targeted proteomics. 
Click chemistry specifically refers to a bioorthogonal ligation event between azide 
and alkyne . The position of azide-alkyne pair can be exchanged, that is, the same 
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reaction can be carried out using the alkyne as the chemical reporter. Wong and 
coworkers reversed the polarity of the reagents, using an alkynyl ManNAc derivative for 
metabolic labeling of cultured cells and CuAAC-mediated reaction with an azide-
functionalized probe for imaging of sialylated glycoproteins . The primary advantage 
of Click chemistry over the Staudinger ligation is its faster rate, high-sensitivity, and 
high-selectivity . Our flow cytometry results and confocal images confirmed the high 
selectivity/specificity of click chemistry for labeling cell surface sialoglycoconjugates. In 
conjunction with LC-MS/MS, we applied this method to comparatively analyze the cell 
surface sialoglycoproteome of non-metastatic (N2) and metastatic (ML2) prostate cancer 
cell lines. Our findings reveal substantial changes in the abundance of proteins that have 
previously been associated with metastatic spread of cancer and the discovery of some 
new cell surface sialoglycoprotein with potential roles in metastasis. The enrichment for 
surface glycoproteins demonstrated by this method provides proof of concept of the 
utility of this approach in the discovery of sialic acid-containing glycoproteins of disease 
significance. 
Although many cellular proteins are glycosylated, they are rarely identified by 
global proteomics approaches. Targeted labeling and enrichment of specific groups of 
glycoproteins simplifies the complexity of a cellular proteome and serves to reduce the 
dynamic range of protein expression. We demonstrate that the application of the 
described method is effective for cell surface glycoprotein identification. A substantial 
enrichment of cell surface glycoproteins of low abundance (based on spectral counts) was 
observed. These included adhesion proteins implicated in cancer development such as 
proocadherin-23 and CUB-domain containing protein 1, protein binding and signal 
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transduction molecules such as leucine-rich repeat-containing protein 15 and focal 
adhesion kinase 1. 
Our approach resulted in a proteome that was enriched to approximately 29% for 
cell surface or excreted proteins. This compares favorably with other proteomic 
approaches using cell surface biotinylation and MudPIT analysis 264'268, in which cell 
surface protein enrichment of ~30% was reported for human HT-1080 fibrosarcoma cell 
line and human CaOV3, OVCAR3, and ES2 ovarian cancer cell lines. More recently, on-
bead tryptic digestion followed by the specific release of N-linked glycosylated peptides 
via peptide-N-glycosidase F (PNGase F) and LC-MS/MS has been reported to 
17^ 178 180 
successfully identify N-linked glycopeptides ' ' . Because the authors assumed 
that all proteins identified by the approach were glycoproteins there was no report of 
target efficiency. Aebersold and co-workers combined this system with the periodate 
oxidation/hydrazide method for the specific analysis of the cell surface membrane 
glycoproteome . Although successful, this technology is still challenging due to a 
potential for false positive identification that arises from the dependence on single 
peptide analysis, 1 Da glycan shift and competition with natural Asn to Asp conversion. 
To eliminate the false positive identification of the N-linked peptides, MS data 
acquisition from more intense isotopic peaks and manual inspection of mass spectra are 
required. Because N-linked glycosylation predominates in secreted and cell surface 
proteins, we would suggest that combining a selective click chemistry approach as we 
have described with this gel-free system for the analysis of the cell surface 
glycoproteome would be a successful alternative strategy. 
133 
The significant number of proteins annotated as nuclear or cytoplasmic that were 
present among our cell surface sialoglycoproteome is noteworthy. To some extent, 
occurrence of these predominantly intracellular proteins may be due to their high 
abundance. Despite our efforts to optimize the labeling protocol and increase wash 
stringency, some proteins classified as intracellular were still precipitated by the SAv 
resin. High-salt (1.5M NaCl) and high-pH (0.1M Na2C03) buffers have been reported to 
reduce such contamination and may reduce this background ' . Another possible 
reason for the contamination is limited cell death during the click reaction. Click reaction 
requires copper as a catalyst, which is toxic to the cell . Mammalian cells can survive 
low concentrations (below 500 urn) of copper(I) for 1 hour 249. However, certain cell 
death was still observed under our optimized click conditions. Fortunately, a new 
generation click chemistry, called stain-promoted cycloaddition, has been developed and 
has been shown to maximally preserve cell viability through bypassing the requirement 
of copper 255'271. Bertozzi's group applied copper-free click chemistry for dynamic in 
vivo imaging, claiming comparable kinetics to the copper-catalyzed reaction and speed 
with no apparent toxicity 272. We have similarly observed identical labeling performance 
and selectivity with much less cytotoxicity when cells were labeled with these copper-
free reagents (data not shown). Improving cell viability could improve proteome 
selectivity and would also allow for kinetic experiments post-reaction via click. Finally, 
one must consider existing evidence for the occurrence of cytoplasmic proteins bound to 
the extracellular membrane or exposed on the cell surface, particularly in aggressive 
cancer cells " . Thus, a portion of these "cytoplasmic" proteins may be glycosylated 
and surface bound. 
The cell surface glycoproteomics approach we describe can also be expanded to 
other types of glycoprotein targets. For instance, in addition to increased sialylation, 
other types of cancer-related glycosylation changes have been reported, such as increased 
cell surface fucosylation, the addition of polygalactosamine units, higher-ordered 
branching of N-linked glycans and mucin-type O-linked glycosylation. Currently, in 
addition to tetraacelated N-azidoacetyl-D-mannosamine for sialic acid, several click pair 
labeled molecules targeted for these cancer-related glycosylation alterations are 
commercially available 250. For example, tetraacetyl fucose alkyne for fucosylate 
proteins, tetraacelated N-azidoacetylgalactosamine for O-linked glycoproteins and 
tetraacelated N-azidoacetylgluctosamine for O-GlcNAC-modified proteins are readily 
available. In addition to cancer, this method is clearly also valuable for analysis of 
glycosylation changes in immune deficiencies, hereditary disorders, and 
neurodegenerative diseases. 
In summary, we report a new glycoproteomic strategy for the analysis of specific 
subclasses of cell surface glycoproteins. The approach combines selective metabolic 
labeling of cell surface glycans, affinity purification of sialylated proteins, SDS-PAGE 
separation, and subsequent LC-MS/MS for protein identification. A total of 80 proteins 
differentally expressed between cell lines were uniquely identified, including many 
integral plasma membrane glycoproteins that were not reported by previous proteomic 
analyses. Given the importance of the cell surface glycoproteins for drug design, 
biomarker discovery, and the regulation of cellular behaviors, the described protocol 
would help expedite the discovery of new cancer biomarker and therapeutic targets in 
diseases and delineation of signal transduction pathways. 
CHAPTER V 
Aim III: VERIFICATION OF EXPRESSION OF CELL-BASED BIOMARKERS IN 
CLINICSAL SAMPLES 
5.1 Introduction 
Biomarker development is a multistep process entailing several essential 
components: discovery, qualification, verification, research assay optimization, clinical 
validation and commercialization . With the application of high throughput genomic 
and proteomic technologies to biological samples, a large number of biomarker 
candidates with apparent differential expression have been reported as candidates for 
novel cancer detection assays. However, few biomarkers have been validated and 
successfully translated into clinical tests. This is in large part due to the incredible 
mismatch between the large numbers of biomarker candidates and the paucity of reliable 
assays, the cost, and the methods for validation studies . Therefore, the critical step in 
biomarker development lies in screening candidate lists to find those few with 
performance characteristics that merit the effort and expense of full validation. 
Biomarker prioritization is often performed on the basis of case biological knowledge, 
the candidate's performance in discovery datasets, and reagent availability 
Depending on the stringency of the discovery process and the number of candidates 
identified, verification may be undertaken on only a subset of qualified candidates. In 
verification, independent methods should be employed to provide better quantification of 
candidates than is typical for discovery. In addition, verification, like validation, should 
be performed on clinical samples that closely represent the population in which a final 
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clinical test would be deployed . The expected output of prioritization and verification 
is a small number of highly credentialed candidates suitable for validation studies. 
Having identified a panel of differentially expressed cell surface sialoglycoproteins 
on a syngeneic metastatic PCa model by our targeted glycoproteomic approach in Aim II 
study, we further prioritized and verified these metastasis-associated candidates for 
additional rationales. Previously, we used an in vitro cell culture model system. 
Cultured PCa cell lines are valuable tools to replicate the progression of the disease, 
especially for complex metastatic events which are difficult to analyze in clinical 
specimens. They are typically easy to establish, maintain and manipulate. However, cell 
line model systems lack the biological complexity and variability that is inherent in real 
patient samples ' . In addition, the bottom-up strategy employed in our previous 
study has the inherent weakness of unambiguously reassembling the peptide sequence 
into their precursor proteins . Therefore, it is necessary to verify their expression and 
determine their clinical utility to warrant further investment in clinical validation studies. 
Specifically, our prioritization was based on the following criteria: (1) candidates are 
significantly differentially expressed in PCa metastatic variants; (2) bioinformatics 
analysis indicates the cell surface location and potential function in cancer invasion and 
metastasis; (3) literature mining shows an inferred role in cancer progression; (4) specific 
antibodies are available since the immunoassays remain the gold standard for ultimate 
clinical application of validated biomarkers. Using this criteria, we selected two 
glycoprotein candidates from our list, CUB domain containing protein 1 (CDCP1) and 
basigin, for downstream experiments (Fig. 33). Here we present the important findings 
for CDCP1 glycoprotein. 
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Figure 33 The work-flow of verification of cell-based biomarkers. After candidate 
glycoproteins are identified, we prioritize them and confirm the differential expression 
in our cell line models using immunoassays. We also evaluate their expression in 
clinical samples including PCa tissues and Expression Prostate Secretion (EPS) urines 
with different aggressiveness. 
CDCP1 is one of the candidates that were preferentially expressed by the highly 
metastatic ML2 cells. CDCP1 is a type I single transmembrane protein also known as 
substractive immunization associated 135 kDa (SIMA135) 280, gpl40 281, and 
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transmembrane and associated with Src kinases (Trask) , and has been assigned the 
cluster of differentiation (CD) designation CD318 283. Physiologically, CDCP1 is 
expressed by stem or progenitor cells in the hematopoietic, mesenchymal, and neural 
984. 98S 98fi 
tissues ' . It is also overexpressed in a number of solid tumors including breast , 
987 988 980 • 900 901 
colon ' , kidney , pancreatic , and lung cancers . To date, its biological 
function has not been well defined. Some experimental data support the role of CDCP1 
909 90^ 9QH 
in cancer progression ' , ECM degradation , anchorage-independent signaling in 
epithelial cells 294, and cancer cell resistance to anoikis 292, a form of apoptosis triggered 
by the loss of cell survival signals generated from the interaction of cells with the 
extracellular matrix. In PCa, although the potential of CDCP1 as a therapeutic target as 
cancer treatment has been evaluated by an anti-CDCPl monoclonal antibody generated 
90S 
from a phage display combinatorial antibody library , its expression and potential 
clinical significance have not been systematically studied. 
In Aim III, we comprehensively examined CDCP1 protein expression in a battery of 
prostate cancer cell lines and clinical samples by applying multiple immuno-based 
methods. We also characterized the glycosylation status of CDCP1 by employing a 
series of glycosidases and glycosylation inhibitors. Importantly, we evaluated the 
potential clinical significance of CDCP1 expression in PCa patient samples, including 
surgical PCa tissues and Expressed Prostatic Secretion (EPS) urine fluids. Overall, our 
139 
studies suggest that CDCP1 is dysregulated in prostate cancer and it might be a useful 
diagnostic marker and therapeutic target for PCa patients. 
5.2 Materials and Methods 
Antibodies and Reagents — The following CDCP1 -specific antibodies were used in the 
study: mAb 41-2, generated by subtractive immunization with a nonmetastatic population 
versus metastatic population of epidermoid HEp-3 carcinoma , and kindly provided by 
Dr James P. Quigley (The Scripps Research Institute, CA, USA); rabbit antibody 
CS4115, generated against the COOH-terminal peptide of CDCP1 (Cell Signaling, 
Danvers, MA, USA); and goat antibody AF2666 recognizing the extracellular domain of 
CDCP1 (R&D Systems, Minneapolis, MN, USA). Murine anti-P-actin (#612656) and 
anti-mAb (#610524) were provided by BD PharMingen (San Diego, CA, USA). Murine 
anti-Golgi 58 kD protein (ab27043) was purchased from Abeam (Cambridge, MA, USA). 
IRDye 700 or IRDye 800 conjugated secondary reagents and Alexa Fluor 488 or Alexa 
Fluor 594 conjugated secondary reagents were from Li-COR Bioscences (Lincoln, PA, 
USA) and Invitrogen (Carlsbad, CA, USA), respectively. Control immunoglobulins 
(IgGs) were from Vector lab (Burlingame, CA, USA). Complete™ protease inhibitor 
cocktail and Halt™ protease inhibitor cocktail were from Roche Applied Sciences 
(Indianapolis, IN, USA) and Pierce (Rockford, IL, USA). PNGase F, Neuraminidase, 
and Endoglycosidase H were from New England Biolabs (Beverly, MA, USA). High 
capacity streptavidin agarose resin and protein A/G PLUS-agarose were from Thermo 
Scientific (Rockford, IL, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Dulbecco's modified Eagle media (DMEM) and fetal bovine serum (FBS) were from 
Invitrogen. Antibiotics-antimycotic, Click-iT ManNAz metabolic glycoprotein 
reagent, Click-iT™ Biotin Protein Analysis Detection Kit, propidium iodide, TO-PR03, 
4-12% NuPAGE® Bis-Tris gels, and lithium dodecyl sulfate (LDS) buffer were from 
Invitrogen. 2 x Laemmli buffer, 7.5% Criterion® Tris-HCl Gel, Precision protein 
standards, and Bio-Safe coomassie blue were from Bio-Rad (Hercules, CA, USA). All 
other chemicals were from Sigma (St. Louis, MO, USA). 
Cell Lines — Human prostate bone metastasis PC3, prostate carcinoma lymph node 
metastasis LNCaP, prostate carcinoma brain metastasis DU145, and prostate carcinoma 
xenograft 22Rvl cell lines were obtained from the American Type Culture Collection 
(ATCC). PC3 two sublines denoted PC3-N2 (non-metastatic) and PC3-ML2 (highly 
metastatic) were selected based on differential invasiveness and ability to form metastatic 
tumors in SCID mice as described and kindly provided to us by Dr. Stearns' group at 
Drexel University. The lineage-related LNCaP sublines C4, C4-2 and C4-2B were 
resulted from passage and hormone manipulation of LNCaP cells in vivo. They mimic 
the progression of PCa from androgen sensitive (LNCaP and C4) to androgen refractory 
(C4-2 and C4-2B), as well as the increasingly malignant phenotype from primary tumor 
(C4-2) to bone metastases (C4-2B) in a nude mouse host. These cells were developed by 
9QA 9Q7 
Dr. Chung's group ' and provided to us via ViroMed Labs. HPV-18 immortalized 
prostate epithelial cell line RWPE-1 retains some "normal" cell attributes such as 
responsive to growth factors and androgen. The cells were exposed to mutagen and 
sublines WPE1-NB14 and WPE1-NB26 were derived with variable phenotype. The 
WPE1-NB14 and NB26 lines are both anchorage independent but differ in their 
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invasiveness. The WPE1-NB14 is moderatlye invasive in vitro wheras NK26 has a high 
invasive ability. These sublines were developed by Dr.Williams' group at the University 
of Michigan and purchased from ATCC. Another prostate carcinoma lymph node 
metastasis PacMetUTl cell line 2 " was obtained from the University of Texas Health 
Science Center at San Antonio. All of the cells were cultured in the growth medium and 
passaged according to the developer's and manufacturer's instructions. 
Expressed Prostatic Secretion (EPS) Urine Sample Preparation— EPS Urine samples 
were collected from men reporting to the clinic for a prostate biopsy procedure at the 
Urology of Virginia, Sentara Medical Group and Eastern Virginia Medical School 
between 2007 and 2009, under the informed consent and Institutional Review Board 
approved protocols as described 30°. Briefly, following a gentle prostate massage during 
a digital rectal examination (DRE), the first voided urine (10-20 ml) containing the EPS 
was obtained from each individual. Then, they were centrifuged to remove the cell 
pellet/sediment, and the supernatant was aliquoted and stored at -80°C. In this study, 
individual EPS urine sample pools representative of non-cancer (n=15), low-grade PCa 
(n=16), and high-grade PCa (n=14) conditions were compiled. Non-cancer cases were 
defined as being biopsy negative for cancer, low-grade PCa samples were exclusively a 
Gleason grade of 6 (3+3), and high-grade PCa samples were with a Gleason score of 8 
and above, predominantly 9 or 10. Each pool was concentrated to ~200 fold using an 
Amicon Ultra spin filter (10 kDa and 3 kDa cutoff; Millipore) and the aliquots were 
stored at -80°C. Protein concentration was measured by Bradford assay. 
142 
Flow Cytometry Analysis — Confluent cultures of N2 and ML2 cells were harvested 
from the culture dishes by non-enzyme dissociation buffer, washed with 2% FBS in PBS, 
and incubated with mouse-anti-CDCPl mAb 41-2 antibody (6 jag/ml) for 1 h at 4°C. 
After two washes, cells were incubated with Alexa Fluor 488-conjugated goat-anti-mouse 
antibody (2 (J-g/ml) for 30 min at 4°C. Before subjected to flow cytometry analysis, cells 
were treated with propidium iodide (1 ug/ml) in 500 ul 2% FBS in PBS for 20 min at 
4°C. Cells stained without the primary antibody were used as negative controls. Data 
was acquired by FACScalibur and analyzed by Flowjo software. 
Immunofluorescence Staining of Cultured Cell Lines — Cells were seeded onto 6-well 
plates containing glass coverslips and cultured in growth medium to 80% confluence. 
They were washed with ice-cold PBS and fixed in 4% paraformaldehyde for 15 min at 
room temperature. For intracellular staining, the cells were permeabilized with 0.5% 
Triton X-100 in PBS for 10 min at room temperature or ice-cold 100% methanol for 10 
min at -20°C. Cells were subsequently washed twice with PBS, blocked with 3% BSA in 
PBS for 1 h at room temperature. The cells were then incubated with mouse anti-CDCPl 
mAb 41-2 (6 ug/ml) or rabbit-anti-CDCPl CS4115 (1:100 dilution) polycolonal 
antibodies in the blocking buffer overnight at 4°C. After three washes, the cells were 
incubated with Alexa Fluor 488 or 594-conjugated secondary antibodies (2 ug/ml, goat 
anti-mouse or goat anti-rabbit IgG, respectively) in the blocking buffer for 1 h at room 
temperature. Nuclei were stained with TO-PR03. For double staining with click 
labeling, cells were grown in medium supplemented with 20 uM AC4ManNAz or 
ManNAc for 2 days, fixed as above, subjected to click reaction solution (25 ul biotin-
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alkyne, 5 ul CuS04, 5 ul and 10 ul for component D and E, 65 ul PBS, total 100 fal) for 
30 min at room temperature. Cells were then permeablized and incubated with anti-
CDCP1 antibodies as above. The next day, cells were stained with Alexa Fluor 488-
conjugated streptavidin (2 ug/ml) and Alexa Fluor 594-conjugated CDCP1 secondary 
antibody for 1 h at room temperature. For double staining with the ER and Golgi 
markers, cells were fixed and permeabilized as above, incubated with mouse-anti-
calnexin (2.5 ug/ml) or anti-Golgi 58kDa protein (5 |ag/ml) antibodies, and rabbit-anti-
CDCP1 CS4115 (1:100 dilution) overnight at 4°C. The following day, cells were stained 
with Alexa Fluor 488 or 594-conjugated secondary antibodies as above. The cells were 
finally washed twice, mounted to the slides with VectorShield medium (Vector Labs, 
Burlingame, CA, USA), and sealed with nail polish. Cells treated in a similar way but in 
the absence of primary antibodies were included as negative controls. Labeled cells were 
visualized and photographed using a Zeiss LSM510 META confocal imaging system at 
the appropriate excitation/emission wavelengths (Carl Zeiss, Thornwood, NY, USA). 
Tissue Samples and Immunofluorescence Staining — O.C.T.-embedded frozen PCa 
tissues from patients who underwent radical prostatectomy were obtained from our 
Virginia Prostate Center. Cryosectioning was done on a Microm HM 505E cryostat at 
-20°C. A serial cryosection (6 urn) was stained with Hematoxylin and Eosin (H&E) as a 
guide and analyzed by a pathologist to determine tissue morphology. Two additional 
serial sections were mounted on Superfrost microscope slides and used for 
immunofluorecence staining. Tissue sections were fixed immediately after cutting in 4% 
paraformaldehyde in PBS for 15 min, and permeabilized with 0.5% Triton X-100 in PBS 
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for 10 min. They were then blocked with 3% BSA in PBS for 1 h and incubated with 
mouse-anti-CDCPl mAb 41-2 antibody (6 ug/ml) overnight at 4°C. After three washes, 
the cells were incubated with Alexa Fluor 488-conjugated secondary goat-anti-mouse 
antibody (2 fig/ml) in the blocking buffer for 1 h at room temperature. Nuclei were 
stained with propidium iodide (PI) (0.1 |J.g/ml) for 3 min before mounting and sealing. 
An adjacent section treated similarly but in the absence of primary antibody was used as 
the negative control. Slides were viewed and imaged by an Olympus BX51 fluorescent 
microscope fitted with a DP70 digital camera and a Zeiss LSM510 META confocal 
imaging system. 
Deglycosylation Assays — To elucidate glycan components of CDCP1, enzymatic 
deglycosylation experiments were performed. Before PNGase F and Endo H treatment, 
cell lysates (20 ag) from PC3, N2, and ML2 cells were denatured and reduced for 10 min 
at 100°C in 0.5% SDS and 1% 2-mercaptoethanol. For PNGase F digestions, samples 
were adjusted to 1 % Nonidet P 40 and 50 mM sodium phosphate, pH 7.5, and then 
incubated with PNGase F (1,000 NEB units) overnight at 37°C. For Endo H digestions, 
samples were adjusted to 50 mM sodium citrate, pH 5.5. After addition of Endo H (1,000 
NEB units), the mixtures were incubated overnight at 37°C. Neuraminidase reactions 
were incubated overnight at 37°C in 50 mM sodium acetate, pH 6.0 and contained 50 
NEB units neuraminidase per 20 ug of protein. Fetuin was used as the positive controls 
for PNFase F, Endo H, and neuraminidase deglycosylation. For drug treatment, near-
confluent cells were washed twice with PBS and cultivated for 23 h in fresh culture 
media in the absence or presence of 5 ug/ml tunicamycin or 1 ug/ml swainsonine. Cells 
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were then washed twice before addition of M-PER lysis buffer containing lx complete 
protease inhibitor. The cell lysates were collected with a rubber scraper, passed through 
26-gauge needles, and sonicated by 3 times for 10 seconds. The whole cell lysates were 
centrifuged at 14,000g for 15 min to remove cell debris and unbroken cells. The 
supernatant was saved and protein concentration was tested by the BCA protein assay kit. 
Western blot analysis — Whole cell lysates were collected in the M-PER lysis buffer 
containing lx protease inhibitor cocktail. Protein concentrations were measured by the 
BCA protein assay. Cell lysates, streptavidin pull down fractions, and serum-free 
conditioned media were separated by electrophoresis through 4-12% or 7.5% SDS-PAGE 
and then transferred to Immobilon-FL PDVF membranes (Millipore, Billerica, MA, 
USA). Membranes were blocked in LiCor blocking buffer (Rockland Immunochemicals, 
Gilbertsville, PA, USA) diluted with PBS (1:1) and then incubated with anti-CDCPl 
primary antibodies (CS4115, 1:1000; AF2666, 0.2 ug/ml) overnight at 4°C. Following 
extensive washing, membranes were incubated with species-specific IRDye700 or 800-
conjugated secondary antibodies (goat anti-rabbit, 1:15,000; donkey anti-goat, 1:15,000) 
for 1 h at room temperature, and visualized with a LiCor Odyssey infrared imager (LiCor, 
Lincoln, NE, USA). Consistent protein loading was determined by reprobing membranes 
stripped in Restore Western blot stripping buffer with anti-actin antibody (0.05 ug/ml). 
5.3 Results 
5.3.1 Identification of CDCP1 in ML2 Cell surface Sialoglycoprotein Enriched 
Fraction 
Having combined metabolic labeling and click chemistry with LC-MS/MS, we 
successfully identified a panel of cell surface sialoglycoproteins whose expression was 
differential between metastatic (ML2) and nonmetastatic (N2) human prostate cancer 
cells. CDCP1 is one of the candidates that were identified only from metastatic ML2 
cells. Here we present the details about how CDCP1 was confidently identified by this 
technique. After using the streptavidin pull down assay in Aim II, we saw an intense 
signal at sub-150 kDa in eluted fractions from cells treated with ManNAz, which was 
absent in flow-through fractions and eluents from the control group (Fig. 25). 
Specifically, in-blot streptavidin IR-800 detected a higher intensity of this area in the 
ML2 eluent than that of the N2 eluent (Fig. 34A, SAvB). The corresponding bands from 
a Coomassie stained gel (Fig. 34A, CB) were excised and analyzed by LC-MS/MS. 
Three unique peptides from the 135-kDa band of ML2 eluent were determined by mass 
spectrometry to be the recently identified membrane protein CDCP1 (Fig. 34A). The 
positions of these peptides in the sequence of CDCP1 were designated in Figure 34B. 
They spanned the amino acids within intracellular carboxy terminus (peptide 3:700-718), 
extracellular CUB1 (peptide 1:280-297) and CUB3 domains (peptide 2: 582-593). 
Figure 34C showed the fragmentation pattern of nanoelectrospray ionization MS/MS of 
the doubly charged (m/z 910.3) tryptic peptide, which corresponded to the C-terminal 
tryptic fragment of human CDCP1. There was no CDCP1 identified in N2 or the control 
fractions, although the overall protein pattern and content was indistinguishable for N2 
and ML2 eluents (Fig. 34A, CB). 
147 
SAvB CB 
N2 ML2 N2 ML2 
250 -
Peptide 1: R.VEYYIPGSTTNPEVFK.L 
Peptide 2: R.OQVACLTFFKE 
Peptide 3: K.GPAVGIYNGNINTEMPR.Q 
s-ga&as m 
B 








CUB2 CUm TM CytoplwnicDoiMln 





Figure 34A-B Identification of CDCP1 in ML2 cell surface sialoglycoprotein enriched 
fraction. (A) N2 and ML2 cells were metabolically treated with AC^ManNAz and 
conjugated with biotin-alkyne on live cells via click reaction. The total cell lysate was 
extracted and pulled down with streptavidin resins. Aliquots of the purified 
sialoglycoproteins were examined by in-blot streptavidin-IR 800 (SAvB) detection, 
and the remaining samples were stained with Bio-Safe coomassie blue (CB). Three 
tryptic peptide fragments determined by LC-MS/MS (peptides 1 to 3) were indentified 
within the sequence of CDCP1. (B) Schematic representation of human CDCP1 
structural features including N-terminal signal peptide, 3 extracellular CUB-like 
domains, 14 potential N-glycosylation sites, transmembrane domain, and intracellular 
cytoplasmic domain. Dark boxes indicate the positions of tryptic peptides identified by 
LC-MS/MS. 
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Figure 34C Identification of CDCP1 in ML2 cell-surface sialoglycoprotein enriched 
fraction. (C) Representative mass spectra of tryptic CDCP1 digestion. Top panel: MS 
spectrum of the CDCP1 tryptic peptides; arrow indicates ion at m/z= 910.31 (2+) 
selected for MS/MS. Low panel: MS/MS spectrum of the peptide 
K.GPAVGIYNGNINTEMPR.Q, annotated using the y-ions series. 
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5.3.2 CDCP1 Structural Features 
The schematic representation of human CDCP1 structure features was included in 
Figure 34B. Consistent with a predicted cell surface protein, CDCP1 contains a signal 
peptide at position 1-29, an extracellular domain at 30-665, a transmembrane domain at 
666-686, and cytoplasmic domains at 687-836. It was reported that the extracelluar 
domain harbors three regions with low homology to complement protein subcomponents 
Clr/Cls, urchin embryonic growth factor, and bone morphogenetic protein 1 (CUB) 
domains, which could be involved in proteinrprotein and protein:carbohydrate 
interactions . Importantly, there are 14 consensus N-glycosylation sites predicted in 
the extracellular part, as well as a palmitylation motif and five tyrosine residues present 
in the intracelluar domain, indicating the potential function of CDCP1 in outside-in signal 
transduction 283. The predicted mass for full length CDCP1 is 92.9 kDa and 90.1 kDa for 
mature CDCP1 after signal peptide cleavage. However, the apparent molecular weight in 
Western blot is 135-140 kDa indicating extensive glycosylation 280. UniProtKB database 
suggests that CDCP1 may have two truncated isoforms: CDCP2 (73 kDa) which is 
missing 187 amino acids from its N-terminal and CDCP3 (34 kDa) that lacks 502 amino 
acids from its C-terminal and is a secreted form. To date, there has been no evidence 
about the presence of these two isoforms. 
5.3.3 CDCP1 Expression in Prostate Cell Lines 
To verify our proteomic results, we compared CDCP1 levels in cell surface 
glycoprotein enriched fractions and whole cell lysates by Western blot. N2 and ML2 
cells were metabolically labeled, conjugated with biotin-alkyne, and lysed as described 
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above. An equal volume of streptavidin pull down eluents was resolved by SDS-PAGE 
and detected by a rabbit polyclonal antibody generated against peptides near the C-
terminus. Consistent with the observed LC-MS/MS differential of CDCP1 between PC3 
variants, Western blot analysis of the cell surface glycoprotein pool demonstrated that 
CDCP1 levels were ~3.4-fold greater on the surface of ML2 compared with N2 cells 
(Fig. 35A). The level of CDCP1 (135 kDa) in ML2 total cell lysate was also higher (1.5-
fold) than N2 lysate, albeit not as dramatically as in the surface fraction (Fig. 35B). 
Besides 135 kDa full-length CDCP1, N2 and ML2 cells also manifested another 
truncated (70 kDa) species, a proteolysis product of 135-kDa species, as recently reported 
. Although LMW-CDCP1 presented marginal levels in both N2 and ML2 streptavidin 
pull down fractions (Fig. 35A), we could not identify this species by our targeted 
glycoproteomic approach, mostly like because its levels were beyond MS detection 
threshold. Interestingly, LMW-CDCP1 displayed a lower level (1.7-fold) in ML2 lysate 
than N2 lysate. Therefore, the ratio of HMW-CDCP1 to LMW-CDCP1 seemed to be 
correlated with metastatic ability of prostate cancer cells. There was a slight difference in 
the apparent molecular weight of this protein between N2 and ML2 cells, possibly 
reflecting different glycosylation status of CDCP1 in metastatic cells. 
Since increased levels of CDCP1 were observed in some aggressive epithelial tumor 
cells , we set out to investigate the expression of CDCP1 in a panel of prostate cell 
lines. As shown in Figure 36, CDCP1 protein was detected in all 13 prostate cell lines 
examined but with various expression levels: 10 clearly expressed both forms of CDCP1: 
PC3 and its two sublines, LNCaP and its three sublines, RWPEl's two sublines, and 
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Figure 35 Verification of CDCP1 expression in N2 and ML2 cells. (A) N2 and ML2 
cells were metabolic labeled with AC4ManNAz, and conjugated with biotin-alkyne 
via click chemistry. Then total cell lysates were extracted and subjected to 
streptavidin pull-down assays as described previously. The eluted fractions were 
analyzed by Western blot with CDCP1 antibody (pAb4115). Cells treated with 
natural ManNAc were used as controls by following the same experimental 
procedures. (B) Western blot analysis of total cell lysates of RWPE1, PC3, N2, and 
ML2 with CDCP1 antibody. P-actin was included as a loading control. 
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Figure 36. Verification of CDCP1 expression in prostate cell lines. Whole cell 
lysates were prepared from different prostate cell lines and their sublines. Western 
blot analysis was performed with primary antibody specific to CDCP1 (pAb4115). 
P-actin was included as a loading control. PC3 & Sublines: PC3 (androgen-
independent), developed from a skeletal metastasis; N2 and ML2, selected from PC3 
cell line; N2 is non-metastatic while ML2 is metastatic. LNCaP & Sublines: LNCaP 
(androgen-dependent), isolated from the lymphnode of a confirmed metastatic PCa 
patient; C4, C4-2 and C4-2B, developed from LNCaP; C4-2, androgen-independent 
and tumorigenic; C4-2B, androgen-refractory and bone metastatic. RWPE-1 & 
Sublines: RWPE-1, HPV-18 immortalized prostate epithelial cell line response to 
growth factors and androgen; WPE-NB-14, tumorigenic and moderately invasive; 
WPE-NB-26, tumorigenic and highly invasive. DU145 (androgen-independent), 
isolated from a brain lesion of a metastatic PCa patient. PacMetUTl, isolated from a 
lymph node of PCa patient. 
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PacMetUTl, and 22Rvl prostate cells. Among these cells, the highest CDCP1 
expression was found in androgen-independent prostate cancer cell lines of the PC3 
lineage followed by DU145 cells. Lower CDCP1 expression was found in androgen 
dependent LNCaP cells, its androgen refractory C4-2 and C4-2B sublines, as well as 
RWPE1 subline cells. In LNCaP and RWPE1 prostate cancer progression models, the 
correlation of ratio of HMW-CDCP1 to LMW-CDCP1 with invasive activity appeared 
not strong in panels of tumor cell line from same origins but with more aggressive 
phenotypes. 
5.3.4 Characterization of CDCP1 Glycosylation 
CDCP1 was identified in our cell surface sialoglycoprotein enriched fractions. The 
apparent molecular mass of CDCP1 in SDS-PAGE (135 kDa, Fig. 35A) exceeded that 
predicted by primary sequence analysis (90 kDa). Moreover, there are 14 potential N-
linked glycoprotein sites in the extracellular part of human CDCP1 (Fig. 35B). All of 
these observations highlight the possibility of CDCP1 glycosylation. However to date, 
no study about the carbohydrate structure of CDCP1 has been reported. 
To address CDCP1 glycosylation, we first employed three glycosidases with 
different specificities to enzymatically digest CDCP1 in vitro. Whole cell extracts were 
treated with N-glycosidase F (PNGase F) that cuts off entire N-linked glycans, 
neuraminidase which hydrolyzes terminal sialic acid units, or Endoglycosidase H (Endo 
H) that preferentially cleaves high mannose-containing and hybrid oligosaccharides (Fig. 
37A). Then proteins were separated by SDS-PAGE, and subjected to Western blot 
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Figure 37 Characterization of CDCP1 glycosylation in vitro. (A) Schematic 
representation of cleavage sites for the three highly specific glycosidases, PNGase F, 
Endo H, and neuraminidase, respectively on a complex type of N-linked 
oligosaccharide. (B-D) Western blot analysis of untreated and PNGase F (B) 
neuraminidase (C), and Endo H (D) hydrolyzed lysates from PC3, N2, and ML2 
cells. The blots were probed with specific CDCP1 antibody (pAb4115). P-actin was 
included as a loading control. 
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of 135 kDa and 70 kDa bands and generation of lower molecular weight bands of 
approximately 90 kDa and 60 kDa, respectively, the former corresponding to the mass of 
deglycosylated HMW-CDCP1 form. After digestion with neuraminidase, the size of the 
HMW band decreased slightly, whereas the changes of LMW band were not detectable 
(Fig. 37C). These results indicated higher sialic acid content in N-glycans of the HMW-
CDCP1 than the LMW species, which was consistent with the previous cell surface 
glycoproteomic data. In that experiment, we could only detect the marginal levels of 
LMW-CDCP1 expression compared to the significantly high levels of HMW-CDCPlin 
the cell surface sialoglycoprotein enriched fractions (Fig. 35A). Deglycosylation with 
Endo H led to a mass shift of 25 kDa for HMW-CDCP1 (Fig. 37D), less than what would 
be expected for the full cleavage of N-glycans (45 kDa). This result demonstrated that 
high-mannose or hybrid oligosaccharide chains only contributed to a portion of the N-
glycans present on HMW-CDCP1. In contrast, Endo H treatment of LMW-CDCP1 
produced several broad bands closer to or even lower than that after N-glycan removal 
(Fig. 37D), suggesting the presence of different glycoforms of LMW-CDCP1 containing 
a higher extent of mannose or hybrid glycosylation, and implying occurrence of O-
glycans on this CDCP1 species. 
To further study the glycosylation status of CDCP1 in vivo, we treated cells with a 
N-linked glycosylation inhibitor tunicamycin (TM) or a mannosidase inhibitor II 
swainsonine (SW) under conditions optimal for drug activity but minimal for 
cytotoxicity. Whole cell extracts were then obtained and examined by Western blot 
analysis. Addition of TM, a nucleoside antibiotic which prevents the formation of the 
dolichol intermediate necessary for oligosaccharide addition of the nascent polypeptide 
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chain caused a significant decrease in cellular HMV-CDCP1, which was similar to the 
results produced with the PNGase F treatment (Fig. 38A). Surprisingly, TM did not 
affect the migration of LMW-CDCP1 in gel. Addition of SW, which blocks converting 
N-glycans from hybrid-type to complex-type during mannose processing in Golgi, 
slightly decreased the masses of HMW-CDCP1, but had no effect on LMW-CDCP 1 
levels (Fig. 38B). This result reflected the addition of complex glycosylation to HMW-
CDCP1 but not LMW-CDCP 1, consistent with results from the Endo H treatment. 
Like sialylation, fucosylation is another form of glycosylation commonly present on 
cell surface glycoproteins. Altered fucosylation has been also associated with cancer 
progression and metastasis . To determine whether CDCP1 is a carrier of cell surface 
fucosylation, we applied our targeted glycoproteomic strategy for cell surface fucosylated 
glycoproteins. N2 and ML2 cells were metabolically labeled with alkyne fucose and 
probed with biotin-azide via click chemistry. Then, total cell lysates were subjected to a 
streptavidin pull-down assay and the eluted fractions were analyzed by Western blot with 
CDCP1 antibody. As shown in Figure 39, the same levels of HMW-CDCP1 were 
detected in N2 and ML2 treated fractions (fucalkyne), but absent in control groups (fuc), 
indicating fucosylation of HMW-CDCP1 to the same degree in N2 and ML2 cells. 
Conversely, there was no detectable fucosylation on LMW-CDCP 1. 
Taking together, the above data suggested that although both CDCP1 species 
contained heavy N-linked glycans and were modified by fucose, the type and extent of 
carbohydrate moieties attached were different; the carbohydrate present on the HMW-
CDCP1 harbored three types of N-glycosylation and was terminated by a significant 
amount of sialic acid residues. In contrast, high-mannose/hybrid-type N-glycans and 
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Figure 38 Characterization of CDCP1 glycosylation in vivo. (A-B) PC3, N2, and 
ML2 cells were treated with or without tunicamycin (5 |ag/ml, A) or swainsonine (1 
l-ig/ml, B) for 23 h. The total cell lysate was extracted and analyzed by Western blot 
with CDCP1 antibody (pAb4115). P-actin was included as a loading control. 
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Figure 39 Fucosylation of CDCP1 in N2 and ML2 cells. N2 and ML2 cells were 
metabolic labeled with alkynl fucose (fuc_alkyne) and probed with biotin-azide 
via click chemistry. Then total cell lysates were extracted and subjected to 
streptavidin pull down assays. The eluted fractions were analyzed by Western blot 
with CDCP1 antibody. Cells treated with natural fucose (fuc) were used as 
controls by following the same experimental procedures. 
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probably O-glycans were primarily present on LMW-CDCP1. 
5.3.5 Cellular Expression of CDCP1 in N2 and ML2 Cells 
CDCP1 expression in N2 and ML2 cells was further substantiated by analysis of 
CDCP1 protein expression on the cell surface by flow cytometry (Fig. 40A) with a 
mouse monoclonal antibody (mAb 41-2) generated in subtractive immunization 280. Both 
living N2 and ML2 cells showed high levels of cell surface CDCP1, but ML2 cells (Mean 
fluoresence intensity, MFI, 377) seemed to have more CDCP1 on the cell surface than N2 
cells (MFI, 290). Immunofluorescence staining of permeabilized N2 and ML2 cells, 
using the same antibody, showed a clear plasma membrane localization of CDCP1 (Fig. 
40B). Surprisingly, some intracellular juxtanuclear staining was also found in both N2 
and ML2 cells. No positive immunostaining of N2 and ML2 cells was observed in the 
absence of the primary antibody indicating the specificity of the antibody for human 
CDCP1. A similar finding was observed staining using another antibody CS4115 (data 
not shown). 
Since the glycosylation processing and transport pathway of a cell surface 
glycoprotein usually go via the ER and Golgi apparatus, we further examined the 
subcellular location of CDCP1 in N2 and ML2 cells by co-localization studies. First, we 
wanted to confirm the plasma membrane localization of CDCP1. As expected, 
simultaneously applying glycan chemical labeling and immunoflurecence staining with 
CDCP1 antibody revealed complete cell surface co-localization (Fig. 41, yellow 
coloring), consistent with the initial technique used to identify CDCP1. We next 
investigated which particular intracellular compartments CDCP1 was located, using 
Figure 40 Cellular expression of CDCP1 in N2 and ML2 cells. (A) Flow cytometry 
analysis of CDCP1 expression in N2 and ML2 cells. N2 and ML2 cells dissociated 
from the flasks were incubated with CDCP1 antibody mAb 41-2 (closed histograms) 
or blocking buffer (open histograms) and then with goat anti-mouse IgG conjugated 
with Alexa 488. PI staining was used to gate living cells. Data was acquired by 
FACScalibur and analyzed by Flowjo software. (B) Immunofluorescence analysis of 
CDCP1 expression in N2 and ML2 cells. N2 and ML2 cells growing on coverslips 
were fixed with 4% paraformaldehyde and permeabilized with ice-cold 100% 
methanol. They were incubated with CDCP1 antibody mAb 41-2 (top panel) or 
blocking buffer (bottom panel), stained with goat anti-mouse IgG conjugated with 
Alexa Fluor 488 (green). The nuclei were stained with TO-PR03 (blue). Fluorescent 
images were captured by Zeiss confocal microscopy. 
Figure 41 Analysis of CDCP1 subcellular location by colocalization. N2 cells 
were treated with AC4ManNAz for 2 days, fixed with 4% paraformaldehyde, 
and conjugated with biotin-alkyne via click reaction. Cells were then 
permeabilized with 0.5% Triton X-100, and stained with streptavidin-Alexa 
Fluor 488 (green) and anti-CDCPl antibody (pAb 4115), Alexa Fluor 594-
conjugated secondary reagents (red). The nuclei were stained with TO-PR03 
(blue). Fluorescent images were captured by Zeiss confocal microscopy. 
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double immunostaining of CDCP1 and an ER-resident marker calnexin or a Golgi 
complex marker 58 kDa protein in N2 cells. As shown in Figures 42 and 43, cells 
expressing endogenous CDCP1 displayed a perinuclear and associated reticular staining 
typical of the ER (Fig. 42) along with a juxtanuclear pattern typical of the Golgi 
apparatus (Fig. 43). Merging images with CDCP1 signal resulted in considerable 
punctuate overlapping patterns, indicating CDCP1 was localized and processed in ER and 
Golgi complex. Taking together, immunofluorescent and co-localization data indicated 
that CDCP1 went along with the secretory pathway and mainly localized on the plasma 
membrane in prostate cancer cells. 
5.3.6 CDCP1 Expression in Prostate Cancer Tissues 
The expression pattern of CDCP1 protein in four frozen sections of human prostate 
cancer tissues was examined by immunofluorescence with the use of mAb 41-2 (Fig. 44). 
CDCP1 was present on normal prostate epithelial cells as well as on malignant cells. 
However, the staining intensity and subcellular staining pattern were significantly 
different between malignant and adjacent normal epithelial cells. In contrast to a 
previous report that found the staining of malignant glands was generally less 
prevalent and less intensive than benign glands, we observed that human prostate 
epithelial cancer cells had overall higher reactivity than the matched normal ones (Fig. 
44A, b-c), although CDCP1 expression levels varied among tumor cells in the same case. 
Malignant epithelial cells expressing CDCP1 protein usually belonged to a single acinus 
or to a few adjacent acini (Fig. 44A, h-i). Staining was predominantly localized on the 
plasma membrane in cancerous epithelial cells as shown by the confocal images (Fig. 
Figure 42 Analysis of CDCP1 ER subcellular location by Immunolocalization. 
N2 cells growing on coverslips were fixed with 4% paraformaldehyde, and 
permeabilized with ice-cold 100% methanol, and stained with anti-CDCPl 
antibody (pAb 4115), Alexa Fluor 488-conjugated secondary reagents (green), 
and anti-calnexin antibody, Alexa Fluor 594-conjugated secondary reagents 
(red). The nuclei were stained with TO-PR03 (blue). Fluorescent images were 
captured by Zeiss confocal microscopy. Arrow indicated the punctuate 
colocalization patterns of CDCP1 and calnexin. 
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Figure 43 Analysis of CDCP1 Golgi subcellular location by Immunolocalization. 
N2 cells growing on coverslips were fixed and permeabilized with 0.5% Triton 
X-100, and stained with anti-CDCPl antibody (pAb 4115), Alexa Fluor 488-
conjugated secondary reagents (green) and anti-Goldi 58 kD protein antibody, 
Alexa Fluor 594-conjugated secondary reagents (red). The nuclei were stained 
with TO-PR03 (blue). Fluorescent images were captured by Zeiss confocal 
microscopy. Arrow indicated the punctuate colocalization patterns of CDCP1 and 
Golgi58 kD protein. 
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44C, d-f). The basal surface contained more concentrated CDCP1 than the apical and 
lateral membranes. In contrast, in adjacent normal cells the majority of the CDCP1 
targeted was in a discrete juxtanuclear compartment, close to basal side. The staining on 
the plasma membrane appeared to a much lesser degree than in cancer cells (Fig. 44C, a-
c). The proportion and intensity of cancerous cells expressing CDCP1 protein in a given 
tissue section were heterogeneous, but it seemed to increase with the high Gleason score 
(Fig. 44D). Other cell types including blood cells, endothelium, vascular smooth muscle, 
neuroendocrine cells, and prostatic stoma fibroblasts, were negative. Control sections 
that were incubated with the secondary, but not the primary antibody, were free of 
staining (Fig. 44B). In summary, the expression of CDCP1 proteins in prostate cancer 
tissues was altered as it presented extensively on the plasma membrane of malignant 
epithelial cells with elevated level of expression. 
5.3.7 Shedding of CDCP1 Ectodomain from Conditioned Media and EPS Samples 
A number of integral cell surface proteins, such as c-met and CD44 are also 
produced as soluble molecules303'304. Western blot analysis, probing with an antibody 
generated against the CDCP1 extracellular domain (AF2666), was employed to examine 
whether PCa cells produce a soluble form of CDCP1. The concentrated serum-free 
conditioned media (SFCM) from DU145 cells was used as a positive control because a 65 
kDa CDCP1 ectodomain was recently reported in DU145 SFCM302. As shown in 
Figure 45A, the antibody detected several immunoreactive bands (55 kDa, 42 kDa, 33 
kDa, and 28 kDa) in EPS urine, possibly the ectodomain shedding of CDCP 1. After 
normalization of total protein loading, as shown in Figure 45B, band at 55 kDa was 
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Figure 44A-B Expression of CDCP1 in prostate patient tissues. (A) 
Immunofiuorescent analysis of CDCP1 expression in matched normal (N) and 
cancerous (T) prostate tissues from a PCa patient (Gleason score = 3+4). Successive 
sections (6 um) were stained with H&E (a, d, g) or anti-CDCPl antibody (mAb41-
2) and Alexa Fluor 488-conjugated secondary reagents (green, b-c, e-f, h-i). Nuclei 
were stained with PI (red, b, e, h). d-f and g-i showed high magnification (x400) of 
the normal glands (N) and tumor glands (T) marked in the top panels (white box), 
respectively. Images were captured by Olympus fluorescent microscopy. 
Magnification for top panel xlOO, for middle and low panels x400. (B) Negative 
control for CDCP1 staining. Slides stained in the absence of primary CDCP1 
antibody were used as negative controls 
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Figure 44C Expression of CDCP1 in prostate patient tissues. (C) Immunofluorescent 
analysis of CDCP1 subcellular location in matched normal and cancerous prostate 
tissues from a PCa patient (Gleason score = 3+4). PCa sections were stained with 
anti-CDCPl antibody (mAb41-2, green) and/or PI (red) and representative images 
for normal glands (a-c) and tumor glands (d-e) were demonstrated, b-c and e-f 
showed high magnification of the normal glands and tumor glands marked in the left 
panels (white box), respectively. Images were captured by Zeiss cofocal microscopy. 
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Figure 44D Expression of CDCP1 in prostate patient tissues. (D) Three more PCa 
tissues were analyzed for CDCP1 expression. Top panels, tissue specimens were 
stained with H&E and examined by the pathologist. Bottom panels, 
immunofluorescent staining of CDCP1 in the circled tumor areas of H&E sections. 
Middle panels, immunofluorescent staining of CDCP1 in matched normal areas. 
Red fluorescence showed PI staining for nuclei. Representative PCa Gleason scores 
are indicated. 
Figure 45 Shedding of CDCP1 ectodomain into the extracellular compartment. (A) 
Detection of CDCP1 ectodomain in the conditioned media and expressed prostatic 
secretion (EPS) samples. Western blot analysis of conditioned media from DU145 
cell lines and EPS samples from non-cancer, non-aggressive PCa, and aggressive PCa 
were performed with a goat antibody generated against the extracellular domain of 
CDCP1 (AF2666). The detected low molecular weight signals (55 kDa, 42 kDa, 33 
kDa, and 28 kDa) in EPS urine may indicate the ectodomain shedding forms of 
CDCP1. (B) Sypro Ruby stained gel of samples shown in the left panel indicating the 
total protein loading. 
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present at a higher level in the aggressive PCa EPS urine pool than in the non-aggressive 
PCa and non-cancer pools. 
5.4 Discussion 
PCa is the most common occurring malignancies in men and advanced metastatic 
PCa is currently incurable. Identifying the mediators that drive metastasis may offer 
insights into how to monitor or prevent PCa progression. By utilizing a novel cell surface 
glycoproteomic approach and a PCa metastatic cell model derived from PC3 cells, we 
uniquely identified CDCP1 protein in the metastatic ML2 cells, indicating a potential role 
of CDCP1 in PCa progression. The function of CDCP1 in cancer progression is also 
highlighted in other independent studies to identify CDCP1 by employing several 
different biased genetic and protein based approaches. Using cDNA chip hybridization 
techniques to search for genes preferentially expressed in solid tumors relative to normal 
tissues, Scherl-Mostageer et al. identified CDCP1 as a novel human tumor-associated 
gene in 2001, which is highly transcribed in lung and colon cancer derived cell lines 
Two years later, Hooper et al. first isolated the complete CDCP1 protein sequence using 
subtractive immunization intended to generate antibodies towards cell surface epitopes 
preferentially expressed by highly metastatic relative to non-metastatic carcinomas 280. In 
2005, aiming at searching for cell-cycle phase-specific mediators of activated Src family 
kinases (SFKs), Bhatt et al. identified CDCP1 as a mitotic substrate of SFKs in human 
MDA-MB-468 breast cancer cells. They also showed that overexpression of CDCP1 led 
to cell loss of adhesion phenotype . Subsequently, Uekita et al. also identified CDCP1 
• 9Q9 
as a SFK interacting protein in human A459 lung adenocarcinoma cells . In these 
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cells, phosphorylated CDCP1 was required to overcome anoikis and permit in vitro 
anchorage-independent growth. In addition, CDCP1 was identified as a molecule 
associated with important signaling proteins such as protein kinase C8 (PKC8)305. 
Supporting the role of CDCP1 in cancer progression, upregulated CDCP1 expression has 
9&fi 987 9R& 9RQ 900 9Q1 
been observed in breast , colon ' , kidney , pancreatic , and lung cancer 
patients and a number of epithelial cancer cell lines 280'282'292'293'306. 
Further characterization of CDCP1 in this study showed that there are two forms of 
CDCP1 protein in most PCa cell lines, the 135 kDa full-length and a shorter 70 kDa 
species. Similar sized CDCP1 species have been observed in many other human 
epithelial cell lines such as breast cancer MDA-453 and MDA-468 cells, pancreatic 
cancer BxpC3 cells, esophageal cancer TE7 cells, and several lung and colon cancer cell 
'i Of. 
lines . As reported, the LMW-CDCP1 can be expressed endogenously or induced 
9 H1 "X 0 9 9 R1 
through the action of exogenous serine proteases such as trypsin ' , plasmin and 
989 "^09 
matriptase ' . Currently the endogenous mechanisms and functional relevance of this 
cleavage is not clear. Here our data showed that the ratio of HMW-CDCP1 to LMW-
CDCP1 is highly relevant to the metastatic potential of PCa cells. Supporting this 
proposal, we observed a trend that membranous expression of CDCP1 was more intense 
in high-grade aggressive PCa tissues than low-grade PCa (Fig. 44D). Other data coming 
from in vitro experiments and animal models also strengthened the involvement of 
HMW-CDCP1 in cancer progression. In another congenical metastatic epidermoid 
carcinoma cell model, the expression levels of 135 kDa CDCP1 were much higher in the 
highly metastatic variant of Hep3 over non-metastatic variants 280. Also overexpression 
of CDCP1 in HeLa cells conferred these relatively non-aggressive cells with higher 
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efficiency in experimental metastasis in mice 307. Moreover, Uekita et al. demonstrated 
that reduction of 135 kDa CDCP1 by siRNA significantly inhibited the metastasis of 
A549 lung adenocarcinoma cells in vivo, but had no effect on primary tumor growth in 
9Q9 
mice . Recently, this group showed that HMW-CDCP1 promoted migration, invasion, 
and anchorage independence of highly invasive gastric cancer cell lines in vitro as well as 
enhanced the peritoneal dissemination in mice of these cells . Taking advantage of the 
function-blocking mAb 41-2 which mainly targets HMW-CDCP1, and chick embryo 
metastasis model, Quigley's group elegantly showed that CDCP1 functions as an anti-
apoptotic molecule and facilitates tumor cell survival at the late stages of the metastatic 
cascade, likely during or soon after extravasation307. Unlike HMW-CDCP1, there is 
little accumulative data for the function of LMW-CDCP1 in cancer progression. In our 
cell model system, we found that the expression levels of LMW-CDCP1 are negatively 
associated with the malignant abilities of PCa cells. Some studies showed that LMW-
CDCP1 was tyrosine phosphorylated under several cellular events including proteolysis 
302
 and cell adhesion 94. The phosphorylation promoted the formation of the 
CDCP1 :Src:PKC8 multiprotein complex 302, suggesting a role of LMW-CDCP1 in 
signaling transduction. However, the contribution of such phosphorylation for disease 
progression, especially for cancer metastasis, remains undefined. Therefore, further 
exploration of the essential roles of two CDCP1 forms in cancer progression should be of 
high priority. 
For other lineage-related PCa cell pairs, the trend seemed not as pronounced, as only 
low levels of HMW-CDCP1 were detected in the invasive cell lines. This can be 
explained because the different cell models reflect the distinct properties of PCa 
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progression, for example, the LNCaP derivative sublines mainly mimic the progression 
of PCa hormone independent, whereas RWPE-land its sublines represent the early stages 
of tumorigenesis and invasiveness. Thus it is not surprising to see the weak trend in these 
models. Additional congenically matched pairs of high and low metastatic tumor cell 
lines as well as accurate in vivo animal models will have to be examined to establish 
whether a clear link exists between two species of CDCP1 expression and the extent of 
malignant progression. 
The existence of 14 consensus N-glycosylation sites in the extracellular domain and 
5 tyrosine residues in the intracellular COOH terminus of CDCP1 suggests functional 
involvement of CDCP1 in outside-in signal transduction. Compared to extensive studies 
of CDCP1 phosphorylation, the glycosylation status and its roles are not yet understood. 
The work reported here for the first time characterizes the glycosylation of CDCP1. 
Deglycosylation of CDCP1 with PNGase F and Endoglycosidase H showed that both 
CDCP1 forms contain N-glycans of high-mannose or hybrid types. Despite these 
common glycosylation features, the CDCP1 forms differ in extent and type of certain 
glycosylation modifications. We previously identified HMW-CDCP1 by virtue of it 
being predominant in the cell surface sialoglycoprotein enriched fraction of metastatic 
ML2 cells, indicating sialylation of CDCP1. Neuraminidase treatment confirmed the 
presence of sialic acid. Therefore, these two independent experiments both indicated that 
HMW-CDCP1 carries more sialic acid in its N-glycans than LMW-CDCP1. In another 
one of our recent projects aimed at the identification of cell surface fucosylated 
glycoproteins, HMW-CDCP1 rather than LMW-CDCP1 was also identified in cell 
surface fucosylated glycoprotein enriched fractions of N2 and ML2 cells, suggesting the 
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existence of core-fucosylated N-glycans on HMW-CDCP1. More interestingly, we 
observed that the extent of sialylation of HMW-CDCP1 also correlated with the 
metastatic potentials of PCa cells consistent with the increasing evidence that 
hypersialylation is one of the most common changes of N-glycosylation during malignant 
transformation and progression 98''10. Our data raises the possibility that glycosylation 
signatures, especially sialylation, affect roles of two CDCP1 species in cancer 
progression. It is well known that glycosylation is critical in determining a protein's 
stability, conformation, folding, and binding affinity for other molecules 85. In addition, 
glycans per se are adhesion molecules directly involved in cell recognition . The 
negative charge and the terminal position of sialic acid can determine the ability of a 
protein to interact with other molecules and even cells. As reported, CDCP1 interacted 
with a number of adhesion and matrix proteins including cadherins and syndecans 
Actually, CDCP1 overexpression stabilizes a detached cellular phenotype and has a poor 
ability to spread plastic, which was ascribed to the intracellular constitutive 
9SO 0Q4. 
phosphorylation by SFKs ' . Therefore, it is attractive to think that the glycosylation 
of CDCP1 is the extracellular signal. Together with intracellular phosphorylation, it may 
modulate cell adhesion as well as epithelial tumor attributes such as anchorage-
independent growth, anoikis resistance, and metastasis. Current detailed N-glycan 
profiling of two CDCP1 forms as well as elucidation of the possible roles of sialylation of 
CDCP1 in relation to cancer progression are being pursued in our laboratory. 
Another interesting finding from this study is the dysregulated expression of 
CDCP1 in primary PCa tissues. By using sensitive immunofluorecent staining instead of 
routine immunohistochemistry, we observed significant alterations in expression levels 
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and subcelluar locations of this protein in PCa tissues compared to adjacent normal 
tissues. Moreover, although only a small number of patient samples were examined, it 
appeared that the expression pattern of CDCP1 was more obvious in high-grade 
aggressive PCa. Our result is opposite of a previous report in which Siva et al. found 
lower CDCP1 mRNA and protein expression in cancerous PCa cells than normal ones 295. 
Since CDCP1 is a protein that is processed by multiple post-translational modifications 
including glycosylation, phosphorylation, and proteolysis, mRNA levels can not 
accurately reflect the amount of functional protein. The difference in protein staining 
levels may mainly result from the usage of two distinct antibodies. Here we used a 
murine monoclonal antibody mAb 41-2, which was generated by subtractive 
immunization 280 and demonstrated functional blocking of experimental and spontaneous 
metastasis of Hela-CDCPl and PC3-hi/diss cells in mice and chicken embryo model 
systems . In contrast, Siva et al. made the mouse-anti-CDCPl antibody 25 A11 by 
whole cell panning and subtraction with red blood cells . This antibody decreased PC3 
cells migration and invasion in vitro and exhibited inhibitory effects on primary tumor 
growth and metastasis of PC3 cells in a mouse xenograft model, when coupled to the 
cytotoxin saporin, either directly or via a secondary antibody 295. The mechanistic 
differences between these two antibodies are unclear and await further exploration. 
Other variations such as prostate tissues, and staining technology (immunofluorescence 
vs immunohistochemistry) could also contribute to the difference. However, consistent 
with our results, dysreglulated CDCP1 expression has been also observed in a number of 
T O O 
cancers and is reported to have important clinical utility . In 2008, Awakura et al. 
analyzed CDCP1 expression by immunohistochemistry in 230 renal cell carcinomas and 
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showed that 33.5% patients had high levels of CDCP1 expression which inversely 
correlated with the disease-specific and recurrent-free survival . In another study, 
Ikeda et al. performed the similar examination in 200 lung adenocacinoma patient 
samples and demonstrated that 30.0% cases were classified as expressing moderate to 
high levels of CDCP1. High CDCP1 expression is associated with the occurrence of 
lymph node metastasis, high relapse rate, and poor prognosis . Recently Miyazawa et 
al. evaluated 145 pancreatic cancer samples and indicated the elevated expression of 
CDCP1 was significantly correlated with decreased overall survival of these patients 290. 
Taken together, these clinicopathological studies and cell-based investigations strongly 
supported that CDCP1 can be used as a cancer prognostic marker and could potentially 
be targeted to disrupt epithelial cancer progression. Indeed the murine anti-CDCPl 
antibodies, exhibiting function-blocking activity of metastasis as mentioned above, have 
underscored the potential of CDCP1 as a therapeutic target as cancer treatment. More 
recently, the human antibody specifically against CDCP, obtained from human single 
chain Fv (scFv) phage displayed libraries by subtractive panning, was shown to 
effectively inhibit in vivo metastasis and in vitro colony formation of human carcinoma 
cells without toxin conjugation309. The properties of immuno-tolerance and efficiency of 
anti-metastasis make the human anti-CDCPl antibody a promising candidate for further 
therapeutic development. Although significant for several epithelial cancers, the clinical 
relevance of CDCP 1 expression in PCa has not been reported as of now and a large-scale 
analysis of CDCP 1 expression in PCa samples will warrant future investigation. 
The detection of CDCP 1 fragments in PCa patient EPS urine samples is a significant 
finding. Proximal fluids, including EPS urine, are found adjacent to a given tissue or 
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organ and represent a repertoire of secreted proteins and shed cells reflective of the 
physiological and pathological states of that tissue 30°. Thus, they are potential sources of 
proteins and genetic biomarkers for cancer. In this study, EPS urine was collected in the 
clinic by forced (or expressed) ejection of prostatic fluids into the urethra following 
prostate massage. The presence in vivo of a 55 kDa CDCP1 ectodomain shed from cell 
surface, and the relatively higher levels of CDCP1 fragment in aggressive PCa EPS 
urines, indicates that CDCP1 has the potential as a diagnostic maker for prostate cancer. 
Hooper et al. detected a membrane-shed moiety of CDCP1 of approximately 110 kDa in 
the serum-free conditioned medium of human epidermoid carcinoma cell line, which 
would be predicted to contain most of the extracellular domain . They also described 
strong immunohistochemical staining in the goblet cells of normal colon crypts, the 
lumen of glands and in the glandular mucus of colon carcinoma, suggesting the 
production of a soluble form of CDCP1. Bhatt et al. and He et al. reported that CDCP1 
undergoes proteolytic digestion by the serine proteases after amino acids R368 or K369 
and this cleavage is linked to intracellular signaling pathways ' . The presence of 
CDCP1 ectodomain in clinical samples prioritizes CDCP1 as a diagnostic marker worth 
future validation. 
In summary, most PCa cell lines expressed the 135 kDa full-length and a truncated 
70 kDa species of CDCP 1 protein. Both CDCP1 forms contain heavy N-linked 
oligosaccharides rich in high-mannose or hybrid-type chains and terminated by sialic acid 
residues. However, the ratio of high to low molecular weight CDCP1, as well as the 
glycosylation levels of 135 kDa CDCP1 correlated to the metastatic status of variant PC3 
cell lines. Flow cytometry and immunocytochemistry data confirmed elevated levels of 
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CDCP1 in metastatic ML2 cells, and also demonstrated that this protein is processed by 
ER/Golgi network and concentrated on the plasma membrane. Immunofluorescent 
staining of human PCa tissues indicated that CDCP1 exhibited increased intensity and 
extensive cell surface staining in malignant epithelial cells. In contrast, CDCP1 was 
targeted to a discrete juxtanuclear compartment and the plasma membrane staining in 
matched normal cells appeared much weaker. Shedding of CDCP1 ectodomain was 
detected by Western blot at elevated levels in aggressive PCa patient EPS urine samples. 
Our data indicate that expression of CDCP1 protein is dysregulated in PCa and it has the 
potential utility as a therapeutic target and a diagnostic marker for PCa progression. 
CHAPTER VI 
CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 AIM I (Chapter III): Characterization of cell-surface lectin-binding patterns 
associated with metastasis in human prostate cancer cells. 
A. Our optimization of lectin staining protocols determined that the use of non-
enzymatic dissociation buffer for cell suspension preparation provides the best balance of 
dissociation efficiency, cell viability, and cell-surface carbohydrate retention. 
Additionally, our results show that blocking buffer, staining buffer, cell confluence, and 
the concentrations of lectin are potential sources of variation affecting successful lectin 
flow cytometry analysis. Lectin staining of unfixed cells is superior to fixed cells for 
cytohistochemistry analysis for representation of the true surface binding patterns. 
B. Lectin flow cytometry and microscopy revealed that the cell-surface 
glycoconjugates of PC3 and its variants contain a diversity of carbohydrate groups and 
are extensively sialylated. 
C. Total cell-surface carbohydrate profiling by lectin binding showed that the 
metastatic potential of PC3 variants is inversely correlated with the level of cell-surface 
a2-6 linked sialic acid. 
6.2 Future Directions of Aim I 
In Aim I, the predominant carbohydrate detected by lectin flow cytometry for PC3 
and its variants was sialic acid while other residues showed relatively weaker signals, 
initially suggesting that these carbohydrates were low contents on the PCa cells. 
However, terminal sialic acid can mask other lectin binding sites and the extent of 
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masking effect is various m . One aspect of future studies will use a neuraminidase for 
enzymatic removal of sialic acid to reveal the real abundance of underlined sugars. 
Besides sialylation, fucosylation, and N-acetylgalactosamine (GalNAc) studied in 
this Aim, well-characterized lectins for other types of aberrant cancer-related 
glycosylation are also available. For example, lectin L-PHA recognizes pi-6 branching 
of N-linked oligosaccharides, a common feature of most cancers 86. Lectins AHA and 
EC A react with two different linkages of T antigen, Gal beta l-3GalNac, and Gal beta 1-
4GlcNac, respectively. The expression of these carbohydrates was reported to correlate 
with metastatic sites of prostate cancer . Therefore, the future employment of a wider 
spectrum of and linkage-specific lectins will be useful to intensively characterize cell-
surface glycosylation patterns associated with PCa metastasis. 
Our data reported the use of flow cytometry as an effective technique for detecting 
differences in cell-surface lectin binding in fresh cultured cells. To make more clinical 
relevant conclusions, in the future we can extend it to spilled cells from fresh prostate 
cancer tissues or fine-needle aspirates, and compare lectin binding patterns of primary 
PCa tumor to metastases from other sites such as the lymph nodes. 
6.3 AIM II (Chapter IV): Targeted identification of metastasis-associated cell-
surface sialoglycoproteins in prostate cancer. 
A. We have developed a robust MS-based glycoproteomic methodology for the 
selective identification of specific subclasses of cell-surface glycoproteins. The approach 
combined metabolic labeling of cell-surface sialyl glycans, chemical probing of the 
labeled sugar with biotin-alkyne via click reaction, affinity purification of sialylated 
proteins, SDS-PAGE separation, and subsequent LC-MS/MS for protein identification. 
B. Azide-modified sialic acid metabolic precursor (ManNAc) was efficiently and 
specifically incorporated into cell-surface sialylated glycans in PCa cancer cells, as 
demonstrated by flow cytometry and confocal microscopic analysis. Click-activated 
conjugation of the biotin tag following metabolic labeling allows visualization of cell-
surface glycoproteins as well as, observation of intracellular localization of sialylated 
glycoconjugates. 
C. Our optimization of metabolic labeling and click reaction experiments 
determined that ManNAz treatment with 20-40 uM for 1 day and click reaction with 25 
ul of biotin-alkyne with 2.5 ul CuS04 can provide maximum cell viability/vigor. 
D. Specific azide-modified sialoglycoprotein signals were detected by streptavidin-
IR 800 in post-click cell extracts treated with ManNAz, demonstrating the feasibility of 
labeling individual glycoproteins by using this probing system. In addition, there 
appeared to be a major protein band (under 150 kDa) that reacted with streptavidin and 
greater sialylated glycoproteins in the ML2 cell line when compared to the N2 cell line. 
E. The bound and eluted fractions from streptavidin beads produced strong distinct 
glycoprotein patterns visualized by in-blot streptavidin-IR 800 detection and ID-PAGE 
analysis, indicating efficient capture and enrichment of the azide-labeled proteins. 
F. Application of the described targeted glycoproteomic approach to our syngeneic 
PCa cell line model allowed for the identification of total 536 non-redundant proteins. 
Using conservative criteria, 64 proteins (26%) from N2 and 72 proteins (29%) from ML2 
were classified as extracellular or membrane-associated glycoproteins. A selective 
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enrichment of sialoglycoproteins was observed at the affinity chromatography step. 
When compared to global proteomic analysis of the same cells, the proportion of 
identified glycoprotein and cell-surface proteins were on average 3-fold higher in the 
AC4ManNAz labeled cells. Functional clustering of differentially expressed proteins by 
Ingenuity Pathway Analysis demonstrated that the vast majority of the glycoproteins 
over-expressed in the metastatic ML2 subline were involved in cell motility, migration, 
and invasion. 
G. A total of 80 cell-surface glycoproteins differentially expressed between cell lines 
were uniquely identified and proposed as PCa biomarkers specific to metastatic 
competence. 
6.4 Future Directions of Aim II 
In Aim II, our targeted glycoproteomic approach coupled glycan labeling with 
traditional gel-based liquid chromatography tandem mass spectrometry (GeLC-MS/MS) 
technology for glycoprotein identification. GeLC-MS/MS offers a number of benefits for 
protein identification such as increasing the depth of analysis by spreading out the 
complex protein mixture over 20-30 gel slices, removing low molecular weight 
impurities which are often detrimental for MS sequencing, and providing observed mass 
of proteins which is very useful to predict post-translational modifications 
Alternatively, MS-based shotgun technology which directly analyzes complex protein 
mixtures using multidimensional high-pressure liquid chromatography (LC/LC) in 
conjunction with tandem mass spectrometry (MS/MS), has advantages in speed, 
sensitivity, and automation312. In the future, we would combine glycan labeling 
technology with shotgun proteomic platform for the analysis of the cell-surface 
glycoproteome. Specifically, glycoproteins enriched by streptavidin beads as we have 
described will be serially digested with Lys-C and trypsin, yielding a first peptide pool 
representing all of the bound proteins. The peptide pool will be subjected to shotgun 
proteomic analysis and the resulting proteins will be searched against the UniprotKB 
human protein database for glycoprotein assignment. The remaining tagged N-linked 
glycopeptides bound to streptavidin beads will be released via peptide-N-glycosidase F 
(PNGase F), yielding a secondary glycopeptide pool. The glycopeptide pool will be 
analyzed by LC-MS/MS and glycoprotein identification will be read directly from the 
conversion of Asn residues to Asp. Such strategies will offer two extra advantages: an 
increase in sequence coverage of the glycoproteins by crossing-referencing between the 
two pools; and the determination of N-linked glycosylation sites. This would be of 
particular interest in studies where changes of glycosylation occupancy are suspected to 
link with the disease states. 
One possible reason for the significant number of proteins annotated as nuclear or 
cytoplasmic that was present among our cell-surface sialoglycoproteome is copper 
cytotoxity during the click reaction. Fortunately, a new generation of copper-free click 
chemistry can resolve this problem . Improving cell viability could allow for 
subcellular fractionation to increase membrane glycoprotein identification. With 
collaboration with Dr. Binghe Wang at Georgia State University, the development of 
copper-free click chemistry-based glycoproteomic methodology is currently underway. 
The main accomplishment of Aim II was the identification of 80 cell-surface 
glycoproteins differentially expressed between cell lines by our targeted glycoproteomic 
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approach. Here "differentially expressed glycoproteins" refer to glycoproteins which 
were uniquely identified in one cell line. Some glycoproteins identified in both cell lines 
but possibly with differential levels were lost. To overcome such limitations, quantitative 
proteomic techniques are necessary to be incorporated into our glycoproteomic approach. 
In the past decade, several quantitative proteomics techniques have been widely 
employed by the whole proteomics community, including stable isotopic or isobaric 
labeling using chemical reactions (e.g. ICAT and iTRAQ) 313-3145 metabolic incorporation 
(e.g. SILAC) , and enzymatic reactions (e.g. O labeling) , as well as less 
quantitatively accurate label-free approaches 3I7. These techniques are readily adapted 
into our glycoproteomic analysis at different stages. For example, the SILAC technique 
can incorporate stable isotope labeled amino acids into proteins during the cell culturing 
process while the iTRAQ technique can introduce isobaric tags after tryptic digestion of 
1 R 
glycoproteins. O can be incorporated into the N-glycopeptides during enzymatic 
reactions, such as tryptic digestion (incorporation of two 180 into the peptide carboxyl 
• 1 R 
terminal) and PNGase F-mediated hydrolysis (incorporation of one O into the 
asparagine of N-glycosylation sites). Therefore, future attempts will be made to 
incorporate these quantitative techniques into our targeted glycoproteomics to facilitate 
glycoprotein isolation, identification, and quantification in one experiment. 
6.5 AIM III (Chapter V): Verification of expression of cell-based biomarkers in 
clinical samples. 
A. CUB-domain-containing protein 1 (CDCP1) was successfully identified from the 
prominently sialylated band (under 150 kDa) observed in Aim II by GeLC-MS/MS. 
185 
B. Western blot analysis of the cell-surface glycoprotein enriched fractions as well 
as whole cell lysates confirmed the proteomic data, demonstrating the over-expression of 
CDCP1 in metastatic PCa cell line (ML2). Additionally, the 135 kDa full-length and a 
truncated 70 kDa species of CDCP1 protein were found to be expressed in most PCa cell 
lines. 
B. Analysis of deglycosylation cell lysates indicated that both CDCP1 species 
contains heavy N-linked glycans and are modified by sialylation and fucosylation, where 
the type and extent of carbohydrate moieties attached are different. The carbohydrate 
present on the HMW-CDCP1 harbors three types of N-glycosylation, and is terminated 
by a significant amount of sialic acid residues. In contrast, high-mannose/hybrid-type N-
glycans and probably O-glycans are primarily present on LMW-CDCP1 and they are less 
sialylated. 
C. Western blot analysis of our syngeneic PCa cell line model suggested that the 
ratio of high to low molecular weight CDCP1, as well as glycosylation levels of the 135 
kDa CDCP1 is correlated to the metastatic competence of PC3 variants. 
D. Flow cytometry and immunocytochemistry data confirmed elevated levels of 
CDCP1 in metastatic ML2 cells, and also demonstrated that this protein is processed by 
the ER/Golgi network and concentrated on the plasma membrane. 
E. Immunofluorescence microscopy of human PCa tissues revealed dysregulated 
expression of CDCP1 proteins in prostate cancer tissues. CDCP1 exhibits an increased 
intensity of cell surface presentation in malignant gland cells whereas it is confined to a 
discrete perinuclear compartment with only weak plasma membrane staining in matched 
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normal cells. Importantly, CDCP1 expression levels appeared to increase with increasing 
Gleason score. 
F. Shedding of putative CDCP1 ectodomains was detected by Western blot at 
elevated levels in aggressive PCa post-DRE urine samples. 
6.6 Future Directions of Aim III 
The prioritization and verification of candidate biomarkers provides an important 
bridge between discovery and validation. Traditionally, proteins of interest are verified 
using immunoassays, as we did in Aim III, which require high-quality antibodies that 
already exist. For many or most novel candidates, such antibodies will not be available. 
The cost and time associated with the generation and optimization of a specific antibody 
is considerable and makes this option both prohibitively expensive and inefficient for 
high numbers of proteins. For panels of protein candidates, verification by multiple 
reaction monitoring MS (MRM-MS) using a triple quadrupole mass spectrometer 
presents a compelling alternative. MRM on the triple quadrupole mass analyzer is the 
gold standard for developing MS-based quantitative methods. In the MRM mode, an ion 
of interest (the precursor) is preselected with the first mass filter Ql, and induced to 
fragment in Q2 by collisional excitation with a neutral gas in a pressurized collision cell. 
The resulting 'product ions' (that is, the fragmentation products of the selected precursor) 
are mass analyzed using the third quadrupole Q3 152. MRM-MS has much higher 
throughput, accuracy, and sensitivity and allows for substantial multiplexing. 
Importantly, addition of isotopically labeled internal standards allow for absolute 
quantification 5 . By rapid and continuous monitoring exclusively for the specific ions 
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of interest, MRM-MS enhances the lower detection limit for peptides by up to 100-fold. 
Moreover, a moderate number of candidate proteins (30-100) can be simultaneously 
targeted and measured in a single experiment, particularly when using scheduled MRM, 
which incorporates prior knowledge of peptide elution times into the LC-MS/MS 
1 M 
program . MRM-MS has been applied to estimate the levels of give minor 
glycoproteins in human serum 155, to measure the levels of biomarker candidates in a 
mouse model of breast cancer , and to study the N-linked glycosylation reaction in 
congenitial disorders of glycosylation type-I serum . Thus, MRM-MS is an extremely 
powerful for biomarker discovery and candidate validation. With panels of cell-surface 
sialoglycoprotein candidates on hand and triple quadrupole mass spectrometry available 
at our lab, we will be devoted to develop MRM-MS assays for our future candidate 
biomarker verification. 
CDCP1 is type I cell-surface protein with extensive glycosylation. Compared to 
extensive studies of CDCP1 phosphorylation, the glycosylation status and its roles are not 
yet understood. The work reported in Aim III for the first time characterizes the 
glycosylation of CDCP1 by several glycosidases and glycosylation inhibitors. To 
uncover the underlying mechanisms of CDCP1 glycosylation in PCa progression and 
metastasis and discover potential glycan-based biomarkers, a survey of CDCP1 glycome 
is necessary. The complete analysis of CDCP1 glycosylation includes mapping its 
glycosylation sites, determination of sequence and linkage of glycans, and site-specific 
carbohydrate characterization. We have multiple mass spectrometers including MALDI-
TOF/TOF, ESI-LC-MS/MS, and triple quadrupole MS at our lab with the capabilities of 
performing multiple levels of glycan analysis. For example, the monosaccharide 
composition of CDCP1 can be analyzed by MALDI after the glycan is released from 
purified CDCP1. Glycosylation sites of CDCP1 can be mapped by PNGase F treatment 
in conjunction with LC-MS/MS analysis. Determination of the glycan sequence of 
CDCP1 and site-specific glycan analysis can be performed by tandem MS experiments 
by the use of the triple quadrupole MS. Therefore, detailed glycan profiling of two 
CDCP1 forms as well as elucidation of the possible roles of glycosylation of CDCP1 in 
relation to cancer progression will be an interesting project and it will be pursued in our 
laboratory. 
In a small set of PCa tissues, we observed that the expression of CDCP1 in PCa is 
dysregulated and elevated membranous expression of CDCP1 appears to correlate with 
PCa aggressiveness. To further determine the clinical significance of CDCP1 expression, 
a larger cohort of samples will be used to examine CDCP1 expression in PCa tissues 
using immunohistochemistry (IHC). We have a large bank of formalin-fixed paraffin-
embedded (FFPE) PCa tissue blocks representing all stages and grades. The analysis of 
these archived samples with complete pathology and clinical outcome will allow us to 
establish a clearer link between CDCP1 expression and the extent of malignant 
progression. Currently, optimization of IHC conditions for FFPE PCa tissues is being 
pursued at our laboratory. 
The detection of CDCP1 fragments in PCa EPS urine samples patients is significant 
since the finding indicated that the ectodomain shedding of CDCP1 can reach the body 
fluids and serve as early sentinel for cancer detection. Future studies will confirm the 
Western blot results by immunoprecipitation of CDCP1 from EPS with antibody 
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targeting to the N-terminal portion of CDCP1 and analysis of the purified CDCP1 
fragments by mass spectrometry. 
6.7 Concluding Remarks 
Altered glycosylation has been associated with tumor development and disease 
progression. Given the growing evidence that glycans of cell-surface glycoproteins are 
involved in each and every aspect of tumor progression, glycoproteins are becoming 
important targets for the development of biomarkers for cancer diagnosis, prognosis, and 
therapeutic response to drugs. With the guidance of cancer-related changes in 
glycosylation, the marriage of efficient glycoprotein enrichment and sophisticated MS 
technologies offers great opportunities for biomarker research. The studies described 
herein provide an example of glycobiology-driven biomarker discovery. By selectively 
tagging cancer-related cell-surface glycans, we have been able to exclusively target the 
pool of cell surface-expressed glycoproteins for subsequent in-depth MS analysis. The 
successful identification of membrane glycoprotein CDCP1 whose expression is 
dysregulated in PCa provides strong proof-of-principal evidence for our developed 
glycoproteomic approach. There are numerous roles of CDCP1 that may play in cancer 
metastasis including inhibiting apoptosis and aiding in extravasations. Additional, 
CDCP1 may have soluble/shed isoforms which could provide additional critical 
information concerning PCa progression. Much work remains to be done to translate the 
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